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 Phosphonic and phosphinic acid natural products are characterized by their carbon-
phosphorus bonds, and exhibit a variety of bioactivities.  Further, these compounds often contain 
unusual structural features, which arise from remarkable enzymatic transformations.  One 
example comes from fosfazinomycin, an antifungal compound bearing a unique 
phosphonohydrazide (C-P-N-N-C) linkage that joins a valine-arginine dipeptide to methyl-2-
hydroxyphosphonoacetate (Me-HPnA).  This thesis describes my efforts towards determining 
how the nitrogen-nitrogen (N-N) bond is crafted and installed during fosfazinomycin 
biosynthesis.   
 The building blocks used to construct natural products are often derived from metabolites 
coming from central metabolism.  Chapter 2 addresses my efforts to ascertain the biosynthetic 
origins of the N-N bond in fosfazinomycin.  I was able to optimize conditions for the production 
of fosfazinomycin from its native Streptomyces producing organism and conducted stable 
isotope labeling experiments.  The results of those studies revealed that the primary amine from 
aspartic acid is incorporated into the phosphonohydrazine moiety of fosfazinomycin.  Further 
purification and spectroscopic efforts additionally demonstrated that the nitrogen atom 
originating from aspartic acid is donated to the site proximal to the phosphorus.   
 Interestingly, a number of enzymes are conserved in the pathways to fosfazinomycin and 
to kinamycin, another natural product that contains an N-N bond but is otherwise structurally 
unrelated.  In Chapter 3, I describe the discovery of a recurring modular pathway for the 
installation of hydrazine onto diverse chemical structures.  Using a combination of isotope 
labeling studies and in vitro enzymatic assays, I illustrate a biosynthetic route wherein nitrous 
acid, liberated from aspartic acid, is used to build a hydrazine synthon that, after a number of 
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steps, is eventually condensed onto the side chain of glutamic acid to make glutamylhydrazine.  
Glutamylhydrazine then serves as common carrier molecule for hydrazine, which can 
subsequently be deposited onto varying chemical scaffolds.   
 Previous work had shown that fosfazinomycin biosynthesis proceeds in a convergent 
manner with the Me-HPnA and argininylmethylhydrazine being formed independently.  My 
attempts at reconstituting the transfer of hydrazine from glutamylhydrazine onto the carboxyl 
group of arginine are described in Chapter 4.  FzmA, an asparagine synthetase homolog, is a 
prime candidate for effecting this transformation, and I used a number of in vitro enzymatic 
assays to test for the desired FzmA activity.  Unfortunately, I was unable to reconstitute the 
formation of argininylhydrazine using FzmA.  I also highlight the discovery of a PqqD-like 
enzyme and a nucleotidyltransferase homolog that may be involved in fosfazinomycin 
biosynthesis.   
 How the N-N bond is crafted in fosfazinomycin still remains a mystery.  Chapter 5 
recounts my failed efforts towards reconstituting the enzymatic formation of the N-N bond.  I 
discuss a number of potential biosynthetic strategies that may be at play in N-N bond 
construction, and the biochemical approaches I took to investigate them.  I also describe the 
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CHAPTER 1: INTRODUCTION 
 
1.1 PHOSPHONIC ACID NATURAL PRODUCTS: STRUCTURE AND BIOACTIVITY 
 Phosphonic and phosphinic acid natural products are characterized by their carbon-
phosphorus (C-P) bonds.  These compounds often structurally resemble phosphate esters, but the 
C-P bond is much more resistant to hydrolysis than the oxygen-phosphorus bond found in 
phosphate esters.1  This structural mimicry imbues phosphonic acid natural products with a 
variety of bioactivities.  For example, the Z-2-amino-5-phosphono-3-pentenoic acid (APPA) 
warhead of the plumbemycins and the rhizocticins inhibits threonine synthase by impersonating 
the native substrate, L-homoserine phosphate (Figure 1.1).2-3  Plumbemycin and rhizocticin, 
antibacterial and antifungal agents, respectively, are phosphonic acid oligopeptides and the 
identities of the amino acids present are responsible for the selective import of each compound 
into its respective target organism (Figure 1.1).4-6  Fosfomycin, also called Monurol, inactivates 
UDP-N-acetylglucosamine enolpyruvyl transferase (MurA), shutting down cell wall 
biosynthesis, by structural imitation of phosphoenolpyruvic acid (Figure 1.1).7-9  Fosmidomycin 
and FR-900098, which have antiplasmodial activities, are structural analogs of 1-deoxy-D-
xylulose 5-phosphate and inhibit 1-deoxy-D-xylulose 5-phosphate reductoisomerase in the non-
mevalonate pathway to isoprenoids (Figure 1.1).10-11  Many man-made phosphonic acids also 
leverage structural mimicry to phosphate esters found in biology for bioactivity.  For instance, 
glyphosate, the active ingredient of the herbicide RoundupTM, inhibits 5-enoylpyruvylshikimate-
3-phosphate synthase by imitating the natural substrate, phosphoenolpyruvic acid (Figure 1.1).12  
Other examples come from acyclic nucleoside phosphonates such as cidofovir (used clinically to 




Figure 1.1 The structures of naturally occurring and synthetic phosphonic and phosphinic acids.  
The structures are grouped with their respective analogs from central metabolism, which are 
colored in red.   
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 While many phosphonic acids are structurally analogous to phosphoesters, others derive 
their bioactivities from similarities to carboxyl groups and tetrahedral intermediates found in 
carbonyl chemistry.  Dehydrophos is another peptidic phosphonic acid natural product, and like 
the rhizocticins and plumbemycins, the short amino acid sequence is responsible for import of 
the molecule into the cell (Figure 1.1).14  Once inside the target cell, dehydrophos is converted 
to methyl acetylphosphonic acid, an analog of pyruvic acid and an inhibitor of both pyruvate 
dehydrogenase and pyruvate oxidase.14  Phosphinothricin, another natural product, used under 
the trade name Glufosinate as an herbicide, is phosphorylated once inside the cell and mimics the 
tetrahedral intermediate formed during the conversion of glutamic acid to glutamine by 
glutamine synthase (Figure 1.1).15-16  In nature, phosphinothricin is usually conjugated to a 
dimeric or trimeric peptide sequence, which aids in the transport of the compound into the cell.1, 
17  An example of a synthetic phosphonic acid mimicking a carboxylic acid can be found in 1-
aminoethylphosphonic acid, which is an analog of alanine and inhibits alanine racemase (Figure 
1.1).18   
 
1.2 CONSERVED FIRST STEPS IN PHOSPHONIC ACID BIOSYNTHESIS 
 In almost all known examples of phosphonic acid biosynthesis, the first step is 
conserved—the primary metabolite phosphoenolpyruvic acid (PEP) is converted to 
phosphonopyruvic acid (PnPy) by phosphoenolpyruvate mutase (PepM).12  PepM contains a 
highly conserved active site motif (EDKXXXXXNS), and all known pepM gene sequences can 
be amplified by PCR with four sets of primers.19  Furthermore, pepM sequence identity (when 
above 60%) correlates well with similarity in the gene neighborhood.20  The ease with which 
pepM genes can be identified makes phosphonates particularly well-suited to genome mining 
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efforts.  Indeed a study performed by the Metcalf and van der Donk groups screened the 
genomes of over 10,000 actinomycetes, identified 78 distinct phosphonic acid biosynthetic gene 
cluster (BGC) families, and isolated and elucidated the structures of 19 new phosphonic acid 
natural products.21   
 The conversion of PEP to PnPy by PepM is highly thermodynamically unfavorable with 
an estimated stoichiometric ratio of PEP to PnPy of more than 500 at equilibrium.22  Therefore, 
in phosphonic acid biosynthetic pathways, the formation of PnPy is coupled with a subsequent 
exergonic step.1  Multiple strategies exist to drive this reaction forward, and thus, PnPy 
represents the first major branch point in phosphonic acid biosynthesis.   
 To our current understanding, the most common biosynthetic step after PnPy formation 
by PepM is a decarboxylation reaction catalyzed by phosphonopyruvate decarboxylase (PpD) to 
form phosphonoacetaldehyde (PnAA) (Figure 1.2).23  A variety of enzymatic reactions can then 
be effected to transform PnAA into a multitude of phosphonic acid natural products.  A common 
biosynthetic strategy is the reduction of PnAA to 2-hydroxyethylphosphonic acid (2-HEP) by 
NAD(P)H-dependent oxidoreductases, leading to the biosyntheses of fosfomycin (in 
Streptomyces), phosphinothricin, dehydrophos, and argolaphos.12, 21  2-HEP is also an 
intermediate in the biosynthesis of methylphosphonic acid, a compound thought to be a 
significant source of methane in the oceans.24-26  The biosynthetic pathway to rhizocticin uses 
another route from PnAA.  A class II aldolase first catalyzes the decarboxylation of oxaloacetic 
acid (OAA) to the enolate form of pyruvic acid, which is then joined with PnAA in an aldol 
condensation reaction.4  The same transformation is thought to take place in the biosyntheses of 
plumbemycin and phosacetamycin.12, 27  In the biosynthesis of fosfazinomycin, PnAA is 




 Figure 1.2 Biosynthetic pathways for phosphonic acid natural products.  Steps not yet 
elucidated are shown as dashed arrows.   
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PnAA can be converted to 2-aminoethylphosphonic acid (2-AEP) by a transaminase.  2-AEP 
decorates  a variety of phosphonoglycans and phosphonolipids.12  Further, 2-AEP is thought to 
be an intermediate in the pathway to nitrilaphos and related compounds.21, 29-30 
 An alternative second step to the decarboxylation of PnPy to PnAA in phosphonic acid 
biosynthesis is the condensation of PnPy and acetyl-CoA to form phosphonomethylmalic acid 
(PMM) (Figure 1.2).1  This reaction is catalyzed by a homocitrate synthase homolog and is 
found in the biosyntheses of fosmidomycin and FR-900098.23, 31  Interestingly, in a case of 
convergent evolution, the biosynthetic pathway to fosfomycin is different in Pseudomonas and in 
Streptomyces.  Whereas, Streptomyces species make fosfomycin by converting PnPy to 2-HEP 
through PnAA, Pseudomonas syringae converts PnPy to PMM, like in the pathways to 
fosmidomycin and FR-900098.32  How the fosfomycin pathway in P. syringae proceeds from 
PMM is still under investigation.33   
 The biosynthetic pathways towards phosphonocystoximic acid and valinophos represent 
a third alternative branch from PnPy in phosphonic acid biosynthesis (Figure 1.2).  In the 
biosyntheses of these compounds, a dehydrogenase is proposed to reduce PnPy to 
phosphonolactic acid with the similar reduction of pyruvic acid to lactic acid being highly 
thermodynamically favorable.21  A recent study performed by the Metcalf group on the 
biosynthesis of phosphonocystoximic acid revealed that 2-AEP is very likely a downstream 
biosynthetic intermediate as is the case for the related compound hydroxyphosphonocystoximic 
acid.30  These results exposed another fascinating case of evolutionary convergence.   
 To date, the only phosphonic acid natural products that do not derive from PEP are K-26 
and its related compounds.12  Feeding studies performed in the producing organism, 
Actinomycete sp. NRRL 12379, with deuterated and 15N-labeled tyrosine revealed that parts of 
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the tyrosine molecule is incorporated directly into K-26 (Figure 1.3).  These results preclude the 
possibility of PEP involvement in C-P bond formation in the biosynthesis of K-26; however, the 
enzymatic process in which the C-P bond is crafted here remains unknown.34   
 
Figure 1.3 Isotope labeling studies demonstrate the intact incorporation of the side chain of 
tyrosine into K-26.   
 
1.3 FOSFAZINOMYCIN: STRUCTURE, PRODUCING ORGANISMS, AND 
BIOSYNTHETIC GENE CLUSTER 
 Fosfazinomycin was first discovered as part of a screen for novel antifungal compounds.  
Produced by Streptomyces lavendofoliae 630, fosfazinomycin was found to have some weak 
antifungal activity including causing growth inhibition in Mucor racemosus as well as 
stimulation of hyphal branching in Mucor racemosus, Trichophyton mentagrophytes, and 
Paecilomyces varioti.35  There are two variants of fosfazinomycin, the only difference being the 
extra N-terminal valine found in fosfazinomycin  A that is lacking in fosfazinomycin B (Figure 
1.4a).36  Interestingly, a hydrazine linkage bridges the carboxyl group of arginine with the 
phosphonic acid moiety (S)-methyl-2-hydroxy-2-phosphonoacetic acid (Me-HPnA).36-37  My 
attempts to elucidate the biosynthesis of that hydrazine linkage will be the focus of this thesis, 
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and an introduction on natural products containing nitrogen-nitrogen bonds will be given in 
Chapter 3.   
 
Figure 1.4 The structures of the fosfazinomycins and their biosynthetic gene cluster.  a) The 
structures of fosfazinomycin A and fosfazinomycin B.  b) The fosfazinomycin biosynthetic gene 
cluster from Streptomyces sp. XY332.  Genes are color-coded based on the demonstrated or 
hypothetical functions of their respective gene products.   
 
 In a joint effort by the van der Donk and Metcalf laboratories, Me-HPnA was found in 
the spent media of Streptomyces sp. XY332 and Streptomyces sp. WM6372, two strains earlier 
identified to harbor pepM.38  Further analysis with 31P nuclear magnetic resonance (NMR) 
spectroscopy and mass spectrometry (MS) revealed that the two strains were able to produce 
fosfazinomycin A, and a comparison of the gene neighborhood around pepM in the two strains 
yielded a putative biosynthetic gene cluster (BGC) (Figure 1.4b and Table 1.1).  Additional 
bioinformatic examination identified seven additional potential producing organisms: 
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Streptomyces sp. NRRL S-244, Streptomyces sp. NRRL F-2747, Streptomyces sp. NRRL S-20, 
Streptomyces sp. NRRL S-444, Streptomyces sp. NRRL B-16271, Streptomyces sp. NRRL S-50, 
and Streptomyces sp. S-149.21   
Table 1.1 Proteins encoded by the fzm biosynthetic cluster.   
 Uniprot/NCBI 
Accession 




Asparagine synthetase (Bacillus subtilis strain 168) [36.7%] 
B U5YN71/ 
WP_053787803.1 
27-O-demethylrifamycin SV methyltransferase (Amycolatopsis 
mediterranei strain S699) [36.0%] 
C A0A0N1IYJ9/ 
WP_063785195.1 
Phosphoenolpyruvate hydrolase (Variovorax sp. Strain Pal2) [47.7%] 
D U5YM91/ 
WP_053787801.1 
Phosphonopyruvate decarboxylase (Streptomyces viridochromogenes 
strain DSM 40736) [38.1%] 
E U5YQD4/ 
WP_053787800.1 
3ʹ, 5ʹ-cyclic adenosine monophosphate phosphodiesterase CdpA 
(Streptomyces avermitilis strain ATCC 31267) [38.8%] 
F A0A0M9CNM7/ 
WP_053787799.1 
Pyruvate carboxylase subunit A (Methanothermobacter 
termautotorphicus strain ATCC 29096) [31.4%] 
G U5YN77/ 
WP_053787798.1 




50S ribosomal protein L3 glutamine methyltransferase 
(Bradyrhizobium diazoefficiens strain JCM 10833) [35.0%] 
I U5YM96/ 
WP_053787796.1 
Lysylphosphatidylglycerol biosynthesis bifunctional protein LysX 
(Mycobacterium smegmatis strain ATCC 700084) [22.5%] 
J U5YQD9/ 
WP_078987494.1 




Thymidylate kinase (Thermotoga petrophilia strain RKU-1) [30.8%] 
L U5YN81/ 
WP_053787793 
3-carboxy-cis,cis-muconate cycloisomerase (Pseudomonas aeruginosa 
strain ATCC 15692) [42.7%]  
M A0A0N0UQ79/ 
WP_053787792 
NAD-dependent siroheme synthase (Nitrosospira multiformis strain 
ATCC 25196) [35%]  
N U5YQN5/ 
KOY56386 




Putative amidase AF_1954 (Archaeoglobus fulgidus strain ATCC 
49558) [38%]  
P U5YN85/ 
WP_053787791 





Table 1.1 (continued) 
Q U5YMA2/ 
WP_030299240 
Mycothiol acetyltransferase (Corynebacterium efficiens strain DSM 
44549) [38.2%]  
R A0A0M9CPV0/ 
KOY56385 
Adenylosuccinate lyase (Bacillus subtilis) [46.0%%]  
S */ 
WP_078987491.1 
Regulatory protein AfsR (Streptomyces griseus) [43.2%] 
*No Uniprot entry available 
 With a putative BGC and a number of producing organisms in hand, studies could now 
commence in order to elucidate the biosynthesis of fosfazinomycin.  Dr. Xiaomin Yu, a former 
graduate student in the Metcalf group, introduced the putative fosfazinomycin biosynthetic 
cluster (along with ~30 open reading frames both upstream and downstream of the putative 
cluster) into a heterologous producing strain, Streptomyces lividans TK24 to make strain 
MMG604.  However, when MMG604 was cultivated in a variety of conditions, only Me-HPnA 
was observed in the spent media, and no fosfazinomycin could be detected.38  Since only small 
amounts of fosfazinomycin could be detected in the native producing strains, experiments 
involving genetic deletions and build-up of intermediates would have been challenging.  Thus, 
Dr. Zedu Huang, a former post-doctoral associate in the van der Donk group, started to 
reconstitute the biosynthesis of fosfazinomycin in vitro.   
 
1.4 METHYL-2-HYDROXY-2-PHOSPHONOACETIC ACID FORMATION IN 
FOSFAZINOMYCIN BIOSYNTHESIS 
 The fosfazinomycin BGC contains genes that encode for PepM and PnPy decarboxylase, 
FzmC and FzmD, respectively (Table 1.1).38  Thus, the in vitro investigation of fosfazinomycin 
biosynthesis began with PnAA.  The conversion of PnAA to Me-HPnA would minimally require 
oxidation of the aldehyde to a carboxylic acid, methylation of that carboxylic acid to the 
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corresponding methyl ester, and hydroxylation of the alpha carbon (Figure 1.5).  Recombinant 
FzmG, annotated by sequence identity as an α-ketoglutarate (α-KG) dependent non-heme iron 
dioxygenase, oxidized PnAA to phosphonoacetic acid (PnA) in in vitro assays.28  When PnA was 
incubated with recombinant FzmB, a SAM-dependent O-methyltransferase, about 90% 
conversion to the methyl ester product, methylphosphonoacetic acid (Me-PnA), was observed.  
Finally, FzmG, the same dioxygenase that catalyzed the oxidation of PnAA, was able to convert 
MePnA to Me-HPnA.   
 
 
Figure 1.5 The biosynthesis of Me-HPnA from PEP in the Fzm pathway.   
 
1.5 CONVERGENT BIOSYNTHESIS IN THE FOSFAZINOMYCIN PATHWAY 
 With the successful reconstitution of the activities of FzmBG, Dr. Huang turned to 
exploring how the biosynthesis of fosfazinomycin might proceed from Me-HPnA.  For example, 
the installation of the nitrogen-nitrogen (N-N) bond and of the arginine residue might proceed in 
an iterative manner; one nitrogen atom might be conjugated to the phosphorus atom of Me-
HPnA, generating a phosphonoamide species, before addition of another nitrogen atom, making 
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the N-N bond and a phosphonohydrazine species, followed by nucleophilic attack on the 
carboxyl group of arginine.  In another potential pathway, the N-N bond is preformed and 
attached to arginine; the resulting argininylhydrazine might then be conjugated to Me-HPnA.  In 
order to deconvolute these possibilities, Dr. Huang turned to investigating the substrate scope of 
FzmH, a SAM-dependent N-methyltransferase.  Fosfazinomycin contains an N-methyl group, 
and the timing of the installation of this group might give insight into the order in which the 
phosphonohydrazide linkage is formed.  FzmH was able to methylate argininylhydrazine at the 
expected position (Figure 1.6a).  However, when FzmH was incubated with the 
phosphonohydrazine 1.1, the phosphonoamide 1.2, or desmethyl-fosfazinomycin B, no 
conversions to the expected methylated products could be observed (Figure 1.6b).28  These 
results strongly suggest that fosfazinomycin is biosynthesized in a convergent manner, wherein 
Me-HPnA and argininylmethylhydrazine are constructed separately and brought together to form 
fosfazinomycin B in the late stages of the pathway.  Dr. Huang was further able to reconstitute 
the activity of FzmI, a tRNA-dependent peptidyltransferase that converts fosfazinomycin B into 




Figure 1.6 FzmH activity suggests a convergent biosynthetic route.  a FzmH methylates 
argininylhydrazine.  b FzmH was not able to methylate a number of alternative substrates.   
 
1.6 SUMMARY AND OUTLOOK 
 Fosfazinomycin represents a fascinating case in phosphonic acid natural product 
biosynthesis.  Work performed by Dr. Zedu Huang uncovered the biosynthetic route to Me-
HPnA, one half of the molecule.  Further, Dr. Huang showed that fosfazinomycin biosynthesis 
proceeds in a convergent manner with argininylhydrazine being formed as a discreet 
intermediate before methylation by FzmH.  Thus, broadly, two questions still remained.  First, 
how is argininylhydrazine formed, and second, how is argininylmethylhydrazine conjugated to 
Me-HPnA?  My work, presented in this thesis, was primarily concerned with elucidating how 
argininylmethylhydrazine is biosynthesized.   
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 In Chapter 2, I highlight my efforts to determine that aspartic acid is indeed the starting 
point for argininylhydrazine biosynthesis.  I discuss the production of fosfazinomycin from 
Streptomyces sp. NRRL S-149 and the optimization of that producing system for stable isotope 
labeling experiments.  I also describe my attempts to purify fosfazinomycin A from the native 
producing organism and spectroscopic studies to determine the location of isotope incorporation.   
 In Chapter 3, I describe the discovery of an unusual and modular biosynthetic strategy for 
the incorporation of N-N bonds into fosfazinomycin and kinamycin, a structurally disparate 
natural product that contains a diazo group.  Using additional feeding studies, protein refolding, 
and in vitro enzymatic assays, I demonstrated that a hydrazine-moiety is first made from nitrous 
acid and is placed onto the side chain of glutamic acid to make a recurring carrier molecule, 
glutamylhydrazine.   
 In Chapter 4, I discuss my ultimately failed efforts to reconstitute the enzymatic transfer 
of hydrazine from glutamylhydrazine onto arginine in fosfazinomycin biosynthesis.  I detail a 
variety of potential strategies to effect this transformation, focusing largely on FzmA, an 
asparagine synthetase homolog bearing an unusual PqqD-like domain.  I also describe the 
potential involvement of two other proteins, another PqqD homolog, and a nucleotidyltransferase 
homolog.   
Finally, Chapter 5 reports on the unsuccessful attempts to reconstitute the enzymatic 
formation of the N-N bond.  I describe a number of hypotheses for N-N bond formation as well 
as the development of a high-throughput screen to detect hydrazinosuccinic acid.  I also highlight 
the biochemical characterization of FzmP, a heme protein and my efforts to increase the 
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2.1.1 FzmNOPQR are implicated in N-N bond biosynthesis 
 A subset of the genes in the fosfazinomycin biosynthetic gene cluster is conserved with 
the gene clusters of other natural products that either contain or are thought to have biosynthetic 
intermediates that contain N-N bonds including the lomaiviticins, the kinamycins, and fluostatin 
(Figure 2.1).1  These five genes in the fosfazinomycin biosynthetic cluster encode for FzmN, a 
glutamine synthetase homolog; FzmO, an amidase homolog; FzmP, a hypothetical protein; 
FzmQ, a GCN5-related N-acetyltransferase; and FzmR; an adenylosuccinate lyase.  Since 
fosfazinomycin appears to be considerably different structurally than the lomaiviticins and the 
kinamycins except for the presence of an N-N bond, FzmNOPQR was hypothesized to be 
involved in the formation of the hydrazine moiety.  A more detailed treatment on these five 
proteins will be given in Chapter 3.   
 
Figure 2.1 The structures of kinamycin, lomaiviticin, and fluostatin.   
*Parts of this chapter is adapted and reproduced with permission from Huang, Z., Wang, K.K.A., 




2.1.2 FzmR liberates acetylhydrazine from N-acetylhydrazinosuccinic acid 
 As stated above, FzmR is a homolog of adenylosuccinate lyase, an enzyme involved in de 
novo purine biosynthesis in which it catalyzes two steps: the conversion of 5-aminoimidazole-
(N-succinylocarboxamide) ribotide (SAICAR) into 5-aminoimidazole-4-carboxamide ribotide 
(AICAR) and fumarate as well as the conversion of adenylosuccinic acid into adenosine 
monophosphate (AMP) and fumarate (Figure 2.2a).2  In both reactions a nitrogen atom derived 
from aspartic acid is ultimately transferred into or onto the purine ring after an elimination 
reaction.  Dr. Zedu Huang turned to investigating whether FzmR might catalyze a similar 
reaction during fosfazinomycin biosynthesis.  Dr. Huang first incubated recombinant FzmR with 
adenylosuccinic acid, one of the canonical substrates of adenylosuccinate lyase, but no reaction 
could be observed.  Likewise, FzmR was unable to catalyze the elimination of hydrazine from 
hydrazinosuccinic acid, a hydrazine-containing analog of aspartic acid (Figure 2.2b).3  However, 
when FzmR was incubated with N-acetylhydrazinosuccinic acid, the substrate was converted into 
acetylhydrazine and succinic acid (Figure 2.2c).  This reconstitution of FzmR activity provided a 
handle for further investigations into this branch of fosfazinomycin biosynthesis and began to 





Figure 2.2 Reactions catalyzed by adenylosuccinate lyase and FzmR.  a) Adenylosuccinate 
lyases catalyze elimination reactions, converting SAICAR to AICAR and adenylosuccinic acid 
to AMP during purine biosynthesis.  b) FzmR was unable to catalyze the elimination of 
hydrazinosuccinic acid.  c) FzmR was able to liberate acetylhydrazine from N-




2.1.3 FzmQ acetylates hydrazinosuccinic acid to yield N-acetylhydrazinosuccinic acid 
 Since N-acetylhydrazinosuccinic acid was found to be the substrate for FzmR, Dr. Zedu 
Huang attempted to elucidate the preceding step of the biosynthesis.  FzmQ, another one of the 
set of five proteins conserved with lomaiviticin and kinamycin biosynthetic enzymes, is a GCN5-
related N-acetyltransferase and might be responsible for the installation of the N-acetyl group on 
N-acetylhydrazinosuccinic acid.  Indeed, Dr. Huang found that FzmQ was able to form N-
acetylhydrazinosuccinic acid from hydrazinosuccinic acid and acetyl-CoA (Figure 2.3).3  
Further, Dr. Huang showed that this reaction appeared to be physiologically relevant by 
acquiring the kinetic parameters, finding a kcat of 2.1 ± 0.1 s-1, a KM (for hydrazinosuccinic acid) 
of 4.2 ± 0.8 μM, and a catalytic efficiency of 5 × 105 M-1 s-1.  Additionally, FzmQ was not able 
to accept aspartic acid, arginine, or glutamic acid as substrates.  These findings set the stage for 
my studies to determine if these in vitro reactions were physiologically relevant.   
 




2.2 RESULTS AND DISCUSSION 
2.2.1 Production of fosfazinomycin in Streptomyces sp. NRRL S-149 
 Dr. Jiangtao Gao, a former post-doctoral researcher in the van der Donk group, had 
previously demonstrated that Streptomyces sp. XY332 could produce fosfazinomycin.4  
However, in my hands, I was not able to observe reasonable levels of production from that 
organism.  Following some preliminary production screening results from Dr. Kou-San Ju, a 
former post-doctoral researcher in the Metcalf group, I attempted to elicit production of 
fosfazinomycin from Streptomyces sp. NRRL S-149.  A starting liquid culture of the organism 
was cultivated in ATCC Medium: 172 with N-Z Amine with Soluble Starch and Glucose (ATCC 
172), a rich medium.  After 3 d of cultivation the starter culture was used to inoculate a 
production culture in R2AS medium.  After an additional 3 d, fosfazinomycin A could be 
detected in the spent medium by 31P NMR spectroscopy.  The exact conditions used are 
described in 2.4.2 in the methods section of this chapter.  Having established conditions in which 
a producing organism produces fosfazinomycin, I then moved on to further optimize the 
production of fosfazinomycin for stable isotope incorporation studies.   
 The production medium used for initial production, R2AS, contains three major sources 
of nitrogen: yeast extract, peptone, and casamino acids.  These sources of nitrogen could 
interfere with the incorporation of exogenous 15N-labeled precursors in the projected studies.  
Thus, I replaced all three of the above components with 3.8 mM NH4Cl (mod-R2AS); 
gratifyingly, fosfazinomycin was still detected in the spent medium despite the apparently 
smaller cell mass recovered at the end of production.  Unfortunately, when I cultivated 
Streptomyces sp. NRRL S-149 in mod-R2AS supplemented with 15N-Asp, there was no apparent 
incorporation of 15N-isotope into fosfazinomycin.  One explanation for this result is merely that 
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aspartic acid is not a precursor compound for fosfazinomycin.  However, Dr. Ju suggested 
another possibility regarding the culturing conditions employed.  It should be noted that in this 
experiment, the production culture was inoculated from a starter culture of ATCC 172, a rich 
medium.  Dr. Ju hypothesized that since the organism had been cultivated in rich media prior to 
the inoculation of the relatively minimal mod-R2AS production culture, the cells’ metabolism 
had become accustomed to uptaking amino acids and peptides as nitrogen sources.  Thus, when 
aspartic acid was given in the production media, the cells preferentially utilized aspartic acid 
over the NH4Cl for a general nitrogen source.  As a result, the nitrogen atom from aspartic acid 
primarily entered central metabolism rather than entering the fosfazinomycin biosynthetic 
pathway.  Thus, I changed the medium of the starter culture to mod-R2A (mod-R2A without 
sodium succinate and Balch’s vitamins) in order to acclimate the cells to utilize NH4Cl as the 
sole source of nitrogen.  31P NMR analysis suggested that fosfazinomycin could still be produced 
using this new scheme (Figure 2.4ab).  The experimental details are outlined in 2.4.3 in the 
methods section of this chapter.  The assignment of the resonance as fosfazinomycin A was then 





Figure 2.4 Fosfazinomycin A is produced by Streptomyces sp. NRRL S-149 in defined media.  
a) 31P NMR spectrum showing the presence of fosfazinomycin A (13.8 ppm) in the spent 
medium.  b) 1H-31P HMBC (homonuclear multiple bond correlation) NMR spectrum of 
fosfazinomycin A from the spent mediu with assigned cross peaks.  c) 31P NMR spectra of 
synthetic fosfazinomycin A, the spent medium, and spent medium spiked with a synthetic 
fosfazinomycin A standard.  The standard was composed of four diastereomers which resulted in 
four resonances in the 31P NMR spectra.  d) Mass spectrum of fosfazinomycin A ([M+H]+ = 
454) from spent culture medium. 
 
2.2.2 Design of isotope labeling experiments 
 In the experimental scheme outlined thus far, aspartic acid was added to the production 
culture at the onset of cultivation, and the culture was allowed to grow for an additional 3 d 
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before analysis.  Therefore, another source of uncertainty during the proposed labeling 
experiments was the scrambling of the 15N-label by primary metabolism.  For instance, the 
aspartic acid amino group is donated directly to the make the guanidinyl group of arginine.  
Further, the combined activities of aspartate transaminase, glutamate dehydrogenase, and the 
GS/GOGAT cycle can transfer nitrogen atoms from aspartic acid to a variety of amino acids and 
other metabolites (Fig 2.5).5   
 
 
Figure 2.5 Central metabolism can transfer the nitrogen atom on aspartic acid to many locations. 
 
 Thus, I designed a scheme in which a relatively large concentration of 15N-labeled 
aspartic acid would be provided to the Streptomyces sp. NRRL S-149 immediately before the 
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onset of fosfazinomycin production.  Additionally, the culture would be harvested after a 
relatively short time (4 h) to combat the proliferation aspartic acid nitrogen atom throughout 
central nitrogen metabolism.  The experimental details for cultivation are provided in 2.4.4.   
 
2.2.3 Aspartic acid is incorporated into fosfazinomycin A 
 With a satisfactory methodology in hand, I turned my attention towards measuring the 
incorporation of the aspartic acid nitrogen into fosfazinomycin A.  When the fosfazinomycin 
producing organism Streptomyces sp. NRRL S-149 was grown in media containing 15NH4Cl and 
15N-aspartic acid, a doublet signal was observed for fosfazinomycin by 31P NMR spectroscopy (J 
= 10.2 Hz), and MS analysis revealed a peak corresponding to fosfazinomycin A with seven 15N-
incorporations ([M+H]+ = 461) (Figure 2.6ab).  When 15N-labeled aspartic acid was added after 
40 h to medium containing NH4Cl at natural abundance, the doublet was replaced by two 
overlapping signals (Figure 2.6c).  MS analysis showed that the majority of fosfazinomycin was 
unlabeled and a minor fraction contained one 15N atom (Figure 2.6d).  These findings suggest 
that the NMR peaks are made up of a singlet from unlabeled fosfazinomycin A and a smaller 
doublet from material that contains at least one 15N atom in the phosphonohydrazide linkage.  
When unlabeled aspartic acid was used along with 15NH4Cl, again two signals were observed by 
31P NMR spectroscopy (Figure 2.6e).  MS analysis indicated that the majority of the sample 
contained seven 15N atoms and that in about 40% of the samples, one of the 15N atoms was 
replaced by an unlabeled nitrogen atom that must come from aspartic acid (Figure 2.6f).  This 
observation suggests that the incorporation is specific and not the result of scrambling.  
Collectively, these findings indicate that nitrogen from exogenously supplied aspartic acid is 




Figure 2.6 Aspartic acid is incorporated into the phosphonohydrazide linkage of fosfazinomycin.  
31P NMR and MS analysis of fosfazinomycin A produced by Streptomyces sp. NRRL S-149 
cultivated with (a, b) 15NH4Cl and 15N-aspartic acid, (c, d) unlabeled NH4Cl and 15N-aspartic 
acid and (e, f) 15NH4Cl and unlabeled aspartic acid. 
 
 With the currently described labeling data, it is not possible to conclusively determine 
whether both of the nitrogen atoms in the hydrazine moiety derive from aspartic acid. Examining 
the MS data for fosfazinomycin A produced in medium containing 15NH4Cl and aspartic acid (at 
natural isotopic abundance) (Figure 2.6f), the relative abundance of analyte with zero, one, two, 
and three 14N-incorporations could be determined experimentally by subtracting the isotope 
pattern of fosfazinomycin at natural isotopic abundance (Figure 2.4d).  This subtraction 
accounts for the isotopic distribution primarily arising from natural 13C abundance and gives the 
normalized abundance pattern of fosfazinomycin A (Figure 2.7a).  If only one of the nitrogen 
atoms in the hydrazine moiety comes from aspartic acid, then the relative abundance of doubly 
incorporated material would be zero (assuming nonspecific labeling does not take place). 
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However, if it is assumed that aspartic acid is the biosynthetic origin of both nitrogens (and again 
ignoring nonspecific incorporation), then the predicted relative abundance of doubly 14N-
incorporated material (8.6, see below) matches very well with the experimental value (8.3) 
(Figure 2.7a, green bar in experimental cluster of graphs). 
 
Figure 2.7 Analysis of the isotope distribution for fosfazinomycin A produced with 15NH4Cl and 
unlabeled aspartic acid.  a) The experimental relative abundances of fosfazinomycin A with zero, 
one, two, or three nitrogen incorporations from aspartic acid compared to predicted abundances 
assuming either one or two incorporations of nitrogen into the phosphonohydrazide moiety.  b) 
The theoretical partitioning of nitrogen into the phosphonohydrazide moiety.  As nitrogen atoms 
enter fosfazinomycin biosynthesis, the N-N bond is built.  The asterisk denotes a nitrogen atom 
originating from aspartic acid.   
 
The prediction of 8.6 was made as follows.  The experimental mass spectrum of 
fosfazinomycin produced from medium containing 15NH4Cl and unlabeled aspartic acid shows 
that the relative abundances of no 14N incorporations and one 14N incorporation are 100 and 58.7, 
respectively (Figure 2.7a, blue and red bars, respectively). However, the mass spectrometer 
cannot distinguish between nitrogen incorporation at the two different sites of the hydrazine. If 
both sites are assumed to originate from aspartic acid, the abundance of fosfazinomycin labeled 
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at each site in the doubly labeled material would be 29.35 (58.7
2
= 29.35). The partitioning of the 
aspartic acid nitrogen compared to nitrogen arising from 15NH4Cl into fosfazinomycin can then 





= 22.7% (i.e., 22.7% of the hydrazine nitrogens come from unlabeled 
exogenous Asp and 77.3% from endogenously biosynthesized 15N-Asp) (Figure 2.7b).   
Since this partitioning is assumed to arise from the relative concentrations of labeled and 
unlabeled aspartic acid within the cell at the time of fosfazinomycin biosynthesis, it is assumed 
to be the same for both nitrogens.  Thus, the predicted relative abundance of double labeled 
fosfazinomycin (x) can be solved for according to the partitioning scheme shown in Figure 2.7b 
(22.7% =  𝑥
𝑥+29.35
).  Solving for x reveals that double 14N-containing fosfazinomycin would be 
expected to have a relative abundance of 8.6, which is in good agreement with the experimental 
value of 8.3 (Figure 2.7ab).   
However, throughout this prediction, it is assumed that the 14N from Asp does not 
scramble into any other positions.  There is almost certainly some degree of nonspecific labeling 
as the exogenously provided aspartic acid is assimilated into primary metabolism.  Indeed, a 
small amount of triply 14N-labeled material is observed (Figure 2.7a).  Thus, currently, it is not 
possible to unambiguously conclude that both nitrogens derive from Asp since the NMR data 
also do not have sufficient resolution to unambiguously settle the question.   
 
2.2.4 Partial purification of fosfazinomycin A 
 In order to determine which nitrogen in the phosphonohydrazide moiety generates the 
10.2 Hz coupling constant with the phosphorus atom in 31P NMR analysis, uniformly 15N-labeled 
fosfazinomycin was generated by cultivating 105 L of Streptomyces sp. NRRL S-149 in mod-
R2AS containing 15NH4Cl and 15N-labeled aspartic acid as the sole nitrogen sources.  The spent 
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medium was concentrated and subjected to methanol precipitation.  Solid phase extraction was 
then performed with Oasis HLB resin.   
 Attempts to purify fosfazinomycin A using Fe-IMAC or high performance liquid 
chromatography (HPLC) with silica bonded stationary phases (e.g., an Eclipse XDB-C18 column 
or an Atlantis HILIC silica column) resulted in the complete hydrolysis of fosfazinomycin at the 
N-P bond.  Interestingly, the use of a polymer-silica hybrid stationary phase seemed to combat 
fosfazinomycin degradation.  Indeed, the previous LC-MS analyses used in the labeling studies 
were performed using an Xbridge C18 column (ethylene-bridged polymer-silica hybrid bonded 
phase).  Due to the potential for high resolution through HPLC, purification using the 
aforementioned Xbridge C18 column was chosen moving forward.   
 In order to decrease the sample loading for HPLC, size exclusion chromatography (SEC) 
using Sephadex G25 resin in a 2.5 x 160 cm column was used.  Fractions containing 
fosfazinomycin were identified by direct flow mass spectrometry.  Another round of SEC using 
Sephadex LH-20 resin was also performed, but no apparent improvement in purity could be 
observed.  Using the existing method for LC-MS analysis of fosfazinomycin A, the relevant 
fractions from SEC were fractionated by HPLC.  A fraction, collected by retention time, was 
analyzed by 1H NMR spectroscopy and 1H-1H total correlation spectroscopy (TOCSY).  The 
TOCSY analysis suggested that resonances arising from impurities were largely contained within 
six 1H-1H spin systems.  An optimized HPLC method was then used to further decrease the 
number of impurities.  The process for HPLC method optimization is described in 2.4.7 in the 
methods section of this chapter.  Further HPLC purification using a porous graphitic carbon 
(PGC) stationary phase was also optimized.  However, due to concerns regarding sample 




2.2.5 Spectroscopic investigation of the N-P coupling constant 
 The semi-purified material after HPLC cleanup with the Xbridge C18 column was 
subjected to NMR analysis with the goal of determining which nitrogen atom in the 
phosphonohydrazide linkage yields a 10 Hz coupling constant with the phosphorus atom.  The 
most straightforward strategy would be to perform a 1D 15N NMR analysis to directly measure 
the J constants on the nitrogen nuclei.  Unfortunately, the sample yield from purification was too 
low to give the desired sensitivity and spectral resolution.   
 Implementation of a different strategy was performed with the help of Dr. Lingyang Zhu 
(The NMR Lab of the School of Chemical Sciences, UIUC) on a 750 MHz instrument.  1H-31P 
HMBC spectroscopy identified the Me-HPnA α-proton at 4.44 ppm and the N-methyl group at 
2.75 ppm (Figure 2.8a).  It should also be noted that a large amount of degradation was observed 
(cross peaks at (4.38, 10.95 ppm) and (3.67, 10.95 ppm)).  1H-15N CIGAR-HMBC identified 
both the 15N nuclei in the hydrazide linkage at 143 and 173 ppm coupled to the N-methyl protons 
(Figure 2.8b).  A cross-peak arising from the 15N peak at 173 ppm to the Me-HPnA α-proton at 
4.44 ppm allowed the assignment of that nitrogen atom to the proximal position.  Another 1H-15N 
CIGAR HMBC was then performed using a reduced spectral window, and the spectral resolution 
along the 15N dimension was increased to approximately 7 Hz to observe the 10 Hz 31P-15N 
coupling constant.  However, this experiment did not yield useful data due to sample degradation 
occurring during the 5 d required to acquire the various spectra.  Indeed, 1D 1H NMR slices 
taken over the duration of the 1H-15N CIGAR-HMBC experiments show the continuous 




Figure 2.8 NMR analysis of semi-purified fosfazinomycin A.  a) 1H-31P HMBC spectrum 
identifies the N-methyl group at 2.75 ppm.  A large amount of degradant can also be observed.  
The f1 dimension represents 15N and the f2 dimension 1H chemical shifts.  b) 1H-13C CIGAR-
HMBC spectrum assigns the phosphonohydrazide nitrogen atoms (173.0 and 143.0 ppm).  The 
f1 dimension represents 15N and the f2 dimension 1H chemical shifts.  c) 1H NMR spectra taken 
at 1, 2, 3, and 4 d during 1H-13C CIGAR HMBC acquisition shows degradation of 
fosfazinomycin.  The N-methyl group on fosfazinomycin is indicated by the red circle.   
 
 Material from another 20 L of culture was then produced, harvested, and fractionated by 
SEC with G25 resin.  This new material was combined with the mostly degraded NMR sample 
from above and further fractionated by HPLC.  This combined sample was subjected to NMR 
analysis.  In an attempt to slow the degradation of the sample, a probe temperature of 4 ˚C was 
first used; however, this lead to an unacceptable loss in spectral resolution.  Thus, the 
temperature of the probe was raised to 10 ˚C.  As before, 1H-31P-HMBC analysis identified the 
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N-methyl group at 2.75 ppm (Figure 2.9a).  A 1H-15N-CIGAR-HMBC experiment again 
identified the two phosphonohydrazide 15N-signals at 144.0 ppm and 173.4 ppm (Figure 2.9b).  
The 1H-15N-CIGAR-HMBC experiment with a reduced spectral window was again attempted.  
Cross peaks at (2.75, 144 ppm) and (2.75 ppm, 173 ppm) were again observed (Figure 2.9c).  
Extracting the 15N-dimension at 2.75 ppm in the 1H-dimension revealed a singlet at 144.0 ppm 
(the distal nitrogen) and a doublet (J ~9 Hz) at 173.4 ppm (the proximal nitrogen) (Figure 2.9d).  
The results here show that it is indeed the nitrogen adjacent to the phosphorus in the 
phosphonohydrazide linkage that gives rise to the observed 10 Hz coupling constant.  Further, 
the chemical shift of the distal nitrogen (144 ppm) is consistent with the published assignment of 




Figure 2.9 NMR analysis of pooled semi-purified fosfazinomycin A.  a) 1H-31P HMBC 
spectrum assigns the N-methyl group at 2.74 ppm.  b) 1H-13C CIGAR-HMBC spectrum assigns 
phosphonohydrazide nitrogen atoms.  c) 1H-13C CIGAR-HMBC spectrum with decreased 
spectral window.  d) 1D 15N NMR slice generated from the 1H-13C CIGAR-HMBC spectrum at 
2.74 ppm in the 1H dimension shows that the proximal nitrogen atom at 173 ppm is a doublet 
with a coupling constant of 8.9 Hz.  e) The structure of geralcin C with assigned 15N NMR 
chemical shifts.6   
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2.3 SUMMARY AND OUTLOOK 
 The phosphonohydrazide moiety of fosfazinomycin is an unusual structural feature.  The 
reconstitution of the activities of FzmQ and FzmR by Dr. Zedu Huang provided the handle 
necessary to begin to investigate how the N-N bond is crafted.  The labeling studies with aspartic 
acid corroborated the hypothesis that the entry point for this branch of the biosynthetic pathway 
is indeed aspartic acid.  In Chapter 3, I will address our efforts to discover how the nitrogen atom 
from aspartic acid is incorporated into fosfazinomycin.   
 This initial study also yielded useful methodology for further studies regarding 
fosfazinomycin.  The time spent developing cultivation conditions yielded an optimized 
producing system which has since been leveraged for feeding a variety of additional putative 
intermediates (Chapter 3).  While the attempted purification of fosfazinomycin A was largely 
unsuccessful due to both low production and the ease with which the molecule degrades, enough 
material was eventually accumulated in a semi-purified state for the requisite NMR experiments.  
The spectroscopic analysis confirmed that aspartic acid donates its nitrogen atom to, at the very 
least, the hydrazino-nitrogen atom proximal to the phosphorus center in fosfazinomycin.  
Additionally, the optimized HPLC methodology enabled improved LC-MS analysis (Chapter 3).  
One aspect that might be worth revisiting is the Streptomyces lividans TK 24 strain MMG604 
that was constructed by the Metcalf group.  RT-qPCR can be used to determine whether all of 
the genes in the fzm cluster are being transcribed, and undirected metabolomics can be used to 







2.4.1 General methods 
 Unless otherwise noted, all NMR experiments were conducted with an Agilent 600 MHz 
with a OneNMR broadband probe, and the data was analyzed with MestreNova software.   
 
2.4.2 Initial production of fosfazinomycin A in Streptomyces sp. NRRL S-149  
 A frozen 10% glycerol stock of Streptomyces sp. NRRL S-149 was used to streak an R2A 
plate (0.05% yeast extract, 0.05% peptone, 0.05% casamino acids, 0.05% soluble potato starch, 
2.8 mM glucose, 2.7 mM sodium pyruvate, 0.9 mM potassium phosphate dibasic, 0.2 mM 
magnesium sulfate heptahydrate, 1.5% agar).  After incubation at 30 °C for 3 d, a single colony 
was used to inoculate 5 mL of ATCC Medium: 172 with N-Z Amine with Soluble Starch and 
Glucose (ATCC 172, 55.5 mM glucose, 10.0 mM calcium carbonate, 2% soluble starch, 0.5% 
yeast extract, 0.5% N-Z Amine Type A).  After 3 d at 30 °C on a roller drum, 1 mL of the starter 
culture was used to inoculate 25 mL of R2AS medium (0.05% yeast extract, 0.05% peptone, 
0.05% casamino acids, 0.05% soluble potato starch, 2.8 mM glucose, 2.7 mM sodium pyruvate, 
0.9 mM potassium phosphate dibasic, 0.2 mM magnesium sulfate heptahydrate, 40 mM sodium 
succinate, 0.5% Balch’s vitamins).  After 3 d, the cell mass was removed by centrifugation, and 
the spent media was concentrated to ~2 mL by rotary evaporation.  Methanol precipitation was 
performed by adding 8 mL of methanol, and the mixture was cooled at -20 °C for 30 min.  The 
precipitate was then removed by centrifugation, and the supernatant was concentrated to dryness 
by rotary evaporation.  The material was redissolved in ~600 μL of D2O for NMR analysis.  (See 




2.4.3 Production of fosfazinomycin using an R2A starter culture 
 As described above, a frozen 10% glycerol stock of Streptomyces sp. NRRL S-149 was 
used to streak an R2A plate, and after 3 d at 30 °C, a single colony was used to inoculate 5 mL of 
ATCC 172.  The starter culture was then incubated for another 3 d at 30 °C on a roller drum.  
Then, 1 mL of this starter culture was then used to inoculate a seed culture consisting of 25 mL 
of mod-R2A (3.8 mM ammonium chloride, 0.05% soluble potato starch, 2.8 mM glucose, 2.7 
mM sodium pyruvate, 0.9 mM potassium phosphate dibasic, 0.2 mM magnesium sulfate 
heptahydrate) in a baffled 125 mL flask.  After shaking at 180 rpm for 3 d at 30 °C, 20 mL of 
this seed culture was used to inoculate 500 mL of mod-R2AS (3.8 mM ammonium chloride, 
0.05% soluble potato starch, 2.8 mM glucose, 2.7 mM sodium pyruvate, 0.9 mM potassium 
phosphate dibasic, 0.2 mM magnesium sulfate heptahydrate, 100 µM aspartic acid, 40 mM 
sodium succinate, 0.5% Balch's vitamins).  When conducting the preliminary labeling 
experiments, ammonium chloride or aspartic acid were replaced by ammonium chloride [15N, 
99%, Cambridge Isotope Laboratories] and 100 µM L-aspartic acid [15N, 98%, Cambridge 
Isotope Laboratories], respectively at the same concentration.  After 3 d shaking (180 rpm) at 30 
˚C, the culture was harvested and processed as described in section 2.4.2.  (See NB entry for 12-
8-18) 
 
2.4.4 Biotransformation of aspartic acid 
 As described above, a frozen 10% glycerol stock of Streptomyces sp. NRRL S-149 was 
used to streak an R2A plate, and after 3 d at 30 °C, a single colony was used to inoculate 5 mL of 
ATCC 172.  The starter culture was then incubated for another 3 d at 30 ˚C on a roller drum.  An 
aliquot of 1 mL of the seed culture in R2A medium was used to inoculate production cultures in 
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50 mL of modified R2AS media (3.8 mM ammonium chloride, 100 µM L-aspartic acid, 0.05% 
soluble potato starch, 2.8 mM glucose, 2.7 mM sodium pyruvate, 0.9 mM potassium phosphate 
dibasic, 0.2 mM magnesium sulfate heptahydrate, 40 mM sodium succinate, 0.5% Balch's 
vitamins) in 250 mL baffled flasks.  After 40 h of shaking at 200 rpm at 30 °C, aspartic acid 
(15N, 98%, Cambridge Isotope Laboratories) was added to a final concentration of 1 mM. After 
an additional 4 h shaking at 200 rpm at 30 ˚C, the spent media was separated from the cell mass 
by centrifugation. The supernatant was then dried under reduced pressure. The dried spent media 
was extracted three times with 1 mL of methanol. The methanol extract was then dried under 
reduced pressure and the residue reconstituted to 5 mL with distilled water.  Solid phase 
extraction was then performed with an Oasis HLB 100 mg cartridge.  The sample was applied 
onto the resin and washed with 20 mL of distilled water and 20 mL of 5% methanol (v/v in 
distilled water).  Fosfazinomycin A was then eluted from the resin with 15 mL of 20% methanol.  
The eluate was then dried by rotary evaporation and reconstituted in 600 µL of D2O for NMR 
and LC-MS analysis.  Complementary experiments with different combinations of 15N-labeled 
and unlabeled aspartic acid and NH4Cl were also conducted.  (See NB entry series starting on 1-
19-16) 
 
2.4.5 LC-MS analysis of spent media containing fosfazinomycin 
 LC-MS analysis was performed on an Agilent 1100 series LC system coupled to an 
Agilent G1956B single quadrupole mass spectrometer with a Waters XBridge BEH 5µ C18 
column (4.6 mm x 250 mm) using a mobile phase of water (solvent A) and acetonitrile (solvent 
B) at a flow rate of 0.200 mL min-1. The following gradient was used for analysis of 
fosfazinomycin A: 5% B for 5 min, from 5% B to 35% B over 30 min, from 35% B to 95% B 
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over 5 min, holding at 95% B for 15 min, and from 95% B to 5% B over 10 min.  The spectra 
were processed with Agilent ChemStation software before being replotted in Microsoft Excel.  
The percent incorporations of the nitrogen from aspartic acid in samples derived from the 
producing organism grown in 15N-labeled media were calculated after subtracting the mass 
spectrum of fosfazinomycin A at natural abundance.  Thus, the values were already adjusted for 
the presence of natural abundance 13C, which is indicated as normalized abundance.  (See NB 
entry for 1-28-16) 
 
2.4.6 Large scale production of uniformly 15N-labeled fosfazinomycin 
 A 10% glycerol stock of Streptomyces sp. NRRL S-149 was used to streak onto a R2A 
agar.  After an incubation period of 3 d at 30 °C, a single colony was picked and used to 
inoculate 25 mL of liquid ATCC172 media.  The ATCC172 starter cultures were then incubated 
for 3 d at 30 °C on a rolling drum.  The starter cultures were combined, and 1 mL each of the 
starter culture were then used to inoculate ten secondary seed cultures of 25 mL of mod-R2A 
media in 125 mL baffled flasks.  The modified R2A seed cultures were then incubated at 30 °C 
on a shaker at 200 rpm for 3 d.  The ten flasks were then mixed together and 20 mL of the 
modified R2A starter culture were used to inoculate each of ten 500 mL cultures of uniformly 
15N-labeled modified R2AS production media [3.8 mM ammonium chloride [15N, 99%, 
Cambridge Isotope Laboratories], 100 µM L-aspartic acid [15N, 98%, Cambridge Isotope 
Laboratories], 0.05% soluble potato starch, 2.8 mM glucose, 2.7 mM sodium pyruvate, 0.9 mM 
potassium phosphate dibasic, 0.2 mM magnesium sulfate heptahydrate, 40 mM sodium 
succinate, 0.5% Balch's vitamins] in 2 L baffled flasks. After 3 d at 30 ˚C on a shaker at 200 
rpm, the spent media was separated from the cell mass by centrifugation.  The spent media was 
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then concentrated to approximately 40 mL by rotary evaporation.  Then, 160 mL of methanol 
was added, and the mixture was cooled at -20 °C for 1 h, and the precipitates were removed by 
centrifugation.  The supernatant was again dried under reduced pressure and extracted three 
times with 30 mL quantities of methanol.  The methanol extract was then concentrated to dryness 
before being reconstituted to 15 mL in distilled water. Solid phase extraction was then performed 
with a 600 mg Oasis HLB resin cartridge; the sample was applied onto the resin and washed with 
20 mL of distilled water. Fosfazinomycin A was then eluted from the resin with 15 mL of 20% 
methanol (in water). The eluate was then dried by rotary evaporation.  This process was repeated 
21 times to accumulate material from 105 L of total culture.  (For example, see NB entry series 
starting on 11-2-15) 
 Material from between 10 and 20 L of production culture were reconstituted to about 10 
mL in distilled water and applied onto a ~2.5 x 160 cm column packed with Sephadex G-25 fine 
grade resin at 4 °C.  A mobile phase of distilled water was used at a flow rate of approximately 
1.5 mL s-1.  Fractions of 10 to 15 mL were collected by hand and screened for the presence of 
fosfazinomycin by direct flow mass spectrometry.  Briefly, 10 μL of each fraction was injected 
into the flow path of 10% acetonitrile in water at 0.500 mL min-1 in a Agilent 1100 series LC 
system coupled to an Agilent G1956B single quadrupole mass spectrometer.  Uniformly 15N-
labeled fosfazinomycin was monitored for in positive selected ion monitoring (SIM) mode at m/z 
461.  Each fraction was analyzed for 1 min.  (See NB entry for 12-1-15) 
 
2.4.7 HPLC method optimization 
All optimization was carried out on an Agilent 1100 series LC system coupled to an 
Agilent G1956B single quadrupole mass spectrometer.  An existing method used previously for 
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LC-MS analysis of fosfazinomycin A with the Xbridge C18 column (4.6 x 250 mm, 5μ) using a 
mobile phase of water and acetonitrile was first evaluated for chromatographic resolution.  A 
method consisting of a gradient of 5% to 35% acetonitrile over 30 min after a 5 min isocratic 
hold at 5% acetonitrile and a flow rate of 0.200 mL min-1 was used.  The peak shape and 
retention time of fosfazinomycin A were visualized by inline mass spectrometric analysis in SIM 
mode for 15N7-fosfazinomycin (m/z 461) (Figure 2.10a).  A fraction was collected by retention 
time, starting and ending at the extreme ends of the band, and analyzed by 1H NMR spectroscopy 
(Figure 2.10b).  I was able to assign several of the resonances; however, there appeared to still 
be a number of impurities within the sample.  The retention time (tr) of fosfazinomycin A using 
the above method was 16.10 min and the peak full width at half height (w1/2) was 1.14 min.   
 
Figure 2.10 Initial HPLC method parameters.  a) A chromatogram generated from SIM mode at 
m/z 461 for 15N7-fosfazinomycin with calculated values for N (1106.17) and kʹ (0.142).  b) 1H 
chemical shift assignment for fosfazinomycin A.  c) A 1H NMR spectrum of material collected 
from the band shown in panel a.  Putative resonances arising from fosfazinomycin are indicated.   
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Chromatographic resolution (R), defined as the difference in retention time between two 
species (a and b) divided by the sum of their respective w1/2 values (eq. 2.1), is in principle a 
function of theoretical plates (N), selectivity (α), and capacity factor (kꞌ) (eq. 2.2).7-8  N can be 
calculated directly from the chromatogram using tr and w1/2 for a given analyte (eq. 2.3).8  kꞌ can 
likewise be calculated as the quotient of the difference between tr and the hold-up volume (tm) 
(eq. 2.4).8  It should be noted that eq. 1 presents the relationship of retention time with capacity 
factor in an isocratic system.  Since the methods discussed in this chapter predominantly employ 
gradients, the kʹ values reported here are not true representations of the chromatographic 
equilibrium constants.  Rather kʹ values are only used as an estimation of how well the analyte is 
retaining.  Here the tm was estimated roughly as 68% of the empty column volume.  Finally α is 
defined as the quotient of the kꞌ values of the two species (eq. 2.5).8   
𝑅 = 𝑡𝑟𝑎−𝑡𝑟𝑏
𝑤1/2𝑎−𝑤1/2𝑏
      (eq. 2.1) 










      (eq. 2.3) 
𝑘ꞌ = 𝑡𝑟−𝑡𝑚
𝑡𝑚
      (eq. 2.4) 
𝛼 = 𝑘ꞌ𝑏
𝑘𝑎
       (eq. 2.5) 
Thus, the N and kꞌ were determined for fosfazinomycin A using the gradient method 
above to be 1106 and 0.14 respectively (Figure 2.10a).  The α-values for fosfazinomycin and 
any of the overlapping impurity chromatographic bands were not determined since the putative 
impurities were unknown and thus could not be monitored by LC-MS.  In principle, increasing 
only N and kꞌ for fosfazinomycin A will also increase resolution (eq. 2.2) as long α≠1.7  Since 
optimizing kꞌ should, in principle, have a greater mathematical impact on resolution (eq. 2.2), 
increasing the general retentiveness of the method was initially prioritized.  The initial method 
used a linear gradient from 5% to 35% acetonitrile over 30 min (change of 1% min-1) with a flow 
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rate of 0.200 mL min-1.  In order to increase overall retention (increase kꞌ) a revised gradient 
from 5% to 20% (change of 0.5% min-1) was used.  The old flow rate of 0.200 mL min-1 was 
originally used only to elicit better ionization with the electrospray source; thus, it was also 
increased to 1.000 mL min-1 in order to decrease run time and to increase gradient strength.  The 
resulting chromatogram showed a substantial increase in both N (17770 from 1106) and kꞌ (0.22 
from 0.14) representing a 2.9 fold increase in resolution compared to the previous method.   
Since fosfazinomycin A was still eluting very early in the method, a series of isocratic 
methods were run with varying fraction volumes (Φ) of ACN in water (flow rate of 1.000 mL 
min-1) in order to further increase kꞌ (Figure 2.11a).  An increase in kꞌ could be observed with 
decreasing Φ as expected.  However, a concomitant loss of N was also observed when Φ 
decreased below 0.05.  Plotting Φ against ln kꞌ in accordance with linear solvent strength theory 
revealed that the theoretical capacity factor at Φ=0 (kꞌw ) would be 1.43 (eq. 2.6) (Figure 
2.11b).7  Taking phase collapse into consideration, however, it was not feasible to decrease Φ 
much below 0.02.  Thus, it seemed that the stationary phase simply offered only weak retention, 
and further efforts to optimize around kꞌ would ultimately be futile.   
ln 𝑘ꞌ = 𝑙𝑛 𝑘ꞌ𝑤 + 𝑆𝛷     (eq. 2.6) 
 
Figure 2.11 Attempts at optimizing an isocratic method.  a) Fractional volume of ACN (Φ) was 
varied and N and kʹ were calculated from tr and w1/2.  ln kʹ was plotted against Φ in accordance 
with linear solvent strength theory. 
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After failures with HILIC phase HPLC (Xbridge HILIC 5µ, 4.6x250 mm and Atlantis HILIC 5µ, 
4.6x250 mm) and a mixed-mode stationary phase (Synergi Fusion-RP 4µ, 4.6x150 mm) to 
provide either superior retention or acceptable sample recovery, the preliminary improved 
gradient method (5% to 20% acetonitrile in 30 min at 1.000 mL min-1) was revisited.  
Optimization of N was performed in accordance with the van Deemter equation (eq. 2.7) where 
the height equivalent of a theoretical plate (H) is related to the mobile phase linear velocity (µ).  
H is inversely related to N through the length (L) of the column (eq. 2.8).8  The flow rate was 
varied while maintaining the same gradient space and strength (Figure 2.12a).  Further 
mathematical van Deemter analysis showed that a flow rate of about 0.500 mL min-1 was indeed 
optimal for N yielding a final 3.5-fold increase in resolution when compared to the very original 
gradient method (Figure 2.12b).  It should be noted that H was plotted against flow rate and not 
µ; however, since the same column was being used and H and µ are directly related through the 
cross-sectional area of the column, H and µ will be linearly correlated. 
𝐻 = 𝐴 + 𝐵
µ
+ 𝐶µ     (eq. 2.7) 
𝐻 = 𝐿
𝑁
      (eq. 2.8) 
This optimized method was abbreviated to 5% to 7.5% acetonitrile in 10 min (flow rate 












Figure 2.12 The optimization of flow rate leads to an improved method.  a) Flow rate is charted 
against tr and w1/2, which were used to calculate N and kʹ.  b) van Deemter analysis of H vs. flow 
rate.  c) A chromatogram of the optimized method (5.0% to 7.5% acetonitrile in 10 min, F = 
0.500) generated from SIM mode at m/z 461 for 15N7-fosfazinomycin A.   
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CHAPTER 3: THE ROLE OF NITRITE AND THE GLUTAMIC ACID SCAFFOLD IN 
THE BIOSYNTHESIS OF FOSFAZINOMYCIN 
 
3.1 INTRODUCTION 
3.1.1 Diversity and bioactivity of natural products containing nitrogen-nitrogen bonds 
More than 200 natural products containing nitrogen-nitrogen (N-N) bonds have been identified 
with various bioactivities (Figure 3.1a).1  For instance, streptozotocin, a nitrosamine-containing 
compound, exhibits cytotoxic activity and is currently deployed clinically in the treatment of 
gastrointestinal and pancreatic cancers,2 and valanimycin, featuring an azoxy group, is a broad-
spectrum antimicrobial that also displays cytotoxicity towards mouse leukemia cells.1   
Other examples are azamerone containing a pyridazine,3 kutzneride with a piperazic acid,2, 4 the 
fosfazinomycins having a phosphonohydrazide,5 and a group of molecules including 





*Parts of this chapter are adapted and reproduced with permission from Wang, K.K.A., Ng, T.L., 
Wang, P., Huang, Z., Balskus, E.P., van der Donk, W.A. Glutamic acid is a carrier for hydrazine 






Figure 3.1 Structures of compounds discussed in this chapter.  a) Structures of a select group of 
N-N bond-containing natural products.  b) Structures of biosynthetic intermediates discussed in 
this chapter.   
 
3.1.2 N-N bond formation in other natural products 
 Despite the diversity of N-N bonds found in natural products, relatively little is currently 
known about their biosyntheses.  Based on the available biosynthetic gene clusters, the 
biosynthetic logic of N-N bond formation appears to be at least partially shared among certain 
groups of compounds.  Recently, N-N bond formation was reconstituted in vitro for kutzneride, 
showing that N5 on ornithine is oxidized to give N5-hydroxyornithine by a flavin-dependent 
enzyme before the N-N bond is formed by a heme protein (Figure 3.2a).6-7  Similarly, in the 
biosynthesis of s56-p1, lysine is oxided to N6-hydroxylysine, and the N6-hydroxyl is then joined 
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with the carboxyl group of glycine.  The N-N bond is subsequently formed through 
intramolecular nucleophilic attack by the glycine amino group (Figure 3.2b).8  Thus, for both of 
these natural products, one nitrogen is activated to a more electrophilic species and then reacted 
intramolecularly with a nucleophilic nitrogen.   
 
Figure 3.2 Reconstituted or proposed biosynthetic pathways discussed in this chapter.  a) N5 on 
ornithine is activated to a hydroxylamine for nucleophilic attack to form the N-N bond in 
kutzneride.  b) Sbp38 oxidizes Lys, and Sbp40 catalyzes the conjugation to Gly before an 
intramolecular attack forms the N-N bond.  c) Nitrous acid is formed from Asp before 





 A different strategy towards N-N bond formation features the formal reaction of a 
nitrogen-containing intermediate with nitrous acid.  For instance, during cremeomycin 
biosynthesis, CreE, a flavin-dependent monooxygenase, oxidizes aspartic acid to nitrosuccinic 
acid (Figure 3.1b), and a lyase, CreD, subsequently liberates nitrous acid.9  Nitrous acid then 
partakes in diazotization with a primary aromatic amine on an advanced intermediate to form the 
N-N bond in a reaction catalyzed by CreM, a fatty acid-coenzyme A ligase homolog (Figure 
3.2c).10-11  Recently, Dr. Zedu Huang’s work showed that the fosfazinomycin biosynthetic 
enzymes FzmM (UniProtKB A0A0N0UQ79) and FzmL (UniProtKB U5YN81), homologs of 
CreE and CreD respectively, can also produce nitrous acid from aspartic acid with N-
hydroxyaspartic acid (Figure 3.1b) as an intermediate.12  Moreover, I showed in the preceding 
chapter that at least one of the nitrogen atoms in the phosphonohydrazide moiety of 
fosfazinomycin is derived from aspartic acid.  Interestingly, a set of five genes is conserved 
between the biosynthetic gene clusters of fosfazinomycin (fzm) and kinamycin (kin) (Figure 
3.3), suggesting that the two compounds may share biosynthetic steps. These genes are predicted 
to encode homologs of a glutamine synthetase (FzmN/KinL), an amidase (FzmO/KinK), a 
hypothetical protein (FzmP/KinJ), an N-acetyltransferase (FzmQ/KinN), and an 
adenylosuccinate lyase (FzmR/KinM) (Table 1.1).13-14  The roles of these five enzymes in 
installing the N-N bond into two structurally divergent compounds are not known. In our prior 
work concerning the biosynthesis of fosfazinomycin described in Chapter 2, Dr. Zedu Huang 
reconstituted in vitro the activities of FzmQ (UniProtKB U5YN85) and FzmR (UniProtKB 
A0A0M9CPV0).  FzmQ performs the acetylation of hydrazinosuccinic acid to yield N-
acetylhydrazinosuccinic acid (Figure 3.1b), and FzmR catalyzes an elimination reaction of N-




Figure 3.3 Selected segments of the biosynthetic gene clusters of fosfazinomycin and 
kinamycin.13  The five conserved genes in the two clusters are colored based on annotations of 
their gene products using BLAST analysis: glutamine synthetase (blue-gray), amidase (dark 
blue), hypothetical protein (red), N-acetyltransferase (purple), and adenylosuccinate lyase 
(green). The amino acid identities between the homologous enzymes from the fzm cluster from 
Streptomyces sp. XY332 and the kin cluster from Streptomyces murayamaensis ATCC 21414 
(FzmN/KinL, FzmO/KinK, FzmP/KinJ, FzmQ/KinN, and FzmR/KinM) are indicated below the 
kin cluster. fzmL and fzmM, which encode enzymes responsible for forming nitrous acid from 
aspartic acid, are colored in white. 
 
3.2 RESULTS AND DISCUSSION 
3.2.1 Aspartic acid is transformed to nitrous acid 
In the preceding chapter, I showed using stable isotope labeling experiments that at least 
one of the nitrogen atoms in the phosphonohydrazide linkage in fosfazinomycin is derived from 
aspartic acid.12  Furthermore, Dr. Huang’s reconstitution of the activities of FzmM and FzmL 
demonstrated that they produce nitrous acid from aspartic acid; however, we also found that 
under certain conditions, FzmM converted aspartic acid to N-hydroxyaspartic acid.12  In light of 
the recent work on kutzneride and cremeomycin, it was unclear whether the generation of N-
hydroxyaspartic acid by FzmM is a direct intermediate in N-N bond formation (similar to 
kutzneride or s56-p1, Figure 3.2ab) or if N-hydroxyaspartic acid is only an intermediate in the 
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oxidation of aspartic acid to nitrosuccinic acid (similar to cremeomycin, Figure 3.2c).6, 10  In 
order to investigate these possibilities, I performed isotope labeling studies in the native 
producing organism of fosfazinomycin, Streptomyces sp. NRRL S-149.  First, the organism was 
cultivated in a minimal medium with 15NH4Cl and 15N-aspartic acid as the only two sources of 
nitrogen, and analysis by liquid chromatography-high resolution mass spectrometry (LC-HRMS, 
using electrospray ionization) of the spent medium revealed a singly charged peak ([M+H]+ = 
461.1957) corresponding to fosfazinomycin A containing seven 15N atoms (Fig. 3.4a).  Cultures 
grown in uniformly 15N-labeled medium were then fed sodium nitrite at natural isotopic 
abundance (i.e. unlabeled). LC-HRMS analysis of the spent medium revealed a clear increase in 
the peak corresponding to [M+H]+ = 460.1996 (Fig. 3.4b), one mass unit lower than uniformly 
15N-labeled fosfazinomycin. Integration of the peak areas showed that approximately 30% of the 
product contains a single 14N atom originating from nitrite.  I next fed unlabeled N-
hydroxyaspartic acid to Streptomyces sp. NRRL S-149 grown in medium containing 15NH4Cl 
and 15N-aspartic acid as the only two other sources of nitrogen.  As with nitrite, a significant 
peak with [M+H]+ = 460.1993 was observed (Fig. 3.4c), corresponding to a single incorporation 





Figure 3.4 HRMS analysis of 14N-incorporation into 15N-labeled fosfazinomycin.  a) 
Fosfazinomycin A produced by Streptomyces sp. NRRL S-149 cultivated in uniformly 15N-
labeled medium.  The calculated m/z ([M+H]+) for uniformly 15N-labeled (15N7)-fosfazinomycin 
A is 461.1966.  b), c) Spectra from cells cultivated in 15N-labeled media and fed with either (b) 
NaNO2 or (c) N-hydroxyaspartic acid.  The calculated m/z ([M+H]+) for 15N6-fosfazinomycin 
with a single 14N atom is 460.1996.  d), e) Spectra from cells grown in 15N-labeled media and fed 
with either (d) hydrazinosuccinic acid or (e) acetylhydrazine.  The calculated m/z ([M+H]+) for 
15N5-fosfazinomycin with two 14N atoms is 459.2025.   
 
 I next performed tandem mass spectrometry (MS/MS) analysis to determine if the 14N 
atoms from nitrite and N-hydroxyaspartic acid were incorporated into the hydrazide linkage of 
fosfazinomycin.  First, as a control, uniformly 15N-labled fosfazinomycin ([M+H]+ = 461.20) 
was subjected to higher energy collisional dissociation (HCD), and the product and fragment 
ions were assigned (Figure 3.5ab).  Then, the spent medium from the culture cultivated with 
unlabeled sodium nitrite was analyzed focusing on a precursor ion ([M+H]+ = 460.20) 
corresponding to singly 14N-labeled fosfazinomycin (Figure 3.5c).  Analysis of the fragment 
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ions indicated 14N-incorporation only if the fragment contained the N-N bond (ions g, j, and k, 
accented by blue stars).  Likewise, in the sample fed with N-hydroxyaspartic acid, the singly 14N-
labeled fosfazinomycin (precursor ion [M+H]+ = 460.20) was fragmented (Figure 3.5d).  Again, 
only fragment ions containing the N-N bond (ions g, j, and k) contained 14N.  Thus, these feeding 
experiments demonstrate that one of the nitrogens in the phosphonohydrazide linkage in 
fosfazinomycin is derived from nitrite. These data are also consistent with our previous study 
that showed that nitrite is formed from aspartic acid with N-hydroxyaspartic acid as an 
intermediate.  
 Interestingly, work performed by Tai Ng and Dr. Peng Wang, a graduate student and a 
former postdoctoral associate in the group of Prof. Emily Balsksus at Harvard University, 
revealed that nitrous acid is also involved in the biosynthesis of kinamycin.  They found that 
when cultures of Streptomyces murayamaensis ATCC 21414, a producing organism of 
kinamycin D, were supplemented with either 15N-nitrite or 15N-nitrate, the 15N-label was 
selectively incorporated into the proximal nitrogen atom of the diazo group.  This result contrasts 
starkly with the results of previous 15N-nitrite feeding experiments performed with the producers 
of the diazo-containing secondary metabolite SF2415A3, in which only the distal diazo nitrogen 
atom was labeled by either 15N-nitrite or 15N-nitrate.4  The localization of the 15N label in the 
kinamycin experiments shows that this is not the case and supports the involvement of an 





Figure 3.5 MS/MS analysis of fosfazinomycin A.  a) Proposed fragmentation pathway of 15N7-
fosfazinomycin A.  Product and fragment ions containing the N-N bond are indicated by blue 
asterisks and lettering.  b) MS/MS spectrum of 15N7-fosfazinomycin.  c), d) MS/MS spectra of 
15N6-fosfazinomycin by feeding (c) NaNO2 or (d) N-hydroxyaspartic acid (2).  e), f) MS/MS 
spectra of 15N5-fosfazinomycin by feeding (e) acetylhydrazine or (f) glutamylhydrazine.   
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3.2.2 Hydrazinosuccinic acid and acetylhydrazine are biosynthetic intermediates 
 I next performed additional feeding experiments to confirm that hydrazinosuccinic acid 
(3) and acetylhydrazine are also intermediates in the fosfazinomycin biosynthetic pathway 
(Figure 3.1b).  When unlabeled hydrazinosuccinic acid was fed to the producing organism 
grown in 15N-labeled medium, the product ions showed a large increase in a peak two mass units 
lower ([M+H]+ = 459.2013) than the uniformly 15N-labeled product (Figure 3.4d).  The data 
demonstrate about 50% double incorporation of 14N into fosfazinomycin.  Similarly, when 
unlabeled acetylhydrazine was added to the 15N-labeled medium, a large increase in a peak two 
mass units lower ([M+H]+ = 459.2015) relative to the control was observed, indicating two 
incorporations of 14N (40%) into fosfazinomycin A (Figure 3.4e).  MS/MS was then used to 
determine the location of 14N incorporation.  Samples obtained from feeding 3 were analyzed by 
MS/MS using doubly 14N-labeled fosfazinomycin as the precursor ion ([M+H]+ = 459.20) 
(Figure 3.5e).  After HCD, only the fragment ions that retained the N-N bond (ions f, g, j, and k 
indicated by the blue stars) exhibited a −2 Da mass shift compared to the control indicating 
selective incorporation of 14N into the N-N bond of fosfazinomycin.  Likewise, when doubly 
14N-labeled fosfazinomycin (precursor [M+H]+ = 459.20) obtained from feeding acetylhydrazine 
was fragmented, only product or fragment ions containing the N-N bond contained two 14N 
atoms (Figure. 3.5f).  Thus, these data strongly suggest that hydrazinosuccinic acid and 
acetylhydrazine are intermediates in the pathway and that both of their nitrogen atoms are 
incorporated selectively into the phosphonohydrazide linkage of fosfazinomycin, consistent with 
the demonstration in vitro that FzmQR convert 3 to acetylhydrazine.12   
 Again, the intermediacies of hydrazinosuccinc acid and acetylhydrazine were 
corroborated in kinamycin biosynthesis.  Tai Ng and Dr. Peng Wang were able to show that 
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KinNM, the homologs of FzmQR in the kinamycin biosynthetic cluster, were able to convert 
hydrazinosuccinic acid to acetylhydrazine, mirroring the pathway in fosfazinomycin 
biosynthesis.  When 15N2-acetylhydrazine was fed to S. murayamensis, 15N-enrichment in both of 
the nitrogen atoms in the diazo group in kinamycin D was observed, which again mirrored the 
results from the fosfazinomycin biosynthetic pathway.  These results collectively confirmed that 
nitrogen atoms involved in the hydrazide linkage of fosfazinomycin and the diazo group in 
kinamycin have common origins.   
 
3.2.3 FzmO forms glutamylhydrazine 
 FzmQ and FzmR convert hydrazinosuccinic acid to acetylhydrazine,12 and the labeling 
studies described above establish that both of the nitrogen atoms from hydrazinosuccinic acid 
and acetylhydrazine are incorporated selectively into the phosphonohydrazide linkage of 
fosfazinomycin.  Thus, it was reasonable that the next step in the biosynthetic pathway could 
involve acetylhydrazine as a substrate.  FzmN (UniProtKB A0A0M9CP55) is a glutamine 
synthetase homolog, a class of enzymes that canonically catalyzes the formation of glutamine 
from glutamic acid, ammonia, and ATP.  Dr. Zedu Huang showed that FzmN was able to 
catalyze the condensation of glutamic acid and acetylhydrazine to form glutamylacetylhydrazine 
in an ATP-dependent manner.  Tai Ng and Dr. Peng Wang were also able to demonstrate that the 
same reaction could also be catalyzed by KinL, the homolog of FzmN in the kin cluster in 
biotransformation experiments involving E. coli expressing recombinant KinL.   
 I next turned my attention towards FzmO (UniProtKB U5YQN5), an amidase homolog 
shared between the biosynthetic pathways of fosfazinomycin and kinamycin. Despite 
considerable effort, neither Dr. Zedu Huang nor I was able to find conditions to express 
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recombinant FzmO solubly in E. coli.  Thus, I endeavored to refold the protein in vitro.  FzmO, 
expressed with an N-terminal His6-tag, was extracted from inclusion bodies with buffers 
containing guanidine hydrochloride.  After purification with nickel affinity chromatography, the 
protein was diluted into 216 buffers in 96-well plates, and conditions that resulted in solubilized 
FzmO were identified by measuring the turbidity of the wells with a plate reader.15  The refolded 
soluble FzmO was then assessed for enzymatic activity.  Glutamylacetylhydrazine, the product 
of the FzmN-catalyzed reaction, contains an acetyl group that would likely have to be lost prior 
to funneling the hydrazine synthon into fosfazinomycin biosynthesis.  Likewise, in kinamycin 
biosynthesis, removal of the acetyl group would be necessary before the formation of the final 
product.  Thus, I investigated whether FzmO, being an amidase homolog, might catalyze such a 
reaction.  Refolded FzmO was incubated with glutamylacetylhydrazine, and the products in the 
reaction mixture were derivatized with fluorenylmethyloxycarbonyl chloride (Fmoc-Cl) to 
facilitate reversed-phase LC-MS analysis (Figure 3.6a).  When the reaction mixture was 
analyzed by LC-MS, a mass consistent with glutamylhydrazine was detected that was absent 
when FzmO was omitted from the reaction (Figure 3.6bc).  To confirm the presence of 
glutamylhydrazine, a synthetic standard was prepared, and LC-MS analysis revealed that the 
synthetic material eluted with the same retention time as the product of the FzmO-catalyzed 
reaction (Figure 3.6d). The assignment was then confirmed by spiking the synthetic standard 
into the reaction mixture (Figure 3.6e). The FzmO-catalyzed hydrolysis appears to be selective 
for the acetylhydrazide linkage over the glutamylhydrazide bond since glutamic acid could not 






Figure 3.6 FzmO converts glutamylacetylhydrazine (5) to glutamylhydrazine (6).  Mixtures 
from enzymatic assays were derivatized with Fmoc-Cl (Fmoc-6 [M+H]+ = 384).  a) 
Deacetylation of 5 to 6 by FzmO.  b) Extracted ion chromatogram (EIC) (m/z 384) of the 
reaction containing FzmO and 5.  c) EIC (m/z 384) of a sample containing 5 without FzmO.  d) 
EIC for m/z 384 of a synthetic standard of Fmoc-6.  e) EIC (m/z 384) of a reaction mixture 
containing FzmO and 5 spiked with synthetic Fmoc-6.  f) EIC (m/z 368) of Fmoc-Glu standard.  
g) EIC for m/z 368 of the reaction mixture of FzmO and 5.  h) HRMS analysis of 14N 
incorporation into fosfazinomycin A from Streptomyces sp. NRRL S-149 cultivated in 15N-
labeled medium but fed with unlabeled 6.  i) MS/MS analysis of 15N5-fosfazinomycin A from 
feeding 6.  See Figure 3.5a for fragmentation pathway. 
62 
 
3.2.4 Glutamylhydrazine is incorporated into fosfazinomycin 
 I then performed further isotope labeling studies to assess the intermediacy of 
glutamylhydrazine in fosfazinomycin biosynthesis.  Synthetic unlabeled glutamylhydrazine was 
provided to the producing organism, Streptomyces sp. NRRL S-149, cultured in uniformly 15N 
labeled medium.  HRMS analysis of the resulting spent medium revealed a peak two mass units 
lower than uniformly 15N-labeled fosfazinomycin, indicating that two 14N atoms were indeed 
incorporated into fosfazinomycin at 40% enrichment (Figure 3.6h).  Tandem MS analysis on 
this doubly 14N-labeled fosfazinomycin (observed [M+H]+ = 459.2012) suggests that the 14N 
atoms were incorporated selectively into the phosphonohydrazide moiety (Figure 3.6i).   
 Glutamylhydrazine was also confirmed to be an intermediate in kinamycin biosynthesis 
by Tai Ng and Dr. Peng Wang.  15N2-L-glutamylhydrazine, wherein both of the nitrogen atoms in 
the hydrazine moiety are 15N-labeled, was used to supplement a culture of S. murayamaensis.  
Kinamycin D produced by the culture was found to be 60% enriched in 15N in both of the 
nitrogen atoms in the diazo group.  These results show that both the phosphonohydrazide moiety 
of fosfazinomycin and the diazo group of kinamycin derives from hydrazine bound on a 
glutamyl scaffold.   
 
3.3 SUMMARY AND OUTLOOK 
The in vivo feeding experiments presented here demonstrate that one of the nitrogen 
atoms in the N-N bonds of both fosfazinomycin and kinamycin is derived from nitrous acid, 
similar to findings in the biosynthesis of cremeomycin.  But unlike in the biosynthesis of 
cremeomycin, in which the diazo group is formed late in the pathway from a pre-installed 
aromatic amine, in the biosyntheses of fosfazinomycin and kinamycin, the N-N bond is made 
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early, and the hydrazine functionality is carried through multiple enzymatic steps. My feeding 
experiments corroborate the previously reconstituted in vitro activities of FzmQ and FzmR, thus 
firmly establishing that their physiological roles are indeed the acetylation of hydrazinosuccinate 
and the elimination of acetylhydrazine, respectively (Figure 3.7). Furthermore, the reconstitution 
of the activities of KinN and KinM, the homologs of FzmQ and FzmR in the kinamycin 
biosynthetic cluster, and the results of the feeding studies for kinamycin production illustrate that 
these steps are conserved in the biosynthetic pathways towards fosfazinomycin and kinamycin. 
These findings are surprising since previous studies had suggested that the N-N bond in the diazo 
group of kinamycin was fashioned from an aromatic nitrogen-containing precursor, analogous to 
the proposal for cremeomycin, but such a pathway is inconsistent with the labeling studies 
presented here.16   
 
Figure 3.7 The biosynthetic pathways for fosfazinomycin and kinamycin.   
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To follow the fate of acetylhydrazine, we also reconstituted the activities of FzmN and 
FzmO, revealing that acetylhydrazine is first condensed onto the side chain carboxyl group of 
glutamic acid to form glutamylacetylhydrazine before deacetylation to yield glutamylhydrazine.  
The labeling studies in the native producing organisms of both fosfazinomycin and kinamycin 
corroborate that glutamylhydrazine is an intermediate in their biosyntheses.  Glutamic acid is 
present in relatively high concentrations in the cytoplasm of most bacteria, and perhaps for that 
reason, glutamic acid has previously been demonstrated to be a common carrier molecule to 
effect many different types of transformations.17  Most examples come from catabolism, but 
some have been uncovered in secondary metabolism.  For instance, in the biosynthesis of 
butirosin, an intermediate conjugated to an acyl carrier protein (ACP), γ-aminobutyryl-ACP, is 
condensed onto the side chain of glutamic acid, and this glutamylated intermediate undergoes 
two further enzymatic transformations before deglutamylation.17-19 
 The collaborative work with the Balskus group provides further support for a major 
revision in the proposed biosynthetic pathway for kinamycin and other diazofluorene 
polyketides. A previous study had suggested that stealthin C is a biosynthetic intermediate to 
kinamycin on the basis of isotope labeling studies; however, that study measured the 
incorporation of deuterated stealthin C, and only low percentages of incorporation were observed 
(Figure 3.8a).16  Furthermore, the Balsksus group has recently reported that stealthin C can be 
formed nonenzymatically in vivo and in vitro.20  Therefore, stealthin C is likely not an authentic 
intermediate in kinamycin biosynthesis, and instead, the N-N bond is formed independently and 
later added to the polyketide scaffold in a convergent biosynthetic process.  Not only can the 
intact incorporation of the preformed N-N bond into kinamycin be observed, but further studies 
by the Balskus group clearly showed that nitrite incorporates solely into the proximal nitrogen in 
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the diazo functionality, which precludes a pathway involving late-stage diazotization (Figure 
3.8b).  This site-specific incorporation also eliminates the possibility that free hydrazine is 
involved in the biosynthesis of kinamycin, although the exact N-N bond-containing intermediate 
transferred to the polyketide scaffold and the enzymes involved in this process remain to be 
elucidated.   
 
Figure 3.8 Origins of the diazo functionality in kinamycin.  a) Previous work by Gould et al. 
suggested that stealthin C was an intermediate in kinamycin biosynthesis and that the diazo 
group was formed by late-stage diazotization.16  b) Labeling studies performed by the Balskus 
group show that nitrite is incorporated selectively into the proximal nitrogen.   
 
 Collectively, our results show that in the biosyntheses of the structurally highly diverse 
compounds fosfazinomycin and kinamycin, a hydrazine building block is channeled into the 
biosynthetic pathways by a common strategy. The N-N bond is first fashioned by conversion of 
aspartic acid to hydrazinosuccinic acid (3) in a process that involves nitrite but that has yet to be 
fully understood. Then a set of four conserved enzymes transfer the hydrazine moiety onto the 
side chain of glutamic acid before its final installation in the mature natural product (Figure 3.7).  
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This strategy is vastly different than in the biosyntheses of other N-N bond-containing natural 
products for which the N-N bond is formed directly on the scaffold of the final product.  Thus, 
this study brings to light an unexpected pathway for the incorporation of N-N bonds in natural 
products.   
 
3.4 METHODS 
3.4.1 General methods 
 All reagents and materials for the fosfazinomycin and kinamycin biosynthetic studies 
were purchased from Sigma-Aldrich or Fisher Scientific unless otherwise noted.  DNA 
oligonucleotides were obtained from Integrated DNA Technologies (IDT) and Sigma-Aldrich.  
Enzymes used in cloning were procured from New England Biosciences.  DNA sequencing was 
performed by ACGT Inc. or the Roy J. Carver Biotechnology Center (University of Illinois at 
Urbana-Champaign).  NMR experiments were carried out on an Agilent 600 MHz with a 
OneNMR broadband probe, and the data was analyzed with MestreNova software. Gene cluster 
diagrams were constructed with the online Gene Graphics tool.21 
 
Table 3.1 Primers and synthetic oligonucleotides used in cloning.  For primers, lower case letters 






































3.4.2 Isotope labeling experiments 
Streptomyces sp. NRRL S-149 was first cultivated on R2A agar for 2 d at 30 ˚C.  A single 
colony was then picked and used to inoculate 5 mL of  ATCC 172.  After 3 d on a roller drum at 
30 ˚C, 1 mL of the culture in ATCC 172 was used to inoculate a second seed culture in 25 mL of 
modified R2A medium (3.8 mM 15NH4Cl, [15N, 99%, Cambridge Isotope Laboratories], 0.05% 
soluble potato starch, 2.8 mM glucose, 2.7 mM sodium pyruvate, 0.9 mM potassium phosphate 
dibasic, and 0.2 mM magnesium sulfate heptahydrate) in a 125 mL flask.  After 3 d of shaking at 
200 rpm at 30 ˚C, 4 mL of the seed culture was used to inoculate a production culture consisting 
of 100 mL of modified R2AS (same as modified R2A above, supplemented with 100 μM 15N-
aspartic acid [15N, 99%, Cambridge Isotope Laboratories], 40 mM sodium succinate, and 0.5% 
Balch's vitamins) in a 500 mL baffled flask.  The production culture was cultivated for 38 h at 30 
˚C with shaking at 200 rpm.  Then 2 mM of acetylhydrazine, N-hydroxyaspartic acid, 
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hydrazinosuccinic acid, NaNO2, or glutamylhydrazine was added to the culture.  
Glutamylhydrazine was prepared synthetically (detailed in section 3.4.3), and N-hydroxyaspartic 
acid and hydrazinosuccinic acid were obtained enzymatically from fumaric acid and either 
hydroxylamine or hydrazine using ammonia-aspartate lyase (AspB) from Bacillus sp YM55-1 
using an adaptation of a previously reported method; 50 µM AspB was incubated with 20 mM 
fumarate, 20 mM of either hydroxylamine or hydrazine in 50 mM NaH2PO4, pH=7.7 for 8 h at 
ambient temperature.22  The Streptomyces sp. NRRL S-149 production culture was then 
incubated for an additional 8 h at 30 ˚C with shaking at 200 rpm.  The spent medium was 
concentrated 10X under reduced pressure and reconstituted in 80% MeOH.  Precipitate was 
removed by centrifugation, and the supernatant was dried under reduced pressure and dissolved 
in 5 mL of H2O.  Solid phase extraction was performed with 300 mg of Oasis HLB resin 
(Waters). After the sample was loaded onto the resin, the resin was washed with 5% MeOH in 
H2O, and the fosfazinomycin A was eluted with 50% MeOH.  LC-HRMS and LC-HR-MS/MS 
analyses in conjunction with the labeling experiments in Streptomcyes sp. NRRL S-149 were 
performed on a Thermo Q-Exactive Hybrid Quadrupole-Orbitrap Mass Spectrometer coupled to 
a Dionex Ultimate 3000 series HPLC system.  An Xbridge C18 column (4.6 x 250 mm, 5 µ, 
Waters) was used with mobile phase A (H2O with 0.1% formic acid) and mobile phase B 
(acetonitrile with 0.1% formic acid) at a flow rate of 0.5 mL min-1.  The chromatographic 
method consisted of a linear gradient of 5% B to 7.5% B in 10 min, a linear gradient from 7.5% 
B to 95% B in 7 min and a linear gradient from 95% B to 5% B in 11 min.  The autosampler was 
set to 15 °C.  The injection volume was 20 μL.  Mass spectra were acquired under positive 
electrospray ionization (sheath gas flow rate, 53; auxillary gas flow rate: 14; sweep gas flow rate, 
3; spray voltage, 3.5 kV; capillary temp, 269 °C; suxillary gas heater temp, 438 °C).  The full 
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scan mass spectrum resolution was set to 70,000 with the scan range of m/z 100 ~ m/z 1,200, and 
the automatic gain control (AGC) target was 1E6 (1 × 106) with a maximum injection time of 
200 ms.  For MS/MS scan, the mass spectrum resolution was set to 17,500.  AGC target was 5E4 
(5 × 104) with a maximum injection time of 50 ms.  Loop count was 10.  Isolation window was 
1.0 m/z with NCE of 30, 40 and 50 eV.  Data were analyzed and processed with Thermo 
Xcalibur 3.0.63 software.  (See NB entry series starting 10-17-17) 
 
3.4.3 Preparation of synthetic glutamylhydrazine 
 
Figure 3.9 The synthesis of glutamylhydrazine (6). 
 
Boc-L-glutamic acid 1-tert butyl ester (0.909 g, 3 mmol, 1.0 equiv.) was dissolved in 7 
mL of dry CH2Cl2 with PyBOP (1.56 g, 3 mmol, 1 equiv.) and N-methylmorpholine (330 µL, 3 
mmol, 1 equiv.) before the addition of hydrazine (141 µL, 4.5 mmol, 1.5 equiv.), and the 
reaction mixture was stirred at ambient temperature for 15 h (Figure 3.9).  The mixture was 
diluted by the addition of 30 mL of CH2Cl2 and washed sequentially with 12 mL of 5% 
NaHCO3, 12 mL of water, and 10 mL of brine before being dried over Na2SO4.  The product 
(6a) was then purified with flash chromatography (silica gel, 30:1 CH2Cl2 : MeOH).   
1H NMR (600 MHz, CDCl3): δ (ppm) = 7.82 (br, 1H, NH), 5.38 (d, J=4.2 Hz, 1H, NH), 4.11 (m, 
1H, CH), 3.93 (br, 2H, NH2), 2.22 (t, J=7.3 Hz, 2H, CH2), 2.12 (m, 1H, CH2), 1.85 (m, 1H, CH2), 
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1.42 (s, 9H, CH3), 1.41 (s, 9H, CH3) (Figure 3.10).  13C NMR (150 MHz, CDCl3): δ (ppm) = 
172.91, 171.29, 155.95, 82.32, 80.00, 53.40, 30.65, 29.35, 28.26, 27.93 (Figure 3.11).  HRMS: 








Figure 3.11. 13C NMR (150 MHz, CDCl3) spectrum of 6a. 
 
 
The product above (6a) (0.67 g, 2.1 mmol) was then dissolved in 21 mL of CH2Cl2, 21 
mL of TFA, 1 mL of water, and 1 mL of triisopropylsilane cooled in an iced bath (Figure 3.9).  
The reaction was then stirred for 4.5 h before being concentrated under reduced pressure.  The 
mixture was diluted with the addition of 30 mL of water and washed three times with 10 mL of 
ethyl acetate.  The solution was then dried under reduced pressure.  (See NB entry for 6-8-18) 
1H NMR (600 MHz, D2O): δ (ppm) = 3.72 (t, J=6.3 Hz, 1H, CH), 2.43 (m, 2H, CH2), 2.06 (q, 
J=7.24 Hz, CH2) (Figure 3.12).  13C NMR (150 MHz, D2O): δ (ppm) = 172.50, 172.24, 52.98, 






Figure 3.12 1H NMR (600 MHz, D2O) spectrum of 6. 
 
 
Figure 3.13 13C NMR (150 MHz, D2O) spectrum of 6. 
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3.4.4 Cloning of FzmO and AspB 
Genomic DNA was isolated from Streptomyces sp. WM6372, using an Ultraclean 
Microbial DNA Isolation Kit (Mo Bio) following the manufacturer's instructions.  From purified 
gDNA, the gene encoding for FzmO was amplified using the primers listed in Table 3.1 and 
Phusion polymerase. The PCR products were then purified using the QIAquick PCR Purification 
Kit (Qiagen).  pET15b was linearized using NdeI, amplified by PCR with Phusion polymerase 
(primers listed in Table 3.1), and treated with DpnI.  fzmO was ligated into the pET15b 
backbone, using the Gibson Assembly kit from New England Biosciences.  E. coli DH5α was 
used for transformation and plasmid production.  The fidelity of the insertion was verified by  
DNA sequencing.   
 The codon-optimized gene encoding AspB from Bacillus sp. YM55-1 was ordered from 
IDT as a gBlock.  Following PCR amplification with Q5 polymerase (primers and synthetic gene 
in Table 3.1), aspB was ligated into pET15b (digested with NdeI and HindIII) using the HiFi 
Assembly Mix from New England Biosciences.  The fidelity of the insertion was verified by 
DNA sequencing.  (See NB series 7-19-17) 
 
3.4.5 Protein purification and refolding 
pET15b_AspB was used to transform E. coli BL21(DE3).  Transformants were cultivated 
for 12 h at 37 ˚C in LB with 100 µg mL-1 ampicillin, and 40 mL of this culture were then used to 
inoculate 4 L of LB with 100 µg mL-1 ampicillin.  Cultivation continued at 37 ˚C with shaking at 
220 rpm, until the OD600 reached between 0.5 and 0.7, and IPTG (Gold Biotechnology) was 
added to 100 µM.  The culture was grown for an additional 16 h at 18 ˚C with shaking at 220 
rpm.  The cells were then harvested by centrifugation and resuspended in lysis buffer (50 mM 
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NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol) supplemented with 1 mg mL-1 
lysozyme (Gold Biotechnology) and 20 U mL-1 DNase I.  The cell suspension was then 
incubated with mild agitation for 20 min at 4 ˚C.  Cell lysis was achieved by passaging the 
suspension twice through a French pressure cell.  Insoluble cellular debris was removed by 
centrifugation for 45 min at 30,600 g.  The supernatant was then loaded onto 5 mL of Ni-NTA 
resin pre-equilibrated with lysis buffer for 15 min with mild agitation.  The resin was then 
washed with 40 mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% 
glycerol), and the protein was eluted from the resin with 20 mL of elution buffer (50 mM 
NaH2PO4, 300 mM NaCl, 300 mM imidazole, 10% glycerol).  The eluate was then concentrated 
to a volume of 2.5 mL using an Amicon spin filter with a 30 kDa molecular weight cutoff.  
Excess imidazole was removed using a PD-10 column (GE Healthcare) with 3.5 mL storage 
buffer (50 mM NaH2PO4, 300 mM NaCl, 10% glycerol).  (See NB entry for 7-24-17) 
FzmO was expressed using the same methodology as for AspB.  After cell lysis, the 
insoluble fraction was resuspended in pellet wash buffer (50 mM NaH2PO4, 300 mM NaCl, 
0.10% Triton X-100, pH=7.5) and passed through a 20G syringe needle several times.  Again the 
insoluble fraction was isolated from the supernatant via centrifugation, and the pellet was 
resuspended in denaturing buffer (50 mM NaH2PO4, 300 mM NaCl, 6 M guanidine HCl, 10 mM 
imidazole, 10% glycerol, pH=7.5) and incubated at 56 ˚C for 15 min.  After centrifugation, the 
supernatant was applied to Ni-NTA agarose resin (Qiagen).  Nickel affinity purification 
proceeded similarly as with FzmN, except all buffers also contained 6 M guanidine 
hydrochloride.  Protein refolding conditions for FzmO were then screened using a platform 
adapted from another study.15  Briefly, 100 µL of 216 different buffers (Table 3.2) was placed 
into three clear round bottom 96-well plates (Corning).  Each plate also contained 12 positive 
75 
 
control wells, each filled with 91 µg bovine serum albumin in 110 µL of denaturing storage 
buffer (50 mM NaH2PO4, 300 mM NaCl, 6 M guanidine HCl, 10 mM imidazole, 10% glycerol, 
pH=7.5); 12 negative control wells containing 91 µg insoluble FzmO in 110 µL of storage buffer 
(without guanidine hydrochloride) were also included in each plate. Then, 10 µL of a stock 
solution of 1 mg mL-1 FzmO in denaturing storage buffer was diluted into each of the 216 
buffers in the 96-well plates.  The plates were incubated for 12 h at room temperature with gentle 
agitation.  The turbidity of each well was then measured with a Tecan Infinite 200 Pro plate 
reader, reading absorbance at λ=410 nm and a bandwidth of 9 nm using multiple circle-filled 3x3 
reads and 10 flashes per read.  Each plate was prepared and analyzed in triplicate on different 
days.  Hits were defined as conditions that gave rise to absorbance readings within three standard 
deviations of the mean absorbance of the positive control wells.  (See NB entry for 10-7-16) 
 
Table 3.2 Buffer conditions used for refolding FzmO. The 216 solutions were made by 
combinatorially combining each element in a column with one other element from each of the 
other columns.   
Buffer (50 mM) Glycerol NDSB 256 Salt Arginine Glucose 
HEPES, pH=7.0 20% 100 mM 300 mM NaCl 800 mM 250 mM 
HEPES, pH=8.0 0% 0 mM 100 mM NaCl 400 mM 0 mM 
CHES, pH=9.0   100 mM KCl 0 mM  
 
3.4.6 FzmO enzymatic assay 
 In order to test if FzmO is able to deacetylate glutamylacetylhydrazine, 50 µL was 
withdrawn from a well in the 96-well plate that was defined as a hit (~10 µM FzmO in 50 mM 
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HEPES, 100 mM KCl, 20% glycerol, 800 mM arginine, pH = 9.0) in the refolding screen. Then, 
glutamylacetylhydrazine (synthetic material provided by Dr. Zedu Huang) was added to a final 
concentration of 1 mM, and the reaction was allowed to proceed for 11 h at room temperature.  
The protein was then removed by an Amicon Ultra 10K filter, and the reaction mixture was 
derivatized by adding Fmoc-Cl to the reaction mixture (20 mM final). This mixture was 
incubated for 20 min with agitation, and 1-aminoadamantane was added to 50 mM, after which 
incubation continued for another 20 min.   A negative control was also run with the same 
reaction mixture but without any FzmO.  After derivatization, the reactions were analyzed by 
LC-MS using an Agilent 1200 series LC system coupled to an Agilent G1956B single 
quadrupole mass spectrometer with an Xbridge C18 column (4.6 x 250 mm, 5 µ) using mobile 
phase A (H2O) and mobile phase B (acetonitrile) at a flow rate of 1 mL min-1.  The method 
consisted of an isocratic hold at 5% B for 1 min, a linear gradient from 5% B to 95% B in 29 
min, an isocratic hold at 95% B for 10 min, a linear gradient from 95% B to 5% B in 4 min, and 
a final isocratic hold at 5% B for 21 min.  A positive control was also run wherein 500 µM 
Fmoc-derivatized glutamylhydrazine was spiked into the reaction mixture.  Extracted ion 




1. Blair, L. M.; Sperry, J., Natural products containing a nitrogen-nitrogen bond. J. Nat. 
Prod. 2013, 76 (4), 794-812. 
2. Waldman, A. J.; Ng, T. L.; Wang, P.; Balskus, E. P., Heteroatom–heteroatom bond 
formation in natural product biosynthesis. Chem. Rev. 2017, 117 (8), 5784-5863. 
77 
 
3. Cho, J. Y.; Kwon, H. C.; Williams, P. G.; Jensen, P. R.; Fenical, W., Azamerone, a 
Terpenoid Phthalazinone from a Marine-Derived Bacterium Related to the Genus Streptomyces 
(Actinomycetales). Org. Lett. 2006, 8 (12), 2471-2474. 
4. Winter, J. M.; Jansma, A. L.; Handel, T. M.; Moore, B. S., Formation of the pyridazine 
natural product azamerone by biosynthetic rearrangement of an aryl diazoketone. Angew. Chem. 
Int. Ed. 2008, 48 (4), 767-770. 
5. Ogita, T.; Gunji, S.; Fukuzawa, Y.; Terahara, A.; Kinoshita, T.; Nagaki, H.; Beppu, T., 
The structures of fosfazinomycins A and B. Tetrahedron Lett. 1983, 24, 2283-6. 
6. Du, Y.-L.; He, H.-Y.; Higgins, M. A.; Ryan, K. S., A heme-dependent enzyme forms the 
nitrogen–nitrogen bond in piperazate. Nat. Chem. Biol. 2017, 13, 836. 
7. Neumann, C. S.; Jiang, W.; Heemstra, J. R., Jr.; Gontang, E. A.; Kolter, R.; Walsh, C. T., 
Biosynthesis of piperazic acid via N5-hydroxy-ornithine in Kutzneria spp. 744. ChemBioChem 
2012, 13 (7), 972-6. 
8. Matsuda, K.; Tomita, T.; Shin-ya, K.; Wakimoto, T.; Kuzuyama, T.; Nishiyama, M., 
Discovery of unprecedented hydrazine-forming machinery in bacteria. J. Am. Chem. Soc. 2018, 
140 (29), 9083-9086. 
9. Katsuyama, Y.; Sato, Y.; Sugai, Y.; Higashiyama, Y.; Senda, M.; Senda, T.; Ohnishi, Y., 
Crystal structure of the nitrosuccinate lyase CreD in complex with fumarate provides insights 
into the catalytic mechanism for nitrous acid elimination. Febs J. 2018, 285 (8), 1540-1555. 
10. Sugai, Y.; Katsuyama, Y.; Ohnishi, Y., A nitrous acid biosynthetic pathway for diazo 
group formation in bacteria. Nat. Chem. Biol. 2015, 12, 73. 
11. Waldman, A. J.; Balskus, E. P., Discovery of a diazo-forming enzyme in cremeomycin 
biosynthesis. J. Org. Chem. 2018, 83 (14), 7539-7546. 
78 
 
12. Huang, Z.; Wang, K.-K. A.; van der Donk, W. A., New insights into the biosynthesis of 
fosfazinomycin. Chem. Sci. 2016, 7 (8), 5219-5223. 
13. Janso, J. E.; Haltli, B. A.; Eustáquio, A. S.; Kulowski, K.; Waldman, A. J.; Zha, L.; 
Nakamura, H.; Bernan, V. S.; He, H.; Carter, G. T.; Koehn, F. E.; Balskus, E. P., Discovery of 
the lomaiviticin biosynthetic gene cluster in Salinispora pacifica. Tetrahedron 2014, 70 (27–28), 
4156-4164. 
14. Gao, J.; Ju, K. S.; Yu, X.; Velásquez, J. E.; Mukherjee, S.; Lee, J.; Zhao, C.; Evans, B. S.; 
Doroghazi, J. R.; Metcalf, W. W.; van der Donk, W. A., Use of a phosphonate methyltransferase 
in the identification of the fosfazinomycin biosynthetic gene cluster. Angew. Chem. Int. Ed. 
2014, 53 (5), 1334-7. 
15. Vincentelli, R.; Canaan, S.; Campanacci, V.; Valencia, C.; Maurin, D.; Frassinetti, F.; 
Scappucini-Calvo, L.; Bourne, Y.; Cambillau, C.; Bignon, C., High-throughput automated 
refolding screening of inclusion bodies. Protein Sci. 2004, 13 (10), 2782-2792. 
16. Gould, S. J.; Melville, C. R.; Cone, M. C.; Chen, J.; Carney, J. R., Kinamycin 
biosynthesis. synthesis, isolation, and incorporation of stealthin C, an aminobenzo[b]fluorene. J. 
Org. Chem. 1997, 62 (2), 320-324. 
17. Walker, M. C.; van der Donk, W. A., The many roles of glutamate in metabolism. J. Ind. 
Microbiol. Biotechnol. 2016, 43 (2-3), 419-30. 
18. Li, Y.; Llewellyn, N. M.; Giri, R.; Huang, F.; Spencer, J. B., Biosynthesis of the unique 
amino acid side chain of butirosin: Possible protective-group chemistry in an acyl carrier protein-
mediated pathway. Chem. Biol. 2005, 12 (6), 665-675. 
19. Llewellyn, N. M.; Li, Y.; Spencer, J. B., Biosynthesis of butirosin: Transfer and 
deprotection of the unique amino acid side chain. Chem. Biol. 2007, 14 (4), 379-386. 
79 
 
20. Wang, P.; Hong, G. J.; Wilson, M. R.; Balskus, E. P., Production of stealthin C involves 
an S–N-type Smiles rearrangement. J. Am. Chem. Soc. 2017, 139 (8), 2864-2867. 
21. Harrison, K. J.; Crécy-Lagard, V. d.; Zallot, R., Gene Graphics: a genomic neighborhood 
data visualization web application. Bioinformatics 2017, btx793-btx793. 
22. Weiner, B.; Poelarends, G. J.; Janssen, D. B.; Feringa, B. L., Biocatalytic enantioselective 





CHAPTER 4: ATTEMPTS AT RECONSTITUTING THE TRANSFER OF HYDRAZINE 
FROM GLUTAMYLHYDRAZINE ONTO ARGININE 
 
4.1 INTRODUCTION 
4.1.1 Bifunctional bacterial asparagine synthetases 
 FzmA is a homolog of a Type B asparagine synthetase (AsnB) (see Table 1.1 in Chapter 
1).1  AsnB catalyzes the formation of asparagine from glutamine, aspartic acid, and adenosine 
triphosphate (ATP), using glutamine as a nitrogen donor.2  AsnB contains two domains that are 
about 9 Å apart; these domains, as in a number of other amidotransferases such as carbamoyl 
phosphate synthetase or amidophosphoribosyltransferase, are connected by a tunnel.2-3  In the N-
terminal glutaminase domain, an N-terminal cysteine residue, which is conserved with other N-
terminal nucleophile (Ntn) amidotransferases, hydrolyzes the side-chain amide of glutamine and 
releases ammonia.2  Ammonia then travels through the intramolecular tunnel to the C-terminal 
domain.  In the C-terminal domain, the side chain carboxyl group of aspartic acid is first 
activated through adenylation; subsequent nucleophilic attack by ammonia displaces adenosine 
monophosphate (AMP) to create asparagine (Figure 4.1a).   
 
4.1.2 FzmA as a candidate to transfer hydrazine to arginine 
 As outlined in Chapter 3, FzmN catalyzes the creation of glutamylacetylhydrazine from 
acetylhydrazine and glutamic acid, and FzmO catalyzes a deacetylation reaction to yield 
glutamylhydrazine.4  Since FzmH (Chapter 1) methylates argininylhydrazine, a route must exist 
to transfer hydrazine from the side chain of glutamic acid onto the carboxyl group of arginine in 
fosfazinomycin biosynthesis.5  FzmA, the aforementioned asparagine synthetase homolog,  
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Figure 4.1 Selected reactions catalyzed by asparagine synthetase and its homologs.  a) 
Asparagine synthetase (AsnB) transfers ammonia from glutamine to aspartic acid to make 
asparagine.  b) FzmA putatively transfers hydrazine from glutamylhydrazine to arginine.  c) 
TsnB9 transfers hydroxylamine from the side chain of glutamic acid to an acceptor carboxyl 
group during trichostatin biosynthesis.6  
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appears to be a prime candidate to effect this transformation (Figure 4.1b).  The chemistry 
required for this reaction is highly analogous to the reaction catalyzed by canonical asparagine 
synthetases.  In both cases, a small nitrogen-containing molecule is hydrolyzed from the side 
chain of glutamic acid by a glutaminase domain and is then joined to the carboxyl group of 
another amino acid in a distal synthetase domain.  The presence of an intermolecular tunnel 
responsible for joining the two domains makes this hypothesis especially attractive since such a 
channel avoids the liberation of free hydrazine, which is toxic, into the cytoplasm of the 
producing organism.  Further, a recent study provided another example of an asparagine 
synthetase homolog that transfers an N-X moiety from a glutamyl scaffold; in that work, TsnB9,  
catalyzes the transfer of hydroxylamine from the side chain of glutamic acid onto the carboxyl 
group of an advanced intermediate during trichostatin biosynthesis (Figure 4.1c).6   
 
4.1.3 FzmA hydrolyses glutamylhydrazine to hydrazine and glutamic acid 
 Dr. Zedu Huang, a former postdoctoral researcher in the van der Donk group, initially 
expressed FzmA (from Streptomyces sp. XY332) as an N-terminally His6-tagged recombinant 
protein in E. coli Rosetta-2 (DE3).  However, this resulted in insoluble protein.  He then realized 
that asparagine synthetases contain a highly conserved N-terminal cysteine residue that is critical 
for catalysis.  When FzmA was expressed in E. coli bearing a C-terminal His6-tag, soluble 
protein was observed and purified.  Dr. Huang further showed that FzmA acquired in this 
manner was at least partially active.  When FzmA was incubated with glutamylhydrazine, LC-
MS analysis following Fmoc-Cl derivatization revealed that glutamic acid was generated.4  Thus, 
these results showed that FzmA was able to accept glutamylhydrazine as a substrate and liberate 
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hydrazine.  However, Dr. Huang was unable to observe the formation of argininylhydrazine 
using either glutamylhydrazine or free hydrazine as substrates.   
 
4.1.4 PqqD-like proteins and domains 
 Interestingly, FzmA, in addition to the glutaminase and synthetase domains found in 
other asparagine synthetase homologs, contains an extra fragment of about 200 amino acid 
residues at its C-terminus.  Using HHPred, a tool for predicting structural homology based on 
hidden Markov models,7 I discovered that those extra 200 amino acid residues contain a PqqD-
like domain, itself comprised of about 100 residues.  PqqD is a protein found in the biosynthesis 
of pyrroloquinoline quinone (PQQ), a ribosomally synthesized and post-translationally modified 
peptide (RiPP) that serves as a redox cofactor.8-9  Curiously, while PqqD was found to form a 
complex with PqqE, another biosynthetic enzyme in PQQ biosynthesis, and was required for 
activity, it was initially unclear what role PqqD played during that process.10  In 2015, Klinman 
and coworkers established that in the PqqD/PqqE complex, PqqD is responsible for tight 
substrate binding while PqqE carries out catalysis.11  This strategy appears to be prevalent in the 
biosynthesis of RiPPs, with many RiPP biosynthetic enzymes containing PqqD-like domains; in 
these systems, the PqqD-like domain, termed the RiPP precursor peptide recognition element 
(RRE), is responsible for the recognition and binding of the peptidic substrates.12   
 
4.2 RESULTS AND DISCUSSION 
4.2.1 FzmA does not appear to prefer glutamylhydrazine over glutamine 
 Dr. Zedu Huang had shown that FzmA could hydrolyze glutamylhydrazine to yield 
glutamic acid and hydrazine.4  He also showed that FzmA was capable of hydrolyzing glutamine 
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to give glutamic acid and ammonia.  I set out to determine whether or not FzmA shows a clear 
preference for using glutamylhydrazine, our hypothesized on-pathway substrate, over glutamine 
(Figure 4.2a).  I incubated 10 μM FzmA with 1 mM each of glutamine and glutamylhydrazine in 
phosphate buffer.  Using 1H NMR spectroscopy, I could track the γ-protons in the two substrates 
(Figure 4.2b).  As the reaction proceeded, both glutamine and glutamylhydrazine were depleted 
at a similar rate (Figure 4.2c).  Thus, the substrate competition assay shows that FzmA does not 
show a clear preference for glutamylhydrazine over glutamine as a substrate at what are likely 
saturated conditions.   
Figure 4.2 FzmA converts glutamine and glutamylhydrazine to glutamic acid at similar rates. a) 
FzmA is capable of hydrolyzying both glutamylhydrazine and glutamine.  The γ-protons are 
highlighted.  b) 1H NMR spectrum of the γ-protons of glutamine and glutamylhydrazine.  c) 
Graph showing the 1H NMR integration values of the γ-protons of glutamine and 
glutamylhydrazine over time.  Since the resonances for glutamine, glutamic acid, and 
glutamylhydrazine overlap, only a portion of the peaks arising from glutamine and 




4.2.2 FzmA does not liberate acetylhydrazine from glutamylacetylhydrazine 
 FzmA shows hydrolysis activity towards glutamylhydrazine (and glutamine), but we had 
been unable to reconstitute the condensation of hydrazine and arginine.  Thus, we wondered if 
the nucleophile for the condensation step might be acetylhydrazine.  Our reconstitution of FzmN 
activity had placed glutamylacetylhydrazine as a biosynthetic intermediate.4  Therefore, I 
incubated glutamylacetylhydrazine with arginine, MgCl2, and FzmA in the presence of ATP, 
CTP, GTP, or UTP (Figure 4.3a).  By 1H NMR spectroscopy, I could not observe the depletion 
of glutamylacetylhydrazine (methyl group at 1.94 ppm) or the formation of either 
acetylhydrazine or argininylacetylhydrazine with any of the NTPs (Figure 4.3b).  This negative 
result combined with both the labeling studies with glutamylhydrazine and the reconstitution of 
FzmO activity (Chapter 3) likely discounts a pathway wherein glutamylacetylhydrazine directly 
donates acetylhydrazine to the fosfazinomycin structural scaffold.   
 
 
Figure 4.3 FzmA cannot accept glutamylacetylhydrazine as a substrate.  a) FzmA cannot 
hydrolyze glutamylacetylhydrazine.  b) 1H NMR spectra of the reaction of FzmA with 
glutamylacetylhydrazine, arginine, and the indicated NTP.  The peak at 1.92 ppm arises from the 
methyl group on glutamylacetylhydrazine.   
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4.2.3 FzmA cannot catalyze the formation of asparagine 
 Since FzmA was able to hydrolyze glutamine, like the canonical asparagine synthetases, I 
tested if FzmA is able to catalyze the formation of asparagine.  I incubated FzmA with 
glutamine, aspartic acid, MgCl2, and each of the four NTPs.  I followed the reaction by 
monitoring the β-protons of aspartic acid with 1H NMR spectroscopy.  Compared to a negative 
control where FzmA was withheld from the reaction mixture, no change in the 1H NMR 
spectrum could be observed (Figure 4.4).  Thus, we conclude that asparagine was not formed 
with any of the NTPs.  It should be noted that spiking the reaction mixtures with asparagine was 
not done here and should be performed in the future. 
 
 
Figure 4.4 1H NMR spectra of reaction mixtures consisting of FzmA, glutamine, aspartic acid, 
MgCl2, and the indicated NTP.  The chemical shift region corresponding to the β-protons of 
aspartic acid and asparagine is plotted.   
 
4.2.4 Initial attempts to reconstitute FzmA synthetase activity with various NTPs 
 While FzmA could readily liberate hydrazine from glutamylhydrazine, Dr. Huang did not 
observe the formation argininylhydrazine.  I began to study if I could reconstitute FzmA 
synthetase activity.  In canonical asparagine synthetases, the side chain of aspartic acid is 
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activated by adenylation before it is attacked by ammonia.  Thus, I tested if FzmA might use 
nucleoside triphosphates (NTPs) other than ATP for the activation of the carboxyl group of 
arginine.  FzmA was incubated with each of the four NTPs (ATP, CTP, GTP, and UTP) along 
with 13C6-labeled arginine and MgCl2.  13C NMR analysis showed that all of the arginine in 
solution remained unmodified compared to a control reaction where FzmA was withheld (Figure 
4.5a).  31P NMR analysis of the reaction mixtures showed that each of the NTPs was primarily 
transformed into mixtures of their respective NDPs and NMPs (Figure 4.5b).   
 
 
Figure 4.5 NMR analysis of a reaction mixture containing FzmA, 13C6-arginine, 
glutamylhydrazine, MgCl2, and the indicated NTP.  a) 13C NMR analysis shows that arginine is 
unmodified.  Peaks are lettered according to their assignment in the structure shown.  b) 31P 
NMR analysis shows that NTPs are hydrolyzed to a mix of NDPs and NMPs.  Peaks are 





4.2.5 Attempts to reconstitute FzmA synthetase activity with untagged protein 
 FzmA had thus far failed to show any activity related to adenylating or otherwise 
activating the arginine substrate, a reaction that should take place in a C-terminal domain.  Thus, 
we wondered if the C-terminal His6-tag used for purification might be interfering with enzyme 
activity.  I thus constructed a vector to express recombinant FzmA with a C-terminal His6-tag 
that was cleavable with thrombin.  After protein purification with Ni-IMAC, the untagged FzmA 
was acquired by incubating the protein with thrombin.  The experiments in section 4.2.2 were 
then repeated with the untagged FzmA.  However, still, I could not observe any activation of the 
arginine substrate by 13C NMR analysis.   
 I also tested FzmA from five of the other producing organisms that were available.  
FzmA from Streptomyces sp. NRRL F-2747, Streptomyces sp. NRRL S149, Streptomyces sp. 
NRRL S-50, Streptomyces sp. NRRL S-244, and Streptomyces sp. NRRL S-444 were expressed 
and purified as C-terminally His6-tagged proteins.  The tag was removed prior to attempting 
enzymatic assays.  Again, the experiments from section 4.2.2 were repeated with each of the 
FzmA homologs, but no modification of the arginine substrate could be detected by 13C NMR 
analysis.   
 
4.2.6 Efforts towards activating arginine with other enzymes 
 Since we had only observed background hydrolysis of NTPs and no activity that would 
activate the carboxyl group of arginine, I investigated whether another enzyme encoded in the 
fosfazinomycin biosynthetic cluster might be responsible for arginine activation.  Two 
candidates stood out.  FzmK, a thymidylate kinase homolog, and FzmF, an ATP-grasp enzyme, 
are both theoretically capable of activating an electrophilic species through phosphorylation.  
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Thus, FzmK was incubated with FzmA, glutamylhydrazine, 13C6-arginine, one of the four NTPs, 
and MgCl2.  Unfortunately, by 13C NMR analysis, no consumption of arginine (transformed 
either to an activated form of arginine or to argininylhydrazine) could be observed.  The same set 
of experiments was repeated with FzmF, but again, no consumption of arginine could be 
observed.   
 
4.2.7 Cleaving off the PqqD-like domain 
 As mentioned before, FzmA contains a C-terminal PqqD-like domain.  I hypothesized 
that this extra domain, which has no obvious function, might be occluding the nearby synthetase 
domain, leading to the observed lack of substrate activation.  Thus, I made a construct to express 
a truncated version of FzmA without the predicted PqqD-like domain.  I successfully expressed 
and purified this truncated FzmA (1-Gly551-His6).  This enzyme was then assayed for activity 
with glutamylhydrazine, 13C6-arginine, each of the NTPs, and MgCl2.  Unfortunately, again, by 
13C NMR, no modifications on the argininyl scaffold could be observed.   
 
4.2.8 A conserved PqqD-like protein and a nucleotidyltransferase are conserved in 
fosfazinomycin-producing organisms 
 The putative boundaries for the fosfazinomycin biosynthetic gene cluster were originally 
set from fzmA to fzmS by comparing the gene neighborhood of pepM in two producing 
organisms, Streptomyces sp. WM6372 and Streptomyces sp. XY332.1  Unfortunately, at the time, 
the contig used from Streptomyces sp. XY332 was cut off after fzmS.  Since we have not been 
able to experimentally verify the boundaries of the gene cluster through either gene deletion 
experiments or heterologous production, I revisited this issue.  Comparing the gene 
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neighborhoods of all nine of the producing organisms available, I discovered that at least two 
genes upstream of fzmS are conserved.  These genes are predicted to encode for a PqqD-like 
protein and a nucleotidyltransferase, which I optimistically name FzmT (NCBI accession: 
WP_053787789, Uniprot accession: A0A0N0CIJ3) and FzmU (NCBI accession: 
WP_053787788.1, Uniprot accession: A0A0M9CNZ6), respectively.   
 I then performed bioinformatic analysis on FzmU using the Enzyme Function Initiative’s 
Genome Neighborhood Tool (EFI-GNT) (Figure 4.7ab).13  I found that of the 43 closest FzmU 
homologs from the UniProt database, the genes encoding for 36 homologs are also within 10 
open reading frames of a gene encoding for a PqqD-like protein.  Of the 36 examples where 
genes encoding for FzmUT homologs were co-localized, 32 of those are also within 20 open 
reading frames of a gene encoding for an asparagine synthetase homolog such as FzmA.  Lastly, 
29 of the 32 asparagine synthetase homologs that were co-localized with FzmUT homologs were 
also fused to a PqqD-like domain, including FzmA.   
 
 
Figure 4.6 Sequence similarity network of FzmU homologs at E=57.  FzmU from 
fosfazinomycin-producing organisms are colored in red.  The UniProt accession numbers for 








1 A0A0M9CNZ6 Uncharacterized protein Streptomyces sp. XY332  
1 A0A0F4J1S7 Uncharacterized protein Streptomyces sp. NRRL S-444  
1 A0A2T6A5C3 Uncharacterized protein Nocardioides sp. CF167  
1 A0A239NMQ4 Nucleotidyltransferase Streptomyces glauciniger  
1 A0A2N0J1J7 Uncharacterized protein Streptomyces sp. 69  
1 A0A2T7J7S4 Uncharacterized protein Streptomyces sp. CS081A  
1 A0A2L2PYV8 Uncharacterized protein Streptomyces sp. WAC00288  
1 A0A150VYM3 Uncharacterized protein Streptomyces sp. WAC04657  
1 A0A0L8KM06 Uncharacterized protein Streptomyces viridochromogenes  
1 A0A2N4A2K2 Uncharacterized protein Streptomyces sp. OK885  
1 A0A1Q5I883 Uncharacterized protein Streptomyces sp. CB02115  
1 A0A2S4ZAG2 Uncharacterized protein Streptomyces sp. Ru62  
1 A0A0M8S945 Uncharacterized protein Streptomyces sp. WM6372  
1 A0A101J6Y1 Uncharacterized protein Streptomyces regalis  
1 A0A1G7XHE2 Uncharacterized protein Lechevalieria fradiae  
1 A0A1Q5EYS7 Uncharacterized protein Streptomyces sp. TSRI0261  
1 A0A0J7ZAD0 Uncharacterized protein Streptomyces viridochromogenes  
1 A0A0N1G3Q4 Uncharacterized protein Actinobacteria bacterium OK074  
1 G8RZY9 Uncharacterized protein Actinoplanes sp. (strain ATCC 
31044) 
1 A0A0M8VD31 Uncharacterized protein Streptomyces sp. AS58  
1 U5YMV7 Uncharacterized protein Streptomyces sp. MMG1662 
1 A0A1K0FIY9 Uncharacterized protein Couchioplanes caeruleus subsp. 
caeruleus  
1 A0A1Q8CZ36 Uncharacterized protein Actinophytocola xanthii  
1 A0A2M9JDF3 Uncharacterized protein Streptomyces sp. CB01201  
1 A0A1A9CL23 Nucleotidyltransferase Streptomyces sp. Ncost-T6T-1  
1 A0A2G6Z7J2 Uncharacterized protein Streptomyces sp. 2233.5  
1 A0A212TUN5 Uncharacterized protein Streptomyces sp. 2114.4  
1 A0A2A3IJ78 Uncharacterized protein Streptomyces sp. 2321.6  
1 A0A0Q7QBN4 Uncharacterized protein Aeromicrobium sp. Root495  
1 A0A060ZCW4 Uncharacterized protein Streptomyces iranensis  
1 A0A2N0GWT0 Uncharacterized protein Streptomyces sp. Ag109_G2-1  
1 A0A238X5G9 Uncharacterized protein Actinoplanes regularis  
1 A0A0N1N938 Uncharacterized protein Actinobacteria bacterium OK074 
1 A0A1C5BWV0 Uncharacterized protein Streptomyces sp. DconLS  
1 A0A1C5A8Y2 Uncharacterized protein Micromonospora marina  
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Table 4.1 (continued) 
1 A0A1X4GXD1 Uncharacterized protein Streptomyces griseofuscus  
1 A0A0L8L361 Uncharacterized protein Streptomyces resistomycificus  
1 A0A1W5Z4S1 Uncharacterized protein Streptomyces sp. S8  
1 A0A1C6LNG4 Uncharacterized protein Streptomyces sp. AmelKG-D3  
1 A0A1E7LJT3 Uncharacterized protein Streptomyces nanshensis  
1 A0A2S3YC31 Uncharacterized protein Streptomyces sp. ZL-24  
1 A0A1B1ASM4 Uncharacterized protein Streptomyces griseochromogenes  
1 A0A0X3V4J7 Uncharacterized protein Streptomyces regalis  
1 A0A0X3V4K5 Uncharacterized protein Streptomyces regalis  
1 A0A1Q8UCF5 Uncharacterized protein Streptomyces sp. MNU77  
1 A0A209CUM3 Uncharacterized protein Streptomyces sp. CS057  
2 A0A0V8HDJ1 Nucleotidyltransferase Bacillus enclensis 
2 K2NAV9 Uncharacterized protein Bacillus xiamenensis  
2 V6M9Z3 Uncharacterized protein  Brevibacillus panacihumi W25 
2 A0A2I7T0G9 Uncharacterized protein  Bacillus subtilis 
2 A0A2A8VEA6 Uncharacterized protein Bacillus sp. AFS015802 
3 A0A2U4H4Q4 Peptidase Stenotrophomonas maltophilia 
3 B2FLJ3 Putative oligopeptidase Stenotrophomonas maltophilia 
(strain K279a) 
3 A0A0X3RBJ5 Peptidase Stenotrophomonas maltophilia 
3 A0A2J0TTG2 Peptidase Stenotrophomonas maltophilia 
3 J7VKI4 Uncharacterized protein Stenotrophomonas maltophilia 
Ab55555 
3 A0A2U2YUP4 Peptidase Stenotrophomonas maltophilia 
3 A0A1V3D2X7 Peptidase Stenotrophomonas maltophilia 
4 A0A1Q5EJ64 Uncharacterized protein Streptomyces sp. TSRI0261 
4 A0A209DAQ3 Uncharacterized protein Streptomyces sp. CS057 
4 A0A1Z2LDE1 Uncharacterized protein Streptomyces albireticuli 
4 A0A1C6RUA2 Uncharacterized protein Micromonospora pallida 
5 A0A0G3IY69 Uncharacterized protein Mycobacterium sp. EPa45  




5 A0A1X0IZR6 Uncharacterized protein Mycobacterium rhodesiae 
5 W5WDE1 Uncharacterized protein Kutzneria albida DSM 43870  
5 A0A2I0SSI3 Uncharacterized protein Streptomyces sp. A249  
6 A0A0J7Z8G7 Uncharacterized protein  Streptomyces viridochromogenes 
6 D9VMI2 Predicted protein Streptomyces sp. C 
6 A0A1K2FW00 Uncharacterized protein Streptomyces sp. F-1 
6 A0A1H4VCQ7 PqqD Streptomyces misionensis  
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Table 4.1 (continued) 
7 W5VY47 Uncharacterized protein  Kutzneria albida DSM 43870  
7 A0A0N7F2E9 Uncharacterized protein Kibdelosporangium phyohabitans 
7 A0A1W2DJ47 Uncharacterized protein Kibdelosporangium aridum 
7 W7SKK4 ATPase (Fragment)  Kutzneria sp. 744 
- A0A0Q7XX85 Uncharacterized protein Rhizobium sp. Root149  
- A0A2J6TEH7 Glycoside hydrolase 
family 64 protein 
Meliniomyces bicolor E  
- A0A2E7B2P4 Saccharopine 
dehydrogenase 
Hyphomonas sp.  
- C1CY60 Putative peptidase Deinococcus deserti (strain 
VCD115) 
- A0A090Z5Z8 Uncharacterized protein Paenibacillus macerans  
- A0A2S7XXT3 Uncharacterized protein Beauveria bassiana  
- A0A0A2W712 Phosphoinositide 
phospholipase 
Beauveria bassiana D1-5  
- D9WK33 Uncharacterized protein Streptomyces himastatinicus 
ATCC 53653  
- A0A2R4EFY7 Uncharacterized protein  Acidovorax avenae subsp. avenae  
- A0A1S2PIH3 Uncharacterized protein Streptomyces sp. MUSC 1  
- F4GID3 Uncharacterized protein  Sphaerochaeta coccoides (strain 
ATCC BAA-1237)  
- A0A0E9ELI2 Uncharacterized protein Chlamydia trachomatis  
- J4KQA9 Phosphoinositide 
phospholipase 
Beauveria bassiana (strain 
ARSEF 2860)  
- A0A0F7G128 Enoyl-CoA 
hydratase/isomerase 
Streptomyces xiamenensis  
- A0A1H6CWN6 Protein-L-isoaspartate O-
methyltransferase 
Actinomadura echinospora  
- A0A251RNZ3  Enhancer of polycomb-
like protein 
Helianthus annuus  
- A0A1G7VXK4 Nucleotidyltransferase Microbacterium pygmaeum  
- A0A1R0Y7D0 Uncharacterized protein  Paenibacillus borealis  
- A0A060NSB2 Uncharacterized enzyme 
of heme biosynthesis 
Comamonadaceae bacterium B1  
- A0A2I0EYT1 Uncharacterized protein Planococcus sp. Urea-3u-39  
- A0A1G1SHZ0 UPF0061 protein Exiguobacterium sp. SH31  
- A0A0B0ICN3 Uncharacterized protein  Bacillus okhensis  
- A0A0T1WS95  Pilus assembly protein 
TadD 
Rhizobium sp. Root482  
- A0A174BKT5 Uncharacterized protein Coprococcus comes  
- A0A1C5R277 Uncharacterized protein uncultured Ruminococcus sp.  
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Table 4.1 (continued) 
- A0A1C4TCG7 Uncharacterized protein Streptomyces sp. DvalAA-43  
- A0A101NRU5 Uncharacterized protein Streptomyces yokosukanensis  
- A1R3X9 Uncharacterized protein Paenarthrobacter aurescens 
(strain TC1)  
- A0A1Q4WZE0 Uncharacterized protein Saccharothrix sp. CB00851  
- X5EE59 Uncharacterized protein Corynebacterium glyciniphilum 
AJ 3170  
- A0A243Q582 Uncharacterized protein Streptomyces swartbergensis  
- A0A1G3JFU1 Uncharacterized protein Sphingomonadales bacterium  
- A0A2D6H1W9 Uncharacterized protein Blastomonas sp.  
- A0A090YNE7 Nucleotidyltransferase Bacillus mycoides  
- A0A0E2NJP9 Uncharacterized protein Mesorhizobium sp. LSHC414A00  
- A0A261EVG9 Uncharacterized protein Bombiscardovia coagulans  
- A0A132U921 Uncharacterized protein Paenibacillus riograndensis  
- G7VR96 Uncharacterized protein Paenibacillus terrae (strain HPL-
003)  
- A0A109IJQ6 Uncharacterized protein Micromonospora rifamycinica  
- A0A0F7E4S5 Uncharacterized protein  Myxococcus fulvus 124B02  
- A0A1H8Y870 Uncharacterized protein Amycolatopsis saalfeldensis  
- A0A1I0LIA0 Uncharacterized protein Myxococcus fulvus  
- A0A2T4ZLC0 Putative 
nucleotidyltransferase 
Nitrosomonas sp. Nm141  
- A0A1Q4XUW0 Uncharacterized protein Streptomyces sp. CB03911  
- A0A2C2AAA8 Uncharacterized protein  Bacillus cereus  
- A0A2A8CGK6 Uncharacterized protein Bacillus wiedmannii  
- A0A0N0YE02 Uncharacterized protein Streptomyces sp. NRRL S-4  
- C2CMV6 Nucleotidyltransferase Corynebacterium striatum ATCC 
6940  
- A0A098M3D9 Uncharacterized protein Paenibacillus wynnii  
- A0A2G7CQW8 PqqD Streptomyces sp. 61  
- A0A0L8KM62 Uncharacterized protein  Streptomyces viridochromogenes  
- A0A1Q7W9G8 Uncharacterized protein  Catenulispora sp. 
13_1_20CM_3_70 
- A0A2H5YV76 HTH-type transcriptional 
regulator  
bacterium HR26  
- A0A2M8WQ01 Uncharacterized protein Yoonia maricola  
- A0A1E5LJM5 Uncharacterized protein Bacillus solimangrovi  




Table 4.1 (continued) 
- F5XXB5 Uncharacterized protein Ramlibacter tataouinensis (strain 
ATCC BAA-407) 
- A0A0S4K8C4 Uncharacterized protein Janthinobacterium sp. CG23_2  
- S3H810 Uncharacterized protein  Rhizobium grahamii CCGE 502  
- A0A1C5JKB5 Mce-associated 
membrane protein  
Micromonospora inositola  
- A0A0B5EII1 Polyketide synthase type 
I  
Streptomyces albus (strain ATCC 
21838) 
- A0A2R6DFS6 Phosphoglycerate kinase  Halobacteriales archaeon 
QH_6_64_20  
 
 Therefore, due to the high incidence of co-localization of genes encoding for FzmATU 
homologs, it seemed likely that FzmTU are involved either in the same chemical step catalyzed 
by FzmA or that FzmTU are involved in steps immediately preceding or subsequent to the 
FzmA-catalyzed step.  Further, in all our efforts to reconstitute FzmA activity, FzmA has failed 
to activate the carboxyl group of arginine.  FzmU is a nucleotidyltransferase homolog which may 
be able to fill the role of electrophile activation.   
 
4.2.9 Enzyme assays with FzmATU 
 I expressed and purified recombinant FzmT and FzmU as N-terminally His6-tagged 
proteins.  I first attempted to test whether FzmU might be able to activate arginine.  When FzmU 
was incubated with ATP, 13C6-arginine, and MgCl2, no activation of arginine could be observed 
by either 31P or 13C NMR spectroscopy.  I repeated the experiment with CTP, GTP, and UTP in 
lieu of ATP, but the same result was observed.  While this result was disappointing, it was 
possible that FzmATU all needed to work in tandem.  Thus, I next attempted to reconstitute the 
FzmATU-catalyzed formation of argininylhydrazine from glutamylhydrazine, 13C6-arginine, 
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NTPs, and MgCl2.  Unfortunately, again, no conversion of arginine could be observed by 13C 
NMR spectroscopy.   
 In other systems, PqqD-like domains and proteins are often binding a peptide substrate.12  
Thus, we wondered whether FzmATU might work on the same or similar substrates, where both 
the PqqD-like domain of FzmA and FzmT are responsible for substrate binding.  With a small 
substrate such as arginine, though, the PqqD-like structures will have nothing to bind to.  Thus, 
we speculated that the true substrate of a possible FzmA might be a larger biomolecule with 
arginine appended.  One such possible substrate could be Arg-tRNAArg.  To test this hypothesis, I 
purified total RNA, including tRNA, from E. coli.  This purified RNA was added to a reaction 
mixture consisting of FzmA, 13C6-arginine, glutamylhydrazine, ATP, and MgCl2; further 
addition of the ArgRS enzyme from E. coli enabled, in principle, the production of Arg-tRNAArg 
in situ.  The reaction was then monitored by NMR, but no argininylhydrazine could be observed.   
 
4.3 SUMMARY AND OUTLOOK 
 The failure to reconstitute synthetase activity from FzmA was disappointing.  Despite a 
number of approaches, we were never able to achieve anything that resembled activation of the 
arginine electrophile.  It is possible that we missed an important cofactor or cosubstrate.  
However, due to both the annotation of FzmA and the chemistry that is required, I think that this 
is unlikely to be the case.  Another possibility is that the C-terminal region of recombinant FzmA 
is misfolded.  This would explain the lack of activation activity observed despite the active N-
terminal glutaminase domain.  For instance, perhaps a C-terminal residue is vital, and the C-
terminal His6-tag that is present during recombinant expression interferes protein folding.  
Further, it should be noted that thrombin, which cleaves between Arg and Gly in a Leu-Val-Pro-
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Arg-Gly-Ser motif leaves behind a short Leu-Val-Pro-Arg tag, which itself may still interfere 
with the function of the C-terminal domains of FzmA.  This possibility can be addressed by 
expressing FzmA as a tagless protein in E. coli.  Biotransformation experiments or experiments 
involving cell lysate can then be performed.  Any promising results can then be followed up on 
with the purification of tagless FzmA and in vitro enzymatic assays.  Another experiment can be 
performed to probe the synthetase activity of FzmA.  Ammonia can be provided to the enzyme 
both as free ammonia and as glutamine and assayed to test if it can be condensed onto the 
carboxyl group of arginine to make arginine-amide.   
 However, I suspect that the reason for the lack of activation or synthetase activity is that 
we have not sampled the correct substrate.  The detection of the PqqD-like domain of FzmA as 
well as discovery of FzmTU raises the obvious question regarding why the fosfazinomycin 
biosynthetic cluster encodes for two PqqD-like structures.  If these structures play a similar role 
as they do in RiPP biosynthesis, arginine is likely not the correct substrate.  We have started to 
probe whether Arg-tRNAArg might be the true acceptor of hydrazine.  However, in that 
experiment, I used E. coli tRNA with an E. coli ArgRS.  Thus, it is possible that the 
fosfazinomycin biosynthetic machinery, which is from Streptomyces, cannot recognize the 
aminoacylated tRNA from E. coli.  This experiment should be repeated with tRNA and an 
ArgRS from the native producing organism.  Further, aminoacylation assays using 14C-labeled 
arginine should be conducted to ensure that Arg-tRNAArg is being made.14 
 Arginine might also be carried on another biomolecule.  A peptide with a C-terminal 
arginine residue is perhaps another more obvious possible substrate.  A peptidic susbstrate here 
would require a peptidase to eventually liberate argininylhydrazine; curiously, a number of 
FzmU homologs are putatively annotated as peptidases (cluster 3 from Table 4.1).  However, 
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FzmI has been shown to be responsible for installing the N-terminal valine residue in the final 
steps of fosfazinomycin biosynthesis.  If arginine is indeed carried to FzmA on a peptide, this 
would be a very circuitous pathway, indeed.  However, such a pathway cannot be ruled out at 
this stage, especially given the circuitous route to glutamylhydrazine outlined in Chapter 3.4  The 
roles of the PqqD-like domain on FzmA and the PqqD homolog, FzmT should be further 
investigated.  Again, crystallographic data would be helpful here, especially in determining if the 
PqqD-like domain is actually structurally similar to RREs found in RiPP biosynthesis.   
 Another possibility for the lack of desired enzymatic activity is the role of enzyme 
complexes.  The possibility of FzmATU complexation should be investigated using a pull-down 
assay in E. coli co-expressing all three enzymes.  These experiments should then be followed up 
on by size exclusion chromatography.   
 To further address the issue of the role of enzyme complexes, biotransformation 
experiments can be undertaken.  Sets of enzymes can be expressed in E. coli, substrates can then 
be fed, and putative products can be identified with undirected metabolomics.  Good candidate 
enzymes to be co-expressed in various combinations include FzmAEFHKTU.   
 The seemingly nonspecific hydrolysis of NTPs observed by 31P NMR analysis in reaction 
mixtures with FzmA is also troubling.  A study with E. coli AsnB showed inactivating mutations 
in the C-terminal active site unmasked intrinsic ATPase activity that did not appear with wild-
type enzyme.15  Thus, it is possible that FzmA itself is unable to catalyze either the activation of 
or the subsequent attack on arginine.  However, it is also possible that FzmA contains intrinsic 
NTP hydrolysis activity that is not observed with AsnB; it is also not possible to rule out at this 
stage that the observed NTP hydrolysis is not catalyzed by minor impurities in the purification of 




4.4.1 General methods 
 Unless otherwise noted, all reagents were purchased from either Sigma-Aldrich or Fisher 
Scientific.  Synthetic oligonucleotides were purchased from Integrated DNA Technologies 
(IDT).  Enzymes used in cloning were purchased from New England Biosciences (NEB). DNA 
sequencing was performed by ACGT Inc. or the Roy J. Carver Biotechnology Center (University 
of Illinois at Urbana-Champaign).  NMR experiments were conducted on an Agilent 600 MHz 
instrument with a OneNMR broadband probe, and the data was analyzed using MestreNova.    
 






























 To prepare constructs for expressing FzmA, genomic DNA was isolated from 
Streptomyces sp. XY332, Streptomyces sp. NRRL F-2747, Streptomyces sp. NRRL S-50, 
Streptomyces sp. NRRL S-149, Streptomyces sp. NRRL S-244, and Streptomyces sp. NRRL S-
444 using the Ultraclean Microbial DNA Isolation Kit (Mo Bio) following the manufacturer’s 
instructions.  The primers listed in Table 4.2 were then used to amplify fzmA from the genomic 
DNA using Q5 polymerase following the manufacturer’s instructions.  The amplicons were then 
ligated into pET23b (Novagen), which had been digested with NdeI and XhoI, using the HiFi 
Assembly Kit (NEB) following the manufacturer’s instructions using a 2:1 stoichiometry of 
insert to vector.  Aliquots (5 μL) were used to transform 10 μL of NEB-5-α chemically 
competent cells (NEB).  The fidelity of the insertions was verified by DNA sequencing.   
 To make the expression constructs for FzmT and FzmU, the corresponding genes were 
amplified from Streptomyces sp. XY332 genomic DNA with Q5 polymerase following the 
manufacturer’s instructions.  fzmT and fzmU were then ligated into pET15b (Novagen) digested 
with NdeI and XhoI using the HiFi Assembly Kit.  Aliquots (5 μL) were used to transform 10 μL 
of NEB-5-α chemically competent cells (NEB), and the fidelity of the insertions was verified by 
DNA sequencing.  (NB entry for 6-8-18) 
 
4.4.3 Protein expression and purification 
 E. coli BL21 (DE3) transformed with the relevant plasmids constructed in section 4.4.2 
were cultivated in LB with 100 μg mL-1 ampicillin for 12 h at 37 °C, and 40 mL of this starter 
culture was used to inoculate 4 L of LB supplemented with 100 μg mL-1 ampicillin.  Cultivation 
of this culture continued at 37 °C, shaking at 210 rpm until OD600 reached between 0.5 and 0.7.  
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IPTG (Gold Biotechnology) was then added to a final concentration of 100 μM.  The culture was 
then grown for an additional 16 h at 18 °C with shaking at 210 rpm.  The spent culture medium 
was removed via centrifugation, and the cell pellet was resuspended in lysis buffer (50 mM 
NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol) supplemented with 1 mg mL-1 
lysozyme (Gold Biotechnology) and 20 U mL-1 DNAse I.  This mixture was then incubated at 4 
°C for 20 min with mild agitation.  The suspension was then passaged twice through a French 
pressure cell to accomplish cell lysis.  All subsequent steps in the purification of the protein were 
then performed at 4 °C.  Cellular debris was removed by centrifugation for 45 min at 30,600 × g.  
The supernatant was then loaded onto 5 mL of Ni-NTA resin (Qiagen) and incubated with mild 
agitation for 15 min before being allowed to flow through.  The resin was then washed with 40 
mL of wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% glycerol).  The 
protein was eluted with 20 mL of elution buffer (50 mM NaH2PO4, 300 mM NaCl, 300 mM 
imidazole, 10% glycerol), and the eluate was concentrated to a volume of 2.5 mL using an 
Amicon spin filter with a 30 kDa molecular weight cutoff.  The sample was then desalted using a 
PD-10 cartridge (GE Healthcare), eluting with 3.5 mL of storage buffer (50 mM NaH2PO4, 300 
mM NaCl, 10% glycerol) as per the manufacturer’s instructions.  (NB entry for 9-26-17) 
 To remove the C-terminal His6-tag from FzmA homologs, 7 mg of FzmA was incubated 
with 500 U of thrombin in 4 mL of storage buffer.  This mixture was incubated for 12 h at 4 °C 
with mild agitation.  The sample was then incubated with 1 mL of Ni-NTA resin for 10 min at 4 
°C.  The eluate was incubated with 1 mL of p-aminobenzamidine resin (Sigma-Aldrich) with 
mild agitation for 20 min at 4 °C to remove thrombin; then the eluate was collected and 




4.4.4 Competition assay between glutamine and glutamylhydrazine 
 The reaction mixture consisting of 1 mM glutamine, 1 mM glutamylhydrazine (synthesis 
described in Chapter 3), 50 mM NaH2PO4, pH = 7.7, and 9% D2O in a total volume of 473.6 μL 
was placed in a 5 mm bore NMR tube.  A 1H NMR spectrum with PRESAT solvent suppression 
was acquired.  Then 76.4 μL of FzmA (to a total concentration of 10 μM) was added to initiate 
the reaction, and a spectrum was acquired every 4 min for 13 h.  The integrations of the γ-
protons on glutamine and glutamylhydrazine were determined for each spectra using 
MestreNova software and plotted versus time in Microsoft Excel (NB entry for 4-10-18).   
 
4.4.5 FzmA reaction with glutamylacetylhydrazine 
 Reactions were set up in 400 μL scale consisting of 10 μM FzmA, 10 mM MgCl2, 2 mM 
glutamylacetylhydrazine, 2 mM arginine, 5 mM of NTP (ATP, CTP, GTP, or UTP), in 50 mM 
HEPES , pH = 7.5.  A negative control without added enzyme consisting of 10 mM MgCl2, 2 
mM glutamylacetylhydrazine (provided by Dr. Zedu Huang), 2 mM arginine, and 5 mM ATP, in 
50 mM HEPES, pH = 7.5 was also run.  The mixture was incubated at ambient room temperature 
for 12 h.  Metals were then removed by incubating the mixtures with Chelex resin (Sigma-
Aldrich) at room temperature with agitation for 20 min.  The chelex resin and enzyme were then 
removed via centrifugation through an Amicon spin filter with a 10 kDa molecular weight cutoff, 







4.4.6 Attempt at reconstitution of asparagine formation with FzmA 
 Reactions were set up in 400 μL scale consisting of 10 μM FzmA, 10 mM MgCl2, 2 mM 
glutamine, 2 mM aspartic acid, and 5 mM NTP (ATP, CTP, GTP, or UTP), in 50 mM HEPES, 
pH = 7.5.  A negative control was also run consisting of 10 mM MgCl2, 2 mM glutamine, 2 mM 
aspartic acid, and 5 mM CTP in 50 mM HEPES, pH = 7.5.  The mixtures were incubated at room 
temperature for 13 h.  The reaction mixtures were then processed and analyzed identically as for 
the samples in section 4.4.5.  (See NB entry for 11-10-16) 
 
4.4.7 Reactions involving FzmA, NTPs, and arginine 
 Reactions were set up in 500 μL scale consisting of 10 μM FzmA, 10 mM MgCl2, 2 mM 
glutamylhydrazine or hydrazine, 2 mM 13C6-arginine [13C, 98%, Cambridge Isotope 
Laboratories], and 5 mM NTP (ATP, CTP, GTP, or UTP) in 50 mM NaH2PO4, pH = 7.7.  
Reactions were incubated at room temperature for 12 to 14 h.  Then, 50 μL of a 0.5 M EDTA 
stock solution was added along with 50 μL of D2O.  The enzymes were removed by an Amicon 
spin filter with a 10 kDa molecular weight cutoff before NMR analysis.  (See NB entry for 6-15-
18) 
 
4.4.8 Enzyme assays of FzmA with FzmK and FzmF 
 Reactions were set up in 400 μL scale consisting of 10 μM FzmA, 10 μM FzmK, 10 mM 
MgCl2, 2 mM glutamylhydrazine, 2 mM aspartic acid, and 5 mM NTP (ATP, CTP, GTP, or 
UTP), in 50 mM NaH2PO4, pH = 7.7.  A negative control was also run consisting of 10 mM 
MgCl2, 2 mM glutamine, 2 mM aspartic acid, and 5 mM CTP in 50 mM NaH2PO4, pH = 7.7.  
The mixtures were incubated at ambient room temperature for 13 h.  The reaction mixtures were 
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then processed and analyzed identically as for the samples in section 4.4.5.  Reactions with FzmF 
were also run identically as above with 10 μM FzmF used in place of FzmK.  (See NB entry for 
6-2-16) 
 
4.4.9 Enzyme assays involving FzmATU 
 Reactions were set up in 500 μL scale consisting of 10 μM FzmA, 10 μM FzmT, 10 μM 
FzmU, 5 mM MgCl2, 2 mM glutamylhydrazine or hydrazine, 2 mM 13C6-arginine [13C, 98%, 
Cambridge Isotope Laboratories], and 3 mM NTP (ATP, CTP, GTP, or UTP) in 50 mM 
NaH2PO4, pH = 7.7.  Reactions were incubated at room temperature for between 12 and 14 h.  
Then, 50 μL of a 0.5 M EDTA stock solution was added along with 50 μL of D2O.  The enzymes 
were removed by an Amicon spin filter with a 10 kDa molecular weight cutoff before NMR 
analysis.  (See NB entry for 8-6-18) 
 
4.4.10 Enzyme assay using FzmA and Arg-tRNAArg 
 Total RNA was isolated from E. coli  BL21 (DE3) using the Omega E.Z.N.A. RNA 
Isolation Kit following the manufacturer’s instructions, and E. coli ArgRS was purchased from 
Sigma-Aldrich.  Reactions were set up in 100 μL scale consisting of 10 μM FzmA, 10 mM 
MgCl2, 2 mM glutamylhydrazine, 2 mM 13C6-arginine [13C, 98%, Cambridge Isotope 
Laboratories], 5 mM ATP, 5 U/μL ArgRS, and 150 ng/μL in NaH2PO4, pH = 7.7.  A parallel 
reaction was also set up using hydrazine (at 2 mM) instead of glutamylhydrazine as a substrate.  
A negative control was run wherein FzmA was withheld from the reaction mixture.  The 
reactions were incubated at ambient temperature for 12 h before the addition of 10 μL of 0.5 M 
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EDTA.  Enzymes were removed using an Amicon spin filter with a 10 kDa molecular weight 
cutoff, and 400 μL of D2O was added for NMR analysis.  (See NB entry for 6-25-18) 
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5.1.1 The heme cofactor and heme proteins 
 The heme cofactor consists of an iron metal center coordinated by a porphyrin ring, and 
various β-pyrrolic substituents determine the identity of the heme.1  The most frequently 
occurring heme type is heme b, which itself also serves as a precursor for the biosynthesis of 
other hemes, such as heme a and heme c (Figure 5.1).2-3  The highly conjugated porphyrin ring 
imbues heme with unique spectroscopic properties; π→π* transitions give rise to the Soret band 
(an intense peak around 400 nm) and the Q bands (a weaker set of peaks around 550 nm).4   
 
Figure 5.1 The structures of the three most common heme types, heme a, heme b, and heme c. 
 
Proteins containing heme prosthetic groups are involved in a variety of biological 
functions including oxygen transport, electron transfer, gas-sensing, and chemical catalysis.2  
Inside the active site of heme enzymes, the enzyme contributes an axial ligand that coordinates 
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with the heme iron center.  The nature of this axial ligand-interaction fine tunes the properties of 
the iron center, and enzymes within the same class use the same axial ligand.5-6  For instance, 
cytochrome P450s (CYP450s), chloroperoxidases, and nitric oxide synthases all use cysteine, 
peroxidases use histidine, and catalases use tyrosine.5   
 
5.1.2 CYP450-catalyzed nitration 
 Heme proteins, as previously stated, can catalyze a large variety of reactions.  Of 
particular relevance to this study are heme proteins that are either involved in the donation of 
nitrogen atoms to natural product scaffolds or are implicated in the formation of nitrogen-
nitrogen (N-N) bonds in other contexts.  An example of the former can be found in the 
biosynthesis of thaxtomin (Figure 5.2a).7  Thaxtomin phytotoxins were first discovered in 1989 
from the plant pathogen Streptomyces scabies.8  The core scaffold of thaxtomin is assembled by 
nonribosomal peptide synthetases, which join L-phenylalanine with L-4-nitrotryptophan.9  To 
generate L-4-nitrotryptophan, nitrous oxide is first formed from arginine by TxtD, a nitric oxide 
synthase homolog.10-11  TxtE, a cytochrome P450 enzyme, then catalyzes the regioselective 
nitration of tryptophan, using nitric oxide as the nitrogen source.7  In the mechanism proposed by 
Challis and co-workers, the binding of tryptophan to the active site triggers the heme center to 
adopt a high spin ferric state (Figure 5.2b).  After electron transfer, the reduced ferrous heme 
center binds dioxygen to form a ferric superoxide species.7  The ferric superoxide species then 
reacts with nitric oxide, forming a ferric peroxynitrite species, which subsequently undergoes 
homolytic cleavage along the oxygen-oxygen bond to yield compound II (an Fe(IV)=O species) 
and NO2.  Hydrogen atom abstraction from tryptophan by compound II and nitration by NO2 




Figure 5.2 Interesting enzymology in thaxtomin biosynthesis.  a) The biosynthesis of L-4-
nitrotryptophan and the structure of thaxtomin A.  b) The proposed mechanism of tryptophan 
nitration by TxtE.  The heme cofactor is abbreviated.  Figure adapted from Barry et al. Nat. 
Chem. Biol. 2012, 8, 814.7 
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5.1.3 Nitric oxide reductase 
 Nitric oxide reductase (NOR) is a membrane-bound heme-containing enzyme that plays 
an important role during denitrification, catalyzing the reduction of nitric oxide to nitrous oxide 
and forming a N-N bond in the process (Figure 5.3a).12  NOR contains a binuclear active site, 
which includes both a heme b prosthetic group, with histidine as an axial ligand, and a nonheme 
iron ion coordinated to three histidine residues and a single glutamic acid residue.13  A number of 
mechanistic hypothesis have been proposed for the NOR reaction.12-15  While some controversy 
still exists, here I will highlight the “cis-b3 mechanism” which appears to be the one most 
supported by both computational and experimental work.16-17  In this proposed mechanism, the 
first molecule of nitric oxide enters the active site, binds to heme, and displaces a bound 
molecule of water.  The second molecule of nitric oxide then enters and after electrophilic attack, 
forms a hyponitrite species (N2O2).  This species then rotates in the active site, and the N-O bond 
is cleaved to generate nitrous oxide and water.  Proton-coupled electron transfer steps 





Figure 5.3 Nitric oxide reductase.  a) The balanced reaction catalyzed by NOR.  b) The 
proposed cis-b3 mechanism of the NOR-catalyzed reaction.16 
 
5.1.4 A heme protein forms the N-N bond in kutzneride biosynthesis 
 As mentioned in section 3.1.2 and illustrated in Figure 3.2a of Chapter 3, the piperazic 
acid moiety in kutzneride biosynthesis is formed by KtzT.18  KtzT is an enzyme that contains 
heme b and catalyzes the intramolecular attack of the N1 on N5 of N5-hydroxyornithine.  
Curiously, the reaction proceeds in vitro regardless of the oxidation state of the heme iron center.  
Further, hydroxylamine acted as an inhibitor of KtzT activity and produced a shift in the Soret 
band of the KtzT heme, suggesting that the N5-hydroxylamine on the substrate may be directly 
interacting with the heme prosthetic group.  Thus the heme group of KtzT has been proposed to 
act as a Lewis acid in the N-N bond forming reaction by coordinating with the hydroxylamine 
moiety on the substrate and polarizing the nitrogen oxygen bond.  This chemical logic also seems 
to be at play in anaeorobic anammox hydrazine synthetases, which are protein complexes 
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containing heme that are responsible for the formation of hydrazine from ammonia and 
hydroxylamine.19   
 
5.1.5 FzmP as a candidate for N-N bond formation 
As described in Chapter 3, FzmP is one of the five proteins conserved between the 
biosynthetic pathways to fosfazinomycin and kinamycin.20  Unfortunately, FzmP also displays 
little sequence homology to known proteins, and is annotated as a hypothetical protein.  Of the 
five conserved proteins, FzmP is the only one remaining without an assigned function.21-22  Since 
it is still unknown how hydrazinosuccinic acid is formed in this pathway, we wondered if FzmP 
might be involved in this process, particularly in N-N bond formation.   
 
5.2 RESULTS AND DISCUSSION 
5.2.1 FzmP is a heme protein 
 When FzmP from Streptomyces sp. XY332 was initially expressed and purified as a 
recombinant His6-tagged protein from E. coli, it exhibited a faint reddish yellow color.  Dr. Zedu 
Huang and I then investigated the source of this color.  The purified FzmP was analyzed by SDS-
PAGE, and the resulting gels were stained by both coomassie blue (Figure 5.4a) and a stain for 
visualizing the presence of heme (Figure 5.4b).23  The results of the heme staining procedure 
indicated that FzmP contains a heme prosthetic group.  Further, I performed spectroscopic 
analysis of the Q-bands using the pyridine-hemochrome assay, which showed an absorbance 
maximum at 557 nm, characteristic of heme b (Figure 5.4c).24-25  Dr. Huang performed 
additional experiments using LC-MS that confirmed that type b heme was indeed present in 
FzmP expressed in E. coli.  Moreover, using a CO-shift assay, Dr. Huang showed that FzmP was 
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not a cytochrome-like protein.26  We estimated, using the absorbance values from the Soret band 
arising from heme and at 280 nm arising from aromatic residues in the protein, that there was 
roughly a 1:25 molar ratio of heme b to FzmP polypeptide, representing less than 4% heme 
incorporation (assuming that native FzmP contains one heme cofactor per protein).   
 
Figure 5.4 FzmP contains heme b.  a) A coomassie-stained protein gel of FzmP (band indicated 
by red box).  b) A heme stained gel of FzmP in lane 1.  Lane 2 contains a cytochrome c positive 
control.  c) UV-vis spectrum of reduced FzmP in solution with pyridine.  The window is zoomed 
in for the Q-band region.  The λmax at 551 nm is indicative of heme b.   
 
5.2.2 Increasing the incorporation of heme in FzmP 
 Given the precedent for the involvement of heme proteins in the formation of N-N bonds, 
the fact that FzmP was a heme protein appeared to be promising.  Making the assumption that 
FzmP activity is dependent on the presence of its heme cofactor, we sought to increase the 
loading of heme into the protein.  It should be noted that up to this point, FzmP had been 
expressed under a strong promoter (IPTG induction of a T7 promoter in E. coli Rosetta-2 
(DE3)).  A probable explanation for the large proportion of apoprotein is that the native heme 
biosynthetic machinery of the E. coli production strain cannot produce heme quickly enough to 
keep up with recombinant protein expression.  Thus, Dr. Zedu Huang developed a protocol to 
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slow down the expression of FzmP using leaky T7 expression.  Additionally, he supplemented 
the medium with FeSO4 and δ-aminolevulinic acid, a precursor compound in heme biosynthesis.3  
He estimated that this increased the percentage of holoprotein in the sample to between 40 and 
50%.  Achieving 50% heme incorporation was likely sufficient for moving forward with 
enzymatic assays; however, I sought to increase it further for potential crystallographic studies.  I 
was unable to significantly or robustly increase the amount of heme incorporation during 
expression using various media and coexpression with E. coli ferrochelatase.27  Thus, I turned to 
methodologies to load heme into FzmP apoprotein in vitro.  Adapting a protocol for loading 
heme into CYP450s, I was able to increase the proportion of holoprotein to roughly 100% by 
mixing the apoprotein with an excess of hemin (free heme b with a chloride axial ligand) under 
reducing conditions for 3 d.28  Using size exclusion chromatography, I determined that the His6-
tagged FzmP reconstituted with heme appears to be a dimer in solution comparing the elution 
volumes (ve) and the void volume (vo) of the samples and a set of standards (BioRad) (Figure 




Figure 5.5 Size exlusion chromatography analysis of His6-FzmP.  a) Chromatogram of FzmP.  
b) Chromatogram of Bio-Rad Gel Filtration Standards.  c) Table listing the identity of the 
standards, their molecular weights and elution volumes.  d) Standard curve relating the log MW 
of a standard with its elution volume (ve) to void volume (vo) ratio.   
 
5.2.3 Attempting to activate nitrous acid and reconstitute N-N bond formation with 
aspartic acid and nitrous acid 
 As outlined in Chapters 2 and 3, our feeding studies in Streptomyces sp. NRRL S-149 
suggest the intermediacy of nitrous acid derived from aspartic acid in the formation of the 
phosphonohydrazide linkage in fosfazinomycin; these results are further corroborated by the in 
vitro reconstitution of FzmML activity.21-22  Further, the parallel feeding experiments in the 
kinamycin producing system performed by the Balskus group at Harvard University foster 
additional confidence in the biosynthetic hypothesis.22  Thus, Dr. Zedu Huang attempted to 
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reconstitute the formation of hydrazinosuccinic acid from nitrous acid and aspartic acid in the 
presence of FzmP.  Such a reaction would likely involve diazotization of aspartic acid with 
nitrous acid followed by reduction of the diazo functionality to a hydrazine moiety and 
represents the most straightforward path to bridge the gap between nitrous acid and aspartic acid 
(Figure 5.6).  However, he was never able to observe N-N bond formation using these substrates 
with FzmP.   
 
Figure 5.6 Hydrazinosuccinic acid formation through diazotization and reduction.  In this 
hypothesized pathway to N-N bond formation, nitrous acid, liberated from aspartic acid by 
FzmML, participates in diazotization of another molecule of aspartic acid, catalyzed by FzmP.  
A subsequent reductive step generates hydrazinosuccinic acid.   
 
As previously mentioned, in cremeomycin biosynthesis, homologs of FzmML, CreEM, 
also liberate nitrous acid from aspartic acid.29  The N-N bond is then formed through 
diazotization, catalyzed by CreM, a homolog of fatty acid-coenzyme A ligase.30  The reaction is 
ATP-dependent, but it is unclear whether activation occurs through phosphorylation or 
adenylation; additionally, it is unknown whether activation with ATP occurs before or after the 
initial nucleophilic attack on nitrous acid by the primary aromatic amine.30  Though there does 
not appear to be a CreM homolog encoded by the fosfazinomycin biosynthetic gene cluster, we 
hypothesized that a similar activation step on the nitrous acid scaffold might have to occur in our 
system as well.   
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In Chapter 4, I highlighted the discovery of a conserved nucleotidyltransferase homolog, 
FzmU; FzmU homologs are often co-localized with a PqqD-like protein (FzmT in the fzm 
cluster).  Thus, I first tested if FzmTU may work in tandem with FzmP to form the N-N bond.  
When FzmTU were incubated with His6-tagged FzmP (from Streptomyces sp. XY332) in the 
presence of 2-13C-aspartic acid, ATP, NaNO2, MgCl2, and a reducing system consisting of 
NADPH and a flavoprotein reductase from Bacillus megaterium (BMR, donated by Dillon 
Cogan from the laboratory of Satish Nair at the University of Illinois), no change to the 13C-
labeled aspartic acid backbone could be observed by 13C NMR spectroscopy compared to a 
negative control where enzyme was omitted (Figure 5.7).  The reaction was also repeated, 
replacing ATP with CTP, GTP, or UTP; however, in each case, again there was no observable 
reaction.  To test if FzmP is itself capable of utilizing NTPs to activate nitrous acid, I repeated 
the above reactions but omitted adding FzmTU in case there was competition in NTP binding.  
Again by 13C NMR analysis, no change to the aspartic acid scaffold could be observed.   
 





5.2.4 Attempts at using high-throughput screening to identity N-N bond-forming conditions 
 There are numerous possible explanations for the lack of activity observed in section 
5.2.3.  These possibilities can be diverse and include options regarding activities of homologs, 
substrate choice, cofactors, and enzyme combinations, among other things.  In order to 
systematically test many variations, I decided to develop a high-throughput screening 
methodology to identify the formation of hydrazinosuccinic acid, the expected product of the N-
N bond forming reaction.   
 I started by searching for potential probes for hydrazinosuccinic acid detection.  I found 
that naphthalene-2,3-dicarbaldehyde (NDA) was a commercially available compound that had 
been reported to be a fluorescent probe for hydrazine (λex = 403 nm, λem = 500 nm) with a limit 
of detection in the single digit nanomolar range; further, NDA appeared to be able to react with 
and detect sterically hindered hydrazine derivatives such as 1,1-dimethylhydrazine (Figure 
5.8a).31  When NDA was added to synthetic hydrazinosuccinic acid in a 100-fold excess, LC-MS 
analysis revealed that the expected fluorescent compound was observed (Figure 5.8bc).  For 
NDA to serve as a probe in our enzymatic assays, the fluorescent detection of hydrazinosuccinic 
acid must be robust in regards to possible sources of interference.  For instance, aspartic acid 
would likely be a common substrate in the assays and might act as an interferent by reacting with 
the NDA probe.  Since the product of the potential reaction between aspartic acid and NDA 
would not have the same level of conjugation as the NDA-hydrazinosuccinic acid product, it 
likely would have very different fluorescent properties.  However, that reaction could still 
deplete the concentration of NDA in solution and lower the sensitivity of the assay towards 
hydrazinosuccinic acid.  Gratifyingly, NDA proved to be able to detect (above 5σ of noise) down 




Figure 5.8 NDA reacts with hydrazines and forms a fluorescent compound.  a) NDA reacts with 
1,1-dimethylhdyrazine.  b) NDA reacts with hydrazinosuccinic acid to form a fluorescent 
product.  c) Mass spectrum of the NDA-hydrazinosuccinic acid reaction.  d) NDA can detect 
hydrazinosuccinic acid in the presence of 1 mM and 500 μM aspartic acid.  The green and blue 
lines represent the relative fluorescence units vs. concentration of hydrazinosuccinic acid in the 
presence of 500 μM and 1 mM aspartic acid, respectively.  The dashed red line represents the 
fluorescence signal at 5σ of noise.   
 
 Having established that NDA is a viable probe for the detection of hydrazinosuccinic 
acid, I then moved to screen for N-N bond formation.  As I set up the screening campaign, there 
were a number of factors and alternative hypotheses that I sought to investigate.  First, Figure 
5.6 shows the most obvious way to complete the route between nitrous acid and 
hydrazinosuccinic acid, based on analogous chemistry found in cremeomycin biosynthesis.30  
However, unlike in cremeomycin biosynthesis, in the pathway to fosfazinomycin there is no 
apparent reason why the N-N bond must be crafted initially as a diazo-species.  If a diazo 
121 
 
intermediate is not formed, it may be possible that nitrous acid, after being liberated from 
aspartic acid, is further transformed, which opens up the possibility for a variety of other small 
nitrogen-containing molecules (e.g., ammonia, nitric acid, nitric oxide) to be directly involved in 
the formation of the N-N bond.  Further, the N-N bond may not be formed directly on aspartic 
acid.  Instead, it may be possible the N-N bond is fashioned in a completely different manner 
before being deposited intact onto fumaric acid, malic acid, or another related compound (Figure 
5.9).  Thus, for the screen, I expanded the scope of the nitrogen-containing substrates outside of 
just nitrous acid and aspartic acid to include sodium nitrate, nitric oxide (to be generated in situ 
by DEANO),32 ammonium chloride, hydroxylamine, glutamic acid, and glutamine.  I also 
included substrates that might eventually be incorporated into the carbon backbone of 
hydrazinosuccinic acid such as fumaric acid, maleic acid, malic acid, oxaloacetic acid, and 
succinic acid.   
 
 
Figure 5.9 Hydrazinosuccinic acid formation with addition onto fumaric acid.  An alternative 
hypothesis regarding N-N bond formation wherein nitrous acid either (1) directly participates in 
N-N bond formation or (2) is transformed to another unknown species before N-N bond 
formation.  The N-N bond is then incorporated intact onto fumarate or a related structure such as 




 Second, it is possible that the recombinant Streptomyces sp. XY332 FzmP is not active in 
vitro when expressed in and purified from E. coli, and a homolog from another producing 
organism could be easier to work with.  Further, the method in which heme is incorporated may 
affect the activity of the enzyme.  For instance, perhaps the heme prosthetic group is 
incorporated incorrectly in our in vitro reconstitution scheme.  To address these concerns, I 
expressed FzmP from another fosfazinomycin producing organism, Streptomyces sp. NRRL F-
2747 and reconstituted it in vitro with heme b (FzmP dubbed F2747R).  I also expressed FzmP 
from the same organism using leaky T7 expression, acquiring roughly 1:1 ratio of holo- to apo- 
protein (dubbed F2747L).  FzmP, either reconstituted in vitro or produced via leaky expression, 
originating from Streptomyces sp. NRRL S-20 (S20R and S20L), Streptomyces sp. NRRL S-149 
(S149R and S149L), Streptomyces sp. NRRL S-244 (S244R and S244L), and Streptomyces sp. 
NRRL S-444 (S444F and S444L) were also acquired.  Additionally, these enzymes may require 
additional metal cofactors, as is the case with nitric oxide reductase.12   
 Third, FzmP activity may depend on the presence of a partner protein such as FzmM or 
FzmL, which catalyze the preceding chemical step.  Alternatively, another protein capable of 
activating nitrous acid or another nitrogen-containing molecule might be needed.  FzmK, a 
kinase, and FzmF, an ATP-grasp enzyme, appeared to be reasonable candidates.   
 Finally, FzmP activity might require additional cofactors or co-substrates.  The addition 
of cell lysate from the producing organism, Streptomyces sp. NRRL S-149, (harvested after 60 h 
after cultivation in R2AS medium) could address this concern.  Further, it is unknown whether 
the heme iron center of FzmP is required to be reduced for activity.  Dr. Zedu Huang had 
previously demonstrated that a system comprised of Spinach ferredoxin, ferredoxin NADP 
reductase, and NADPH could reduce the FzmP heme iron center to Fe2+.   
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A screening campaign was then started using 384-well plates, individual wells consisted 
of unique conditions built from combinatorially combining the columns in Table 5.1.  Potential 
hits were called based on wells exhibiting a fluorescence intensity within 3σ of the positive 
control wells which hosted 500 μM hydrazinosuccinic acid.  These potential hits were further 
analyzed by LC-MS to monitor for the formation of the NDA-hydrazinosuccinic acid product 
(m/z 297).  Unfortunately, no conditions that could form hydrazinosuccinic acid could be 
identified from the screening effort.   
 
Table 5.1 The substrates, enzymes, and cofactors that were screened with NDA for 
hydrazinosuccinic acid formation.  The composition of each well in the screen was constructed 
by combining at least one element from each column with at least one element from every other 
column in the table.  For columns shaded in gray two ingredients from these columns were added 
per well, and for the column shaded in green, three ingredients (i.e., either two or three enzymes) 
were added per well.  Co-substrates and cofactors were included in wells with the relevant 
enzymes (e.g., ATP for FzmK, NADPH and FAD for FzmM, etc.).  All enzymes used (exept for 

















NaNO3 Fumaric acid XY332R None None None None 
NaNO2 Maleic acid F2747R FeCl3 FzmM FzmK Cell lysate 
DEANO Malic acid S20R FeSO4 FzmL FzmF Spinach Fd/Fr 
NH4Cl Oxaloacetatic acid S149R MgSO4 FzmE   
NH2OH Succinic acid S244R MnSO4    
Asp  S444R CuCl2    
Glu  F2747L ZnSO4    
Gln  S149L KCl    
  S244L     
  S444L     
  S20L     
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5.2.5 FzmP fumarase activity 
 Dr. Zedu Huang had previously observed three cases of enzymatic activity for FzmP 
seemingly unrelated to N-N bond formation.  First, His6-tagged FzmP could catalyze the 
disproportionation of hydrogen peroxide to water and oxygen gas, similar to catalases (Figure 
5.10a).33  Second, in vitro, FzmP converted aspartic acid into succinic acid and ammonia 
(ammonia was derivatized by Fmoc-Cl and detected by LC-MS analysis) after 70 h at ambient 
room temperature (Figure 5.10b).   The reaction appears to be accelerated in in vivo experiments 
inside E. coli; FzmP coexpressed with FzmM was able to convert 13C-labeled aspartic acid into 
succinic acid in less than 16 h.  Third, in vitro, FzmP converted fumaric acid into an unknown 
species after 45 h; interestingly, no reaction could be observed when fumaric acid was replaced 
with its cis-isomer, maleic acid (Figure 5.10cd).   
 
Figure 5.10 Reactions catalyzed by His6-FzmP.  a) FzmP has catalase activity.  b) FzmP can 
convert aspartic acid to succinic acid and ammonia.  c) FzmP can convert fumaric acid into an 
unknown species but d) does not react with maleic acid.   
 
 The FzmP-catalyzed reactions with aspartic acid and fumaric acid are particularly 
interesting since they suggest that FzmP can recognize and bind to the succinyl-type 
substructure, such as the one found in hydrazinosuccinic acid.  Thus, I investigated the nature of 
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the FzmP-catalyzed conversion of fumaric acid.  When FzmP was incubated with 2,3-13C2-
labeled fumaric acid, fumaric acid was converted to malic acid in under 12 h (Figure 5.11a).  
Further, the reaction appears to be dependent on the heme metal center; FzmP stocks prepared as 
~45% holoprotein catalyzed this reaction much more quickly than a preparation consisting of 
~2% holoprotein (Figure 5.11b).  Interestingly, when the reaction was allowed to proceed for up 
to 48 h, both fumaric acid and malic acid were completely consumed, and succinic acid could be 
observed along with a number of unidentified putative oxidation products (Figure 5.11c).   
 Taken altogether, it appears that FzmP exhibits fumarase activity, converting fumaric 
acid to malic acid (on the time scale of around 2 h), and malic acid is then reduced to succinic 
acid after another 36 h.  The reactions here are consistent with the previously observed 
transformation of aspartic acid to succinic acid after 70 h. In that case, ammonia is likely 
eliminated from aspartic acid to generate fumaric acid which is subsequently reduced to succinic 
acid.  During the corresponding in vivo experiments with FzmM, oxidation of aspartic acid 





Figure 5.11 His6-FzmP-catalyzed conversion of 2,3-13C2-fumaric acid.  a) 13C NMR spectra 
showing the conversion of fumaric acid to malic acid after 12 h.  Peaks between 45 and 60 ppm 
labeled as f in the top panel arise from HEPES from the malic acid standard.  b) 13C NMR 
integrations of peaks arising from fumaric acid and malic acid over time reacted with FzmP 
preparations containing 45% holo-FzmP or 2% holo-FzmP.  c) 1H-13C gHSQC spectrum 
showing the formation of succinic acid (red arrow) and other unknown species from a reaction 
mixture containing FzmP, fumaric acid, glycerol and HEPES after 48 h.   
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 The fumarase activity of FzmP observed here is consistent with a hypothesis wherein 
hydrazinosuccinic acid is formed from fumaric acid and a pre-fabricated N-N bond-bearing 
molecule (Figure 5.9).  Thus, I tested whether FzmP is able to catalyze the addition of either 
hydrazine or acetylhydrazine onto fumaric acid; however, no reaction could be observed when 
those components were incubated together (Figure 5.12).  FzmP was similarly unable to install 
nitrite or ammonia onto fumaric acid; however, 13C NMR analysis revealed that FzmP was 
indeed able to catalyze the addition of hydroxylamine onto fumaric acid to form N-
hydroxyaspartic acid.   
 
Figure 5.12 13C NMR analysis of the FzmP-catalyzed reaction of 2,3-13C2-fumaric acid with 
hydrazine, acetylhydrazine, nitrite, ammonia, or hydroxylamine.  FzmP was able to catalyze the 
addition of hydroxylamine onto fumaric acid.  13C resonances arising from the product are 
indicated by the red arrow.   
 
5.2.6 Possible involvement of a ferredoxin-like partner protein 
 A small ferredoxin-like protein, that is absent from the fosfazinomycin pathway, exists in 
the kinamycin pathway in the form of KinI and is conserved in the lomaiviticin and fluostatin 
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biosynthetic clusters, and the presence of KinI was hypothesized to be responsible for the 
difference in the oxidation states of the N-N bond in fosfazinomycin and kinamycin.20  Using 
FzmP BLAST hits as a query, I constructed a sequence similarity network of FzmP homologs 
(Figure 5.13).34  Interestingly, genes that encode for FzmP homologs found predominantly in or 
near putative arylpolyene or ladderane clusters do not co-localize with the other genes 
(FzmNOQR) conserved between the fosfazinomycin and kinamycin biosynthetic clusters; 
however, they are co-localized with a gene encoding for homologs of KinI.  Thus, we wondered 
whether a homolog of KinI might be a partner protein for FzmP.  To explore that possibility, I 
constructed a vector capable of expressing both FzmP (from Streptomyces sp. XY332) and KinI 
(from Streptomyces ambofaciens ATCC 23877).  However, when the cell extract from E. coli 
expressing FzmP and KinI and provided with nitrite and aspartic acid was examined by LC-MS, 
hydrazinosuccinic acid could not be detected.   
 
Figure 5.13 A sequence similarity network of FzmP homologs.  The UniProt accession numbers 
for each node in the clusters is given in Table 5.2. 
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1 H2A446 Uncharacterized protein  Streptococcus macedonicus (strain 
ACA-DC 198) 
1 A0A1B1NY03 Uncharacterized protein  Staphylococcus pseudintermedius 
1 B7GNZ4 Uncharacterized protein  Bifidobacterium longum subsp. infantis  
(strain ATCC 15697) 
1 A0A0M4MHB1 Uncharacterized protein  Bifidobacterium longum subsp. infantis. 
1 A0A0R1Y3V0 Uncharacterized protein  Lactobacillus composti DSM 18527 
1 B1SDM4 Uncharacterized protein  Streptococcus infantarius subsp. 
infantarius ATCC BAA-102. 
1 A0A1C3SM20 Uncharacterized protein  Streptococcus macedonicus. 
1 A0A081JJJ1 Uncharacterized protein  Streptococcus macedonicus. 
1 A0A0U2M047 Uncharacterized protein  Streptococcus gallolyticus. 
1 A0A089LHX2 Uncharacterized protein  Paenibacillus borealis. 
1 A0A0A6RIR5 Uncharacterized protein  Candidatus Thiomargarita nelsonii. 
1 A0A1W6BLG8 Uncharacterized protein  Staphylococcus lutrae. 
1 A0A0G3BI40 Uncharacterized protein  [Polyangium] brachysporum. 
1 S2XBN8 Uncharacterized protein  Staphylococcus sp. HGB0015. 
1 A0A1Q9ILF0 Uncharacterized protein  Staphylococcus pseudintermedius 
1 C5QPH0 Uncharacterized protein  Staphylococcus caprae M23864:W1. 
1 D5WRU8 Uncharacterized protein  Kyrpidia tusciae  (strain DSM 2912) 
1 A0A0T6BUK6 Uncharacterized protein  Bacillus glycinifermentans. 
1 A0A1S1GVS8 Uncharacterized protein  Staphylococcus sp. HMSC62A08. 
1 A0A0S4MFW5 Uncharacterized protein  Staphylococcus capitis 
1 A0A1J4A0N4 Uncharacterized protein  Staphylococcus sp. HMSC036D05. 
1 A0A1Q2TJ95 Uncharacterized protein  Staphylococcus capitis 
1 A0A1J4E9R2 Uncharacterized protein  Staphylococcus sp. HMSC067F07. 
2 A0A0U3PGW8 Uncharacterized protein  Streptomyces sp. CdTB01. 
2 W0HKP2 Uncharacterized protein  Salinispora pacifica 
2 A0A1C6UFJ1 Uncharacterized protein  Micromonospora yangpuensis. 
2 F6K0Z1 Uncharacterized protein  uncultured bacterium BAC 
AB649/1850. 
2 A0A177HJS4 Uncharacterized protein  Streptomyces jeddahensis. 
2 A0A059UDU0 Lom29  Salinispora pacifica. 
2 A4X702 Uncharacterized protein  Salinispora tropica  (strain ATCC 
BAA-916) 
2 A0A0F7FX22 Uncharacterized protein  Streptomyces xiamenensis. 
2 A0A1B1B7Y3 Uncharacterized protein  Streptomyces griseochromogenes. 




Table 5.2 (continued) 
2 A0A136PKM6 Uncharacterized protein  Micromonospora rosaria 
2 A0A0P0J1F9 FlsU2  Micromonospora rosaria 
2 A0A0L8KKJ2 Uncharacterized protein  Streptomyces viridochromogenes 
2 K0EPW1 Uncharacterized protein  Nocardia brasiliensis ATCC 700358. 
2 A0A0B5F564 Uncharacterized protein  Streptomyces albus (strain ATCC 
21838) 
2 A0A1Z3ZUV9 Uncharacterized protein  Nocardia brasiliensis 
2 A0A0F7NGD2 Uncharacterized protein  Streptomyces sp. CNQ-509. 
2 A0A034UK78 Uncharacterized protein  Nocardia brasiliensis NBRC 14402. 
2 A0A0C1DRJ8 Uncharacterized protein  Nocardia vulneris 
2 Q1RQT7 Uncharacterized protein 
SAMT0149  
Streptomyces ambofaciens ATCC 
23877. 
2 Q0JWB7 Uncharacterized protein  Streptomyces ambofaciens 
2 A0A0K2AJN3 Uncharacterized protein  Streptomyces ambofaciens ATCC 23877 
2 A0A0T6LTS3 Uncharacterized protein  Streptomyces vitaminophilus. 
2 A0A1I5DWR8 Uncharacterized protein  Streptomyces sp. cf124. 
2 A0A209B5E6 Uncharacterized protein  Streptomyces sp. CS159. 
2 A0A0N0H9J4 Uncharacterized protein  Streptomyces sp. NRRL WC-3753. 
2 A0A0K8PYB7 Uncharacterized protein  Streptomyces azureus. 
2 H1QD11 Uncharacterized protein  Streptomyces coelicoflavus ZG0656. 
2 A0A1C6M9T1 Uncharacterized protein  Streptomyces sp. AmelKG-E11A. 
2 A0A1W2FUZ9 Uncharacterized protein  Kibdelosporangium aridum. 
2 A0A1Q4VEI3 Uncharacterized protein  Streptomyces uncialis. 
3 A0A1P8TRT4 Uncharacterized protein  Streptomyces silaceus. 
3 A0A0X3W8Z0 Uncharacterized protein  Streptomyces sp. NRRL S-1521. 
3 A0A1H1VNA2 Uncharacterized protein  Streptomyces sp. TLI_053. 
3 A0A0M8UF53 Uncharacterized protein  Streptomyces sp. XY431. 
3 A0A1C6ULT0 Uncharacterized protein  Micromonospora yangpuensis. 
3 A0A0F4JR48 Uncharacterized protein  Streptomyces sp. NRRL S-495. 
3 A0A1C5J8C4 Uncharacterized protein  Micromonospora rifamycinica. 
3 A0A109IQ43 Uncharacterized protein  Micromonospora rifamycinica. 
3 A0A1C4XXM4 Uncharacterized protein  Micromonospora matsumotoense. 
4 A0A104IWC6 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A108CQG3 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A108BRC4 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A0D0H921 Uncharacterized protein  Burkholderia sp. MSHR3999. 
4 A0A104YNM5 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A124YMK6 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A107KND7 Uncharacterized protein  Burkholderia ubonensis. 




Table 5.2 (continued) 
4 A0A106QGK1 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A106JMH9 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A105YIW9 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A104T8J2 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A118HWW0 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A102L1B1 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A0P0KFY6 Uncharacterized protein  Burkholderia plantarii. 
4 A0A0B6RWK3 Uncharacterized protein  Burkholderia glumae PG1. 
4 C5AG45 Uncharacterized protein  Burkholderia glumae (strain BGR1) 
4 A0A246MK46 Uncharacterized protein  Burkholderia glumae  
4 A0A107FIG1 Uncharacterized protein  Burkholderia ubonensis. 
4 A0A1C3K830 Uncharacterized protein  Orrella dioscoreae. 
4 A0A108ABQ4 Uncharacterized protein  Burkholderia stagnalis. 
4 A0A104NJY8 Uncharacterized protein  Burkholderia pyrrocinia  
5 A0A073B0W9 Uncharacterized protein  Saccharopolyspora rectivirgula. 
5 A0A0F5W5X9 Uncharacterized protein  Streptomyces sp. WM6386. 
5 A0A1Z2LD39 Uncharacterized protein  Streptomyces albireticuli. 
5 U5YQR0 Uncharacterized protein  Streptomyces sp. WM6372. 
5 A0A0F4J3Z5 Uncharacterized protein  Streptomyces sp. NRRL S-444. 
5 U5YN85 Uncharacterized protein  Streptomyces sp. XY332. 
6 A0A0K2WWL3 Uncharacterized protein  Corynebacterium striatum. 
6 A0A1F1XBL4 Uncharacterized protein  Corynebacterium sp. HMSC05E07. 
6 C2CRH9 Uncharacterized protein  Corynebacterium striatum ATCC 6940. 
 
5.3 SUMMARY AND OUTLOOK 
 We have thus far failed to reconstitute N-N bond formation with FzmP or with any other 
protein encoded by the fosfazinomycin biosynthetic gene cluster.  One possible explanation for 
this is that we have yet to identify the correct substrates involved in the N-N bond formation.  
Due to the intermediacies of nitrous acid and hydrazinosuccinic acid, our primary hypothesis has 
always involved the diazotization of nitrous acid with aspartic acid (Figure 5.6).  However, we 
do not have experimental evidence to support that this is the case in fosfazinomycin biosynthesis.  
The observation that FzmP can install hydroxylamine onto fumaric acid offers some support for 
the hypothesis outlined in Figure 5.9.  Perhaps the N-N bond is formed first from nitrous acid 
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and another unknown source of nitrogen to give a small R-N-N-O-type structure, which is then 
added onto fumaric acid by FzmP.  The subsequent reductive steps required to arrive at 
hydrazinosuccinic acid may be performed by FzmP as well; indeed FzmP appears to be able to 
reduce malic acid to succinic acid through undetermined means.  It is encouraging, however, that 
FzmP is able to recognize and perform chemistry on succinyl-like substructures.   
 Another activity that was observed for FzmP has been its catalase activity.  This finding 
has not been explored largely because in the prevailing hypotheses, reductive rather than 
oxidative chemistry is required.  It may be worthwhile to revisit whether FzmP may be acting as 
a peroxidase.   
 Another avenue that can be explored is the role of KinI.  KinI is found in the pathways to 
kinamycin and its gene is often co-localized with the genes encoding for homologs of 
FzmNOPQR.  It is also curious that in a number of arylpolyene-like gene clusters, genes 
encoding for FzmP and KinI homologs are co-localized with one another but not with genes for 
homologs of FzmNOQR.  One hypothesis is that a KinI homolog and FzmP either act together or 
catalyze adjacent steps in the biosynthetic pathway.  A more in-depth bioinformatic analysis 
would be necessary to probe whether in cases of clusters encoding FzmNOPQR homologs but no 
KinI homolog, there are KinI homologs encoded elsewhere in the genome.  If a KinI homolog is 
indeed a partner protein with FzmP, it may play a number of potential roles such as electron 
transfer to the heme center of FzmP.  In KinI and KinJ (the FzmP homolog in kinamycin 
biosynthesis) can be co-expressed, and tested to see if they co-purify.  In vitro experiments with 
KinI and KinJ can also determine if KinI can reduce the heme center of KinJ.  This experiment 
can then be followed by a large number of potential enzymatic assays.  In vitro, to probe whether 




5.4.1 General methods 
 Unless otherwise noted, all reagents were purchased from either Sigma-Aldrich or Fisher 
Scientific.  Synthetic oligonucleotides were purchased from Integrated DNA Technologies 
(IDT).  Enzymes used in cloning were procured from New England Biosciences (NEB). DNA 
sequencing was performed by ACGT Inc. or the Roy J. Carver Biotechnology Center (University 
of Illinois at Urbana-Champaign).  NMR experiments were conducted on an Agilent 600 MHz 
instrument with a OneNMR broadband probe, and the data was analyzed using MestreNova 
software.   
 




























In order to construct expression constructs for FzmP, genomic DNA was isolated from 
Streptomyces sp. NRRL F-2747, Streptomyces sp. NRRL S-20, Streptomyces sp. NRRL S-149, 
Streptomyces sp. NRRL S-244, and Streptomyces sp. NRRL S-444 using the Ultraclean 
Microbial DNA Isolation Kit (Mo Bio) following the manufacturer’s instructions.  The primers 
listed in Table 5.3 were then used to amplify fzmP from the genomic DNA using Q5 polymerase 
following the manufacturer’s instructions.  pET15b (Novagen) was digested with NdeI and XhoI.  
The amplicons were then ligated with the linearized pET15b using the HiFi Assembly Kit (NEB) 
following the manufacturer’s instructions using a 2:1 stoichiometry of insert to vector.  Aliquots 
(5 μL) were used to transform 10 μL of NEB-5-α chemically competent cells (NEB).  The 
fidelity of the insertions was verified by DNA sequencing.  (See NB entry for 5-26-17) 
 For the FzmP-KinI co-expression construct, fzmP was amplified from Streptomyces sp. 
XY332 genomic DNA using the primers in Table 5.3.  kinI was amplified from a codon-
optimized synthetic gene (gBlock from IDT) based on the protein sequence of KinI from 
Streptomyces ambofaciens ATCC 23877 (Table 5.3).  pRSF-Duet-1 was digested with NcoI and 
BamHI.  The fzmP amplicon was then ligated with the pRSF-Duet-1 digest in a 3:1 
stoichiometric ratio using the Gibson Assembly mix (NEB), following the manufacturer’s 
instructions.  The reaction mixture was then used to transform E. coli DH5α.  pRSF_1_fzmP was 
isolated from transformants, and the fidelity of the insertion was verified by sequencing.  
pRSF_1_fzmP was then digested with NdeI and XhoI and ligated with the kinI amplicon in a 1:2 
ratio of vector to insert with the HiFi Assembly mix (NEB) to make pRSF_1_fzmP_2_kinI.  The 
ligated plasmid was used to transform NEB-5α cells.  The fidelity of the insertion was verified 




5.4.3 Protein expression and purification 
 To express and purify predominantly apo-His6-FzmP, an E. coli Rosetta-2 (DE3)  
transformant harboring the appropriate construct was cultivated in LB with 100 μg mL-1 
ampicillin for 12 h at 37 °C.  This starter culture (40 mL) was used to inoculate 4 L of LB with 
100 μg mL-1 ampicillin, and this production culture was cultivated for 37 °C, shaking at 210 or 
220 rpm until OD600 reached between 0.5 and 0.7.  Protein expression was induced by the 
addition of IPTG (Gold Biotechnology) to a final concentration of 100 μM.  The culture was then 
placed on ice for 20 min, before being cultivated for an additional 16 h at 18 °C, shaking at 210 
rpm.  The cells were harvested via centrifugation before being resuspended in lysis buffer (50 
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 10% glycerol) supplemented with 1 mg mL-1 
lysozyme (Gold Biotechnology) and 20 U mL-1 DNAse I.  This mixture was then incubated with 
mild agitation at 4 °C for 20 min.  Cell lysis was then achieved by passing the suspension 
through a French pressure cell twice.  Subsequent steps to purify the protein were then performed 
at 4 °C.  Cellular debris was removed via centrifugation (45 min at 30,600 × g).  The supernatant 
was then loaded onto 5 mL of Ni-NTA resin (Qiagen).  The resin and the supernatant were 
incubated together with mild agitation for 15 min.  After the supernatant was allowed to flow 
through the resin, the resin was washed with 40 mL of wash buffer (50 mM NaH2PO4, 300 mM 
NaCl, 20 mM imidazole, 10% glycerol), and the protein was eluted with 25 mL of elution buffer 
(50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, 10% glycerol).  Excess imidazole was 
removed using a PD-10 column (GE Healthcare) with 3.5 mL storage buffer (50 mM NaH2PO4, 
300 mM NaCl, 10% glycerol).  (See NB entry for 3-23-18) 
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 To express and purify higher proportions of holo-FzmP, the same procedure as above was 
followed with the following modifications.  As the production culture reached OD600 ~0.5, δ-
aminolevulinic acid and FeSO4 were added to final concentrations of 800 μM each.  No IPTG 
was added.  The cultures were then cultivated for an additional 60 h at 18 °C, shaking at 210 
rpm.  Harvesting of the cells and protein purification then proceeded identically as for apo-
protein.  (See NB entry for 3-23-18) 
 
5.4.4 Determination of FzmP heme content 
 SDS-PAGE on FzmP was run using standard protocols (160 V in 12% resolving gel).  A 
portion of the protein gel was stained with coomassie blue to visualize FzmP.  Another portion 
was subjected to a heme stain.23  Then, 30 mg of N,N,NʹNʹ-tetramethylbenzidine (TMB) was 
dissolved in 15 mL of MeOH followed by the addition of 35 mL of 0.5 M sodium acetate (pH = 
5.0).  The gel was placed in the solution and incubated for 5 min in the dark followed by the 
addition of 300 μL H2O2.  After another 5 min incubation in the dark, the gel was for bands.  A 
positive control lane was run using cytochrome c.  (See NB entry for 7-21-13) 
 The pyridine hemochrome assay was run adapted from existing protocols.24-25  His6-
FzmP was diluted to 5 mg/mL in 500 μL of storage buffer.  To this protein solution was added 
119 μL pyridine and 59.5 μL of 1 M NaOH.  Likewise a parallel negative control consisting of 
500 μL storage buffer, 119 μL pyridine, and 59.5 μL of 1 M NaOH was constructed.  Each 
sample above was then split into two 300 μL aliquots.  One set of aliquots was reduced by the 
addition of a spatula tip of sodium dithionite and 10 μL of H2O.  The other set of aliquots was 
oxidized by the addition of 10 μL of aqueous 0.1 M potassium ferricyanide.  All tubes were then 
agitated for 15 min at 4 °C.  UV-vis absorbance spectroscopy was then performed on a Cary 
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4000 spectrometer, scanning from 380 nm to 600 nm.  The oxidized negative control was placed 
in a black quartz cuvette (l = 1.0 cm) and used to zero the instrument.  The oxidized sample was 
read.  The reduced sample was analyzed using the reduced negative control as a background that 
was subtracted.  The spectra were plotted using Microsoft Excel.  (See NB entry for 8-5-13) 
 
5.4.5 In vitro FzmP heme reconstitution 
 A sample of His6-FzmP consisting mostly of apo-protein was acquired as described in 
section 5.4.3.  Heme reconstitution was accomplished by incubating 8 μM FzmP with 100 μM 
hemin, 21 mM sodium dithionite, 0.1 M histidine, and 20% glycerol in H2O, pH = 7.0.  This 
mixture was then stirred for 72 h at ambient room temperature under N2(g).  After this incubation 
period, the protein was concentrated to a volume of ~3 mL using an Amicon spin filter with a 30 
kDa molecular weight cutoff.  This solution was then washed five times with 15 mL volumes of 
elution buffer (composition give in section 5.4.3) using the same spin filter above.  The protein 
was concentrated to a final volume of ~1 mL.  This concentrated protein solution was then 
further purified by size exclusion chromatography using an AKTA 900 Purifier FPLC system 
equipped with an XK16 column packed with 120 mL of Superdex 200 prep grade resin (GE 
Healthcare).  A mobile phase of storage buffer (composition give in section 5.4.3) was used at a 
flow rate of 1 mL min-1, and absorbance at 280 nm was monitored.  In order to find the 
relationship the elution volume/void volume of the system with molecular weight of the analytes, 
the Bio-Rad Gel Filtration Standard kit was used with the same flow rate and mobile phase in 





5.4.6 Enzymatic assays with FzmP, aspartic acid, and nitrite 
 For the enzymatic assays with His6-FzmP, aspartic acid, nitrite, and FzmTU, reactions 
consisted of 10 μM His6-FzmT, 10 μM His6-FzmU, 3 mM NTP (ATP, CTP, GTP, or UTP), 2 
mM 2-13C-aspartic acid [13C, 99%, Sigma-Aldrich], 2 mM NaNO2, 10 μM His6-FzmP, 5 μM 
BMR, 4 mM NADPH, and 5 mM MgCl2 in 50 mM NaH2PO4, pH = 7.7 (400 μL total volume).  
Reactions were incubated at ambient room temperature for 12 h, 50 μL 0.5 M EDTA was added, 
and the proteins were removed by an Amicon filter with a 10 kDa molecular weight cutoff.  
Then, 50 μL D2O was added prior to NMR analsysis.  (See NB entry for 8-6-18) 
 
5.4.7 Screening for hydrazinosuccinic acid formation with NDA 
 To initially test the reaction between NDA and hydrazinosuccinic acid, 500 μM 
hydrazinosuccinic acid were incubated in 25% ethanol and 1 mM NaOH for 9.5 h at ambient 
room temperature.  The reaction was then analyzed by LC-MS using an Agilent 1200 series LC 
system coupled to an Agilent G1956B single quadrupole mass spectrometer with an Xbridge C18 
column (4.6 x 250 mm, 5 µ) using mobile phase A (H2O) and mobile phase B (acetonitrile) at a 
flow rate of 1 mL min-1.  The method consisted of a linear gradient from 5% B to 95% B over 10 
min, an isocratic hold at 95% B for 10 min, a linear gradient from 95% B to 5% B over 10 min, 
and a final isocratic hold at 5% B for 30 min.  Detection was achieved in positive ion mode, 
scanning for a range of m/z 100 to 650 and monitoring for m/z 297 in selected ion monitoring 
mode.  Absorbance detection was set for 400 nm.  (See NB entry for 11-8-16) 
 To run the screen, the one, two (gray), or three (green) components from each column in 
Table 5.1 were mixed combinatorially with one, two, or three components from every other 
column in the concentrations indicated in 50 mM HEPES, pH = 7.5.  Wells containing FzmM 
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were also supplemented with 2 mM NADPH and 1 mM FAD; wells containing FzmK or FzmF 
were supplemented with 2 mM ATP and 5 mM MgCl2.  Wells supplemented with 500 nM 
Spinach Fd/Fr were supplemented with 2 mM NADPH.  Components were mixed together in 
Corning 384-well black polystyrene flat bottom assay plates (Corning, Ref 3575).  Positive 
controls (representing 25% conversion enzymatic conversion) consisted of 10 μM FzmP and 500 
μM hydrazinosuccinic acid in 50 mM HEPES, pH = 7.5.  Negative controls consisted of 10 μM 
FzmP in 50 mM HEPES, pH = 7.5.  Buffer (50 mM HEPES, pH = 7.5) was added to wells not 
housing sample, positive controls, or negative controls to combat edge effects.  All wells each 
contained 10 μL of liquid. The 384-well plate was set up according to the plate map in Figure 
5.14, though there were minor variations in layout run to run.   
 
Figure 5.14 A sample plate map for high-throughput detection of hydrazinosuccinic acid 
formation. 
 
 The plates were then incubated at ambient room temperature for 8 h.  A 12 μL volume of 
detection solution consisting of 3.3 mM NaOH, 50 mM NDA, and excess sodium dithionite in 
83% DMSO was then added to each well.  The plates were then incubated in the dark for 12 h.  
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Fluorescence intensity for each well was then analyzed using a Tecan Infinite 200 Pro plate 
reader using Fluorescence Top Reading mode with λex = 400 nm with 9 nm bandwidth, λem = 508 
nm with 20 nm bandwidth.  Gain was set to 70.  The Z-distance was set to 21000 μm, and five 
flashes per well were used with 20 μs integration time.  Lag time and settle time were each set to 
0 μs.  Follow-up LC-MS analysis was performed using the method described above for 
analyzing the reaction between hydrazinosuccinic acid and NDA.  (See NB entries for 3-2-17, 3-
17-18, 3-30-17, 6-30-17, 7-6-17, 8-7-17, and 8-25-17) 
 
5.4.8 Testing FzmP activity on fumaric acid 
 To test what FzmP forms from fumaric acid, 20 μM FzmP (XY332L) was incubated with 
4 mM 2,3-13C2-fumaric acid [13C, 99%, Sigma-Aldrich] in 50 mM NaH2PO4, pH = 7.7 (500 μL 
total volume) for 12 h at ambient room temperature.  The protein was then removed with an 
Amicon spin filter with a 30 kDa molecular weight cutoff, and 50 μL of D2O was added prior to 
NMR analysis.  For spiking, malic acid (at natural isotopic abundance) in 50 mM HEPES buffer 
was added to the reaction mixture to a concentration of about 100 mM.  (See NB entries starting 
on 3-20-18) 
To test if heme incorporation is important for fumarase activity, 20 μM FzmP (XY332L) 
was incubated with 4 mM 2,3-13C2-fumaric acid [13C, 99%, Sigma-Aldrich] in 50 mM NaH2PO4, 
pH = 7.7, and 9% D2O.  A 13C NMR spectrum was then acquired every 15 min, and resonances 
arising from fumaric acid (133.2 to 137.1 ppm) and malic acid (40.2 to 43.5 ppm) were 
integrated for each spectrum and plotted with Microsoft excel.  The same procedure was then 
repeated for predominantly apo-FzmP (XY332R).  (See NB entries for 3-26-18 and 3-27-18) 
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 To test if FzmP (XY332L) is able to install nitrogen nucleophiles onto fumaric acid, 20 
μM FzmP, 4 mM 2,3-13C2-fumaric acid [13C, 99%, Sigma-Aldrich], and 4 mM of a potential 
nucleophile (hydrazine, acetylhydrazine, ammonium chloride, sodium nitrite, or hydroxylamine) 
were incubated in 50 mM NaH2PO4, pH = 7.7 (500 μL total volume) for 12 h at ambient room 
temperature, before the addition of 50 μL of D2O for NMR analysis.  (See NB entry for 3-23-18)  
 
5.4.9 Biotransformation experiment with FzmP and KinI 
 pRSF_1_fzmP_2_kinI was used to transform E. coli BL21 (DE3).  Transformants were 
used to inoculate a starter culture consisting of 5 mL of LB supplemented with 50 μg mL-1 
kanamycin in a culture tube.  After cultivation at 37 °C for 14 h on a roller drum, 250 μL of the 
starter culture was used to inoculate 25 mL of ZYM-5052 autoinduction media.35  Cultivation 
then continued at 37 °C, shaking at 220 rpm until the OD600 reached 0.4.  The temperature was 
decreased to 18 °C, NaNO2 and aspartic acid were each added to 2 mM, and the culture was 
shaken at 220 rpm for an additional 19 h.  The cells were harvested via centrifugation and 
resuspended in 3 mL of 50% methanol.  Cell lysis was achieved with sonication, and cellular 
debris was removed by centrifugation (45 min at 30,600 × g).  Fmoc-Cl was then added to 20 
mM to the reaction mixture.  The reaction was incubated for 20 min with agitation, and 1-
aminoadamantane was added to 50 mM, after which incubation continued for another 20 min.  
The sample was then analyzed with LC-MS using an Agilent 1200 series LC system coupled to 
an Agilent G1956B single quadrupole mass spectrometer with an Eclipse C18 column (4.6 x 150 
mm, 5 µ) using mobile phase A (H2O) and mobile phase B (acetonitrile) at a flow rate of 1 mL 
min-1.  The method consisted of an isocratic hold at 5% B for 1 min, a linear gradient from 5% B 
to 95% B in 11.5 min, an isocratic hold at 95% B for 5.5 min, a linear gradient from 95% B to 
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5% B in 5 min, and a final isocratic hold at 5% B for 13 min.  The formation of 
hydrazinosuccinic acid was monitored using positive mode selected ion monitoring at m/z 149 
and 398.  A parallel negative control was run as described above except the cells harbored an 
empty pRSF-Duet-1 plasmid.  (See NB entry for 3-5-18) 
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